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resumo 
 
 
A hipertensão arterial pulmonar (HAP) é uma doença grave, caracterizada por 
remodelação progressiva da vasculatura pulmonar, frequentemente 
culminando em insuficiência do ventrículo direito (VD) e morte prematura. 
Apesar do progresso que tem sido feito nos últimos anos em termos de opções 
de tratamento, a HAP permanece uma doença incurável, com um mau 
prognóstico e uma elevada taxa de mortalidade. No presente trabalho, 
pretendeu-se explorar o potencial de diferentes abordagens preventivas e 
terapêuticas na HAP experimental. Para isso, três estudos experimentais 
foram realizados a fim de avaliar o impacto do exercício físico (Estudos I e II) 
ou do fármaco terameprocol (TMP) (Estudo III) na HAP. No Estudo I 
mostramos que o exercício físico moderado realizado ao longo da vida induziu 
diferentes adaptações moleculares nos ventrículos esquerdo e direito. 
Especificamente, o VD de animais treinados apresentou maiores alterações 
mitocondriais, mostrando um aumento na expressão de MnSOD e SIRT3, 
sugestivo de uma melhoria da capacidade antioxidante. Para explorar o 
impacto do exercício físico na HAP, no Estudo II avaliou-se o seu potencial 
efeito preventivo na insuficiência do VD secundária a HAP, no modelo animal 
da monocrotalina (MCT) submetido a 4 semanas de exercício físico em tapete 
rolante antes do desenvolvimento da doença. Os resultados indicam que o pré-
condicionamento com exercício físico preveniu a remodelação da artéria 
pulmonar e a disfunção, hipertrofia e fibrose do VD. A nível molecular, o 
exercício físico preveniu o aumento do rácio MHC-beta/alfa e modulou a via de 
sinalização TWEAK/NF-κB. O exercício físico também preveniu o aumento da 
expressão da atrogina-1 e induziu um aumento da atividade da MMP-2. Com o 
objetivo de desenvolver novas estratégias farmacológicas para o tratamento da 
HAP, no Estudo III foi utilizada uma abordagem proteómica baseada em 
espetrometria de massa para procurar as vias moleculares moduladas pelo 
TMP em culturas primárias de células musculares lisas da artéria pulmonar 
isoladas de ratos injetados com MCT. A análise bioinformática dos dados de 
proteómica destacou a "regulação do tamanho da célula" e "resposta ao stress 
do retículo endoplasmático", como processos biológicos sobre-expressos pelo 
TMP, enquanto os processos biológicos "resposta ao TGF-beta" e "transcrição 
do ADN" foram encontrados sub-expressos. Dos fatores de transcrição 
modulados pelo TMP, a sub-expressão do HMGB1 parece estar relacionada 
com o efeito anti-proliferativo deste fármaco. Estas alterações moleculares 
induzidas pelo tratamento com TMP podem ter contribuído para a redução da 
remodelação vascular e consequentemente atenuado a disfunção e hipertrofia 
do VD associadas à HAP induzida pela MCT. Em geral, os nossos resultados 
sugerem que o pré-condicionamento com exercício físico e o tratamento com 
TMP podem ter relevância clínica na HAP. A modulação de vias de sinalização 
associadas à inflamação parece estar relacionada com os efeitos benéficos 
destas estratégias preventivas e terapêuticas. 
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abstract 
 
Pulmonary arterial hypertension (PAH) is a severe disease, characterized by 
progressive remodeling of the pulmonary vasculature, usually culminating in 
right ventricle (RV) failure and premature death. Despite the progress that has 
been made in the last few years in terms of treatment options, PAH remains an 
incurable disease, with a poor prognosis and a high mortality rate. In the 
current work, we intended to explore the potential of different preventive and 
therapeutic approaches in experimental PAH. To accomplish that, three 
experimental studies were performed in order to assess the impact of exercise 
training (Studies I and II) or the drug terameprocol (TMP) (Study III) in PAH. In 
Study I, we show that lifelong moderate exercise training induced different 
molecular adaptations in the left and right ventricles. Specifically, the RV of 
trained animals presented greater mitochondrial changes, showing an 
increased expression of MnSOD and SIRT3, suggestive of improved 
antioxidant capacity. To explore the impact of exercise training on PAH, in 
Study II we evaluated its potential preventive effect on RV failure secondary to 
PAH, in the monocrotaline (MCT) animal model submitted to a 4-week treadmill 
exercise training before disease development. Data indicate that exercise 
preconditioning prevented pulmonary artery remodeling and RV dysfunction, 
hypertrophy and fibrosis. At a molecular level, exercise training prevented the 
increase in beta/alpha-MHC ratio and modulated the TWEAK/NF-κB signaling 
pathway. Exercise training also prevented the increase of atrogin-1 expression 
and induced an increase in MMP-2 activity. Envisioning the development of 
novel pharmacological strategies for PAH treatment, in Study III we used a 
mass spectrometry-based proteomic approach to search for the molecular 
pathways modulated by TMP in pulmonary artery smooth muscle cell primary 
cultures isolated from rats injected with MCT. Bioinformatic analysis of 
proteome data highlighted the “regulation of cell size” and “response to 
endoplasmic reticulum stress” as biological processes up-regulated by TMP, 
while the biological processes “response to TGF-beta” and “DNA-templated 
transcription” were found down-regulated. From the transcription factors 
modulated by TMP, the down-regulation of HMGB1 seems to be related with 
the anti-proliferative effect of this drug. These molecular alterations induced by 
TMP treatment may have contributed to the reduction of the vascular 
remodeling and consequently attenuated RV dysfunction and hypertrophy 
associated to MCT-induced PAH. In overall, our results suggest that exercise 
preconditioning and TMP treatment can be of clinical relevance in PAH. The 
modulation of inflammation-related signaling pathways seems to be behind the 
benefits of these preventive and therapeutic strategies. 
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CHAPTER I. GENERAL INTRODUCTION 
3 
General Introduction 
Pulmonary arterial hypertension (PAH) is a progressive and fatal cardiopulmonary disease, 
which represents Group 1 within the Pulmonary Hypertension World Health Organization 
(WHO) clinical classification system. PAH is defined by a resting mean pulmonary artery 
pressure (PAP) greater than or equal to 25 mmHg, a pulmonary capillary wedge pressure 
less than or equal to 15 mmHg and a pulmonary vascular resistance (PVR) above 3 Wood 
units (Voelkel, Gomez-Arroyo et al. 2012; Hoeper, Bogaard et al. 2013; McLaughlin, Shah 
et al. 2015). According to the current clinical classification, PAH can be idiopathic, 
heritable, drug or toxin induced or associated with other diseases (connective tissue 
diseases, HIV infection, portal hypertension, congenital heart diseases and 
Schistosomiasis) (Simonneau, Gatzoulis et al. 2013). PAH has a complex and 
multifactorial pathogenesis in which vasoconstriction, thrombosis in situ, inflammation 
and vascular remodeling are the main pathological features (Lourenco, Fontoura et al. 
2012; Malenfant, Neyron et al. 2013; Montani, Gunther et al. 2013; McLaughlin, Shah et 
al. 2015). Pulmonary vascular remodeling is characterized by the thickening of all three 
layers of the vascular wall (intima, media and adventitia). This thickening is mainly due to 
hypertrophy and/or hyperplasia of the predominant cell type within each of the layers 
(endothelial cells, smooth muscle cells (SMCs) and fibroblasts), as well as SMC resistance 
to apoptosis. A complex interplay among the different vascular cells, regulated by several 
mediators is a key contributor to the pathological features that characterize this disease 
(Mandegar, Fung et al. 2004; Sakao, Tatsumi et al. 2010; Shimoda and Laurie 2013; 
Guignabert, Tu et al. 2015). All these changes in the pulmonary vascular bed may lead to a 
progressive increase in PVR, imposing a pressure overload to the right ventricle (RV), 
which results in RV hypertrophy and eventually in RV failure and premature death 
(Montani, Gunther et al. 2013; Baldi, Fuso et al. 2014; McLaughlin, Shah et al. 2015).  
Approximately two-thirds of PAH patients are women and the majority are diagnosed with 
40-50 years of age in an advanced stage of the disease (WHO functional class III-IV) 
(Baptista, Meireles et al. 2013; McGoon, Benza et al. 2013). Although a rare disease, with 
an estimated prevalence of 15-50 cases per million (Peacock, Murphy et al. 2007), PAH is 
a fatal condition with a survival estimated as low as 2.8 years after diagnosis if left 
untreated (D'Alonzo, Barst et al. 1991). Until now, only a few molecular pathways 
targeting the pulmonary vascular endothelial dysfunction and vasoconstriction were found 
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to be therapeutically relevant. For instance, treatment with prostacyclin analogs, 
endothelin-1 receptor antagonists or phosphodiesterase type 5 inhibitors was shown to be 
beneficial (Provencher and Granton 2015). During the last years, PAH therapeutic options 
increased patient survival, exercise capacity and quality of life. However, there is currently 
no cure available and further understanding into the disease pathophysiology and treatment 
development is needed to improve PAH clinical management (McGoon, Benza et al. 2013; 
Humbert, Lau et al. 2014). To assist in this demanding task, preclinical models of PAH 
have been crucial to the identification of the molecular pathways underlying PAH 
development and progression and to establish novel therapeutics or improve the existing 
ones. Among preclinical models of PAH, the monocrotaline (MCT) animal model is the 
most commonly used, offering the advantage of mimic several key aspects of human PAH, 
including vascular remodeling, endothelial dysfunction, up-regulation of inflammatory 
cytokines, and RV dysfunction (Maarman, Lecour et al. 2013; Ryan, Marsboom et al. 
2013). Indeed, pharmacological therapies have been tested, using the MCT animal model, 
increasingly targeting pulmonary vascular proliferative and apoptotic pathways, instead 
vasoconstriction (Huang, Liu et al. 2010; Umar, Steendijk et al. 2010; Gurtu and 
Michelakis 2015).  
Exercise training can be seen as an attractive non-pharmacological therapeutic approach 
for PAH, given its anti-inflammatory properties (Gielen, Adams et al. 2003). Recent 
reports support inflammation as an important process in the pathogenesis of PAH-related 
dysfunctional RV (Watts, Gellar et al. 2008; Campian, Hardziyenka et al. 2010; Rondelet, 
Dewachter et al. 2012; Belhaj, Dewachter et al. 2013; Vonk-Noordegraaf, Haddad et al. 
2013) that seems to be modulated by exercise training (Moreira-Goncalves, Ferreira et al. 
2015). Indeed, exercise has been reported to be a beneficial non-pharmacological approach 
in PAH patients’ rehabilitation, being seen as an adjunct to pharmacological treatment 
(Mereles, Ehlken et al. 2006; de Man, Handoko et al. 2009; Grunig, Ehlken et al. 2011; 
Grunig, Lichtblau et al. 2012; Ehlken, Lichtblau et al. 2016). However, the potential 
preventive role of exercise training in individuals with RV failure secondary to PAH is still 
unknown. Despite the unique cardioprotective phenotype promoted by exercise training 
(Ferreira, Moreira-Goncalves et al. 2015), the underlying molecular mechanisms require 
further investigation, particularly those related with long-term exercise training effects on 
RV. This can be of great importance, once RV function is a critical determinant of survival 
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in pathological conditions such as PAH (Vonk-Noordegraaf, Haddad et al. 2013; La 
Gerche and Claessen 2015).  
Considering the questions raised, the global purpose of this work was to investigate novel 
non-pharmacological (exercise training) and pharmacological (terameprocol (TMP)) 
approaches to the clinical management of PAH. The present thesis is divided in five 
chapters. In the chapter I a state of the art regarding PAH pathophysiology, available 
therapeutic options and animal models to study the disease is presented (Reviews I-IV). 
Chapter II specifies the aims of the work. In the chapter III are presented the experimental 
studies, including the experimental design, the methods used, results obtained and a 
discussion of each study. A general discussion of the results and the main conclusions are 
presented in the chapters IV and V, respectively.   
 
List of studies – Theoretical background: 
Review I 
R. Nogueira-Ferreira, R. Ferreira, and T. Henriques-Coelho (2014). “Cellular interplay in 
pulmonary arterial hypertension: Implications for new therapies”, Biochimica et 
Biophysica Acta – Molecular Cell Research 1843(5): 885-893. 
Review II 
R. Nogueira-Ferreira, D. Moreira-Gonçalves, M. Santos, R. Ferreira and T. Henriques-
Coelho (2016) “Mechanisms underlying the impact of exercise training in pulmonary 
arterial hypertension”, (submitted). 
Review III 
R. Nogueira-Ferreira, G. Faria-Costa, R. Ferreira, and T. Henriques-Coelho (2016). 
“Animal models for the study of pulmonary hypertension: potential and limitations”, 
Cardiology and Cardiovascular Medicine 1(1): 1-22. 
Review IV 
R. Nogueira-Ferreira, R. Vitorino, R. Ferreira, and T. Henriques-Coelho (2015). 
“Exploring the monocrotaline animal model for the study of pulmonary arterial 
hypertension: A network approach”, Pulmonary Pharmacology and Therapeutics 35: 8-16. 
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Abstract 
Pulmonary arterial hypertension (PAH) is a devastating disease characterized by 
progressive increases in pulmonary vascular resistance that can ultimately lead to right 
ventricle failure and death. Patients with PAH present symptoms such as shortness of 
breath, fatigue, dizziness and chest pain, which impact negatively the functional capacity 
and quality of life. Despite the advances in recent years in disease-targeted therapies, PAH 
remains a disease without a cure and with a high mortality rate and an urgent need of 
effective therapeutic strategies. Exercise training is an established treatment in left heart 
failure and chronic obstructive pulmonary disease. Although exercise training was 
discouraged in PAH because of safety concerns, recent studies support that supervised 
exercise training can also provide benefits in patients with stable PAH. However, the 
molecular mechanisms underlying these improvements are still poorly understood. This 
review summarizes the emerging clinical and experimental studies describing the 
molecular alterations related with exercise training in PAH. 
 
Keywords: animal models, clinical trials, exercise training, pulmonary arterial 
hypertension 
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1. Introduction 
Pulmonary arterial hypertension (PAH) is a devastating disease characterized by a 
progressive increase in pulmonary vascular resistance, which can lead to right heart failure 
and premature death. By the time of diagnosis, most individuals are in the New York Heart 
Association (NYHA)/World Health Organization (WHO) functional class III or IV. The 
most commonly reported symptoms are dyspnea and fatigue, which limit physical function 
and quality of life (QOL) [1, 2]. Its pathophysiology remains poorly understood but 
includes vascular changes, namely vasoconstriction, vascular remodelling, thrombosis and 
inflammation (reviewed by [3, 4]). Current available therapies comprise supportive therapy 
(anticoagulants, diuretics and supplementary oxygen) and disease-targeted therapies 
(vasodilators and anti-proliferative agents) but with limited success. Unfortunately, PAH 
remains a progressive disease without a definite cure [5]. Thus, search for efficient 
approaches to treat this disease or, at least, to improve the patients’ quality of life is 
imperative. 
Exercise training is widely recognized by its preventive and therapeutic effects in several 
chronic diseases [6]. For instance, in chronic obstructive pulmonary disease or left heart 
failure, exercise training has been reported as an efficient and safe therapeutic approach, 
improving exercise capacity, symptoms, QOL and survival [7, 8]. In the setting of PAH, 
only now exercise training started to be recognized as safe and beneficial. Until recently, 
guidelines for PAH treatment recommended that any physical activity should be limited as 
it could aggravate the disease progression and increase the risk of sudden cardiac death [9, 
10]. In 2009 the guidelines were revised and a short recommendation was included stating 
that patients should be encouraged to be active within symptom limits and, when 
deconditioned but controlled under medical therapy, may undertake supervised exercise 
training [11]. This change of position was based on data from a limited number of clinical 
trials showing that supervised and structured exercise training programs (moderate-
intensity exercise) could improve cardiopulmonary function, exercise capacity and QOL, 
without major adverse events or clinical worsening, in stable PAH patients [12-14]. More 
recently, three important meta-analysis have been published and further strengthened the 
concept that exercise is safe and beneficial for well medicated PAH patients [10, 15, 16]. 
Despite consensus in the literature regarding the favorable effect of exercise training 
programs in PAH specific clinical outcomes such as exercise tolerance and QOL, the 
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mechanisms underlying these clinical improvements are not yet well established. 
Considering what we know from other chronic diseases, particularly left heart failure, it 
could be possible that both cardiopulmonary and skeletal muscle changes induced by 
exercise training could play a role in PAH. In this review we will summarize the molecular 
evidences retrieved from experimental and clinical studies supporting the therapeutic and 
preventive effect of exercise training in the set of PAH. 
 
2. Mechanisms underlying the beneficial effects of exercise training in PAH 
Understanding the mechanisms that explain the benefits of exercise training will help to 
clarify the impact of different exercise programs (considering the type and intensity of 
exercise training programs) on PAH progression. Table 1 summarizes what has been 
described until now in terms of molecular changes induced by exercise training in both 
clinical and pre-clinical studies. Information was selected from papers collected by 
searches done in PubMed using the terms “exercise training”, “rehabilitation”, “pulmonary 
hypertension” and “pulmonary arterial hypertension” in the title or abstract. Additionally, 
the references listed in all selected papers were also hand searched. At the end, 16 studies 
were considered for the molecular analysis of the impact of exercise training on PAH.  
 
2.1.1. Clinical studies 
Comment on available studies 
Amongst the 17 studies exploring the effects of exercise training in PAH patients 
(Supplementary Table S1), only 7 included biochemical measures of some molecular 
mediators in training patients, though not directly related to PAH disease (Table 1). The 
majority of participants in the clinical studies were women, which is consistent with the 
predominance of PAH in female subjects. Furthermore, the age of the participants was also 
in accordance with the age at which the majority of patients are diagnosed (40-50 years of 
age) [17]. Patients were mostly in II-IV WHO/NYHA functional class with the majority 
belonging to functional class III. It is important to highlight that exercise training was 
reported to provide functional improvements even in patients in the class IV, which 
represents the worst stage in terms of functional impairment [18]. Regarding PAH 
etiology, most of the patients presented idiopathic PAH, associated with connective tissue 
diseases or congenital heart diseases, which are the most prevalent forms of PAH [19]. In 
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all these studies the exercise protocol was performed under supervised conditions and 
included a combination of aerobic (treadmill or cycle ergometer) and resistance training. 
Study duration ranged between 3 and 15 weeks. The frequency of exercise training varied 
between 2 and 7 sessions/week with a duration of 30-60 minutes/session. Patients were 
trained in hospitals or rehabilitation centers and the majority continued with a prescribed 
exercise-training program at home but in contact with the specialists to guarantee patient’s 
safety and compliance. Despite the general agreement that exercise training is beneficial 
and safe, there are several questions that need to be addressed before any recommendation 
for the PAH population. There is a need for multicentric randomized clinical trials (the 
majority of the clinical trials were performed by the same research group); to test the safety 
and efficacy of home-based interventions; to determine the best exercise program for 
maximal benefits (frequency, intensity, duration, mode); and to clarify the time point of the 
disease when exercise training should be recommended and/or limited.  
 
Cardiac adaptations 
Analysis of N-terminal-pro brain natriuretic peptide (NT-proBNP) has been used as 
biomarker of right ventricle (RV) function, prognosis and monitoring of therapeutic 
intervention in PAH. It reflects cardiomyocyte injury, inflammation and ventricular 
remodelling, once it is secreted in response to an increase in ventricular wall stress [20, 
21]. NT-proBNP levels remained unchanged in almost all studies, suggesting that the 
exercise training programs in use did not impact cardiac function. In one study with PAH 
associated with congenital heart diseases, NT-proBNP serum-levels slightly decreased 
after 3 weeks of exercise training but significantly increased after 15 weeks in comparison 
with baseline data [22]. However, no measures of cardiac function were available and 
several limitations (e.g. changes in the exercise program or missing values at the last 
follow-up visit) have been pointed that could explain these results. There is one 
randomized clinical trial that assessed RV function after 15 weeks of exercise training and 
showed increased cardiac index at rest and during exercise [23], thus suggesting 
improvement of RV function. Unfortunately, no molecular analysis was performed in this 
study. The effects of exercise training on right ventricular function and remodelling have 
not yet been established, neither the underlying molecular mechanisms.  
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Table 1 – Molecular changes induced by exercise training in clinical and experimental pulmonary arterial 
hypertension. 
 
Characterization of 
subjects 
Exercise intervention Effect of exercise Reference 
Human studies 
 Idiopathic PAH 
(19) 
 NYHA – FC II-
III (84% III)  
 42 ± 13 years 
 79% female 
12 weeks institution based  
3 days/week: 
 bicycle training 
 quadriceps strength and 
endurance training  
↑ skeletal muscle (vastus 
lateralis) type I fiber 
succinate dehydrogenase 
activity 
= NT-proBNP levels in the 
blood 
[24] 
 Associated PAH 
(8) 
 NYHA – FC II-
III (63% III)  
 28 ± 6 years 
 63% male 
3 months institution based  
2 days/week:  
 10 min warm-up, with 
stretching of long muscle 
groups  
 resisted exercises (1–2 kg)  
 aerobic interval training in 
a bicycle ergometer during 
24 min with bases at 10–
25W and 30-second peaks 
of 20–50W (80% of HR 
reached in the 6MWT) 
From 3
rd
 to 12
th
  month: 
 daily flat-ground walking 
 similar rehabilitation 
exercises as done in the 
rehabilitation sessions 
= NT-proBNP, hemoglobin 
and ferritin levels in the 
blood 
[25] 
 Idiopathic PAH 
(5) 
 WHO – FC II-III 
(60% II) 
 40 ± 15 years 
 80% female 
12 weeks institution based  
3 days/week:  
 10 to 15 min of cycling 
exercise with initial 
workload set at 60% of the 
maximal workload 
achieved during 
incremental exercise test 
 2 sets of 10 to 12 
repetitions for 6 to 8 
different exercises 
involving single muscle 
groups (arms and 
quadriceps)  
 15 min of brisk walking 
on a treadmill (85% of the 
mean speed of 6MWT) 
= skeletal muscle (vastus 
lateralis) citrate synthase, 
3-hydroxyacyl CoA 
dehydrogenase and 
phosphofructokinase 
activities 
[26] 
 Idiopathic PAH 
(10), Associated 
PAH (10) and 
CTEPH (2) 
 NYHA – FC II-
III (59% II)  
 52 ± 4 years 
 68% female 
12 weeks institution based  
2 days/week  
1-hour sessions of exercise 
training, two 6-week blocks (60-
80% of CPET HRmax): 
 first block: interval 
training with treadmill 
walking, cycling, and step 
= NT-proBNP levels in the 
blood 
 
[27] 
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climbing   
second block: longer 
periods of continuous 
aerobic exercise, with 
resistance training by step 
climbing, unsupported 
arm/leg exercises with and 
without dumbbells (500-
1000 g), and supporting 
body weight over a chair 
 daily home-based exercise 
with stair-climbing and 
brisk walking  
 Associated PAH 
(21)   
 WHO – FC II-IV 
(43% II)  
 52 ± 18 years 
 95% female 
3 weeks institution based: 
 7 days/week at low 
workloads (10 to 60 W) of 
interval bicycle ergometer 
training with a lower 
workload for 1⁄2 min and 
a higher workload for 1 
min, 10 to 25 min/day. 60 
min of walking, 5 
days/week (flat-ground 
and uphill walking)  
 30 min of dumbbell 
training of single muscle 
groups (500 to 1000 g) 
and 30 min of respiratory 
training, 5 days/week 
12 weeks home based:  
 bicycle exercise training, 
once daily, 15-30 min, 5 
days/week  
 respiratory exercise and 
dumbbell training every 
other day, 15-30 min  
 walking twice a week 
= plasma NT-proBNP and 
C-reactive protein levels  
 
[28] 
 Associated PAH 
(20) 
 WHO – FC II-III 
(70% III) 
 48 ± 11 years 
 80% female 
Same as [28]. ↑ serum NT-proBNP levels  [22] 
 PAH (61) and 
CTEPH (26) 
 WHO – FC II-IV 
(79% III)  
 56 ± 15 years 
 54% female 
Same as [28]. 
= NT-proBNP levels in the 
blood 
[23] 
Animal studies 
Male Sprague-Dawley rats 
with PAH induced by 
chronic hypoxia 
 Treadmill running 
 10 weeks 
 5 days/week 
 60 min/session  
 6 weeks: progressed to 30 
m/min 
↑ RV and LV α1-
adrenoceptor and β-
adrenoceptor densities 
↓ RV and LV muscarinic 
receptor density 
(assessed by radioactive 
[29] 
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 4 weeks: 30 m/min 
 10º incline 
ligand binding assay) 
Male Wistar rats with 
PAH induced by 
monocrotaline (60 mg/kg) 
 Treadmill running  
 3-5 weeks 
 5 days/week 
 First week: 60 min/session  
 Second to fifth weeks: 50 
min/session  
 10-30 m/min 
 0º incline 
↑ erythrocyte superoxide 
dismutase and glutathione 
S-transferase activities  
↓ erythrocyte lipid 
peroxidation and catalase 
activity  
= erythrocyte glutathione 
peroxidase activity  
[30] 
Male Wistar rats with 
PAH induced by 
monocrotaline (60 mg/kg) 
 Treadmill running  
 3 weeks 
 5 days/week 
 First and second weeks: 
60 min/session  
 Third week: 50 
min/session  
 60% VO2 max 
↓ RV p-GSK-3β/GSK-3β 
protein expression  
[31] 
Male C57BL/6J mice with 
PAH induced by chronic 
hypoxia  
 Treadmill running  
 3 weeks 
 5 days/week 
 30 min/session 
 60% VO2 max  
↑ lung PDE1c mRNA 
expression  
↓ lung eNOS and PDE5 
mRNA expression 
= lung PDE1a, sGCb1, 
PDE1b, PDE4a, PDE4b, 
sGCa3 and iNOS mRNA 
expression 
[32] 
Male Wistar rats with 
PAH induced by 
monocrotaline (60 mg/kg) 
 Treadmill running  
 3 weeks 
 5 days/week 
 First and second weeks: 
60 min/session  
 Third week: 50 
min/session 
 60% VO2 max  
↑ RV p-Akt protein  
expression  
↓ RV hydrogen peroxide 
concentration and caspase-
3 protein expression 
= RV PI3K, Akt and 
Bax/Bcl-2 protein 
expression 
[33] 
Male Sprague-Dawley rats 
with PAH induced by 
monocrotaline (50 mg/kg)  
 Treadmill running  
 1 bout of 45 min 
 75% VO2 max 
↑ lung p-eNOSSer1122/eNOS 
protein expression  
↓ lung p-eNOSThr495/eNOS 
protein expression  
= RV caspase-3 activity 
[34] 
Male Wistar rats with 
PAH induced by 
monocrotaline (60 mg/kg) 
 Treadmill running  
 4 weeks 
 5 days/week 
 First week: progressed to 
60 min/session at 25 
m/min 
 Second to fourth weeks: 
60 min/session at 25 
m/min 
 0º incline 
 Training occurred prior to 
randomizing to control vs. 
PAH groups 
↑ RV NF-κB p105/p50, 
NF-κB p65 protein 
expression and MMP-2 
activity  
↓ RV beta/alpha MHC, 
TWEAK and atrogin-1 
protein expression 
= RV myostatin, p-Smad3, 
p38 MAPK, TNF-α, 
Erk1/2, NF-κB p100/p52, 
Rel-B, TRAF6, MuRF1, p-
Akt, p-FoxO3A protein 
expression and MMP-9 
activity 
[35] 
Male Wistar rats with 
PAH induced by 
monocrotaline (60 mg/kg) 
 Treadmill running 
 4 weeks (early 
intervention)  
Early and late 
interventions:  
↑ RV SERCA2a protein 
[36] 
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 2 weeks (late intervention) 
 5 days/week 
 60 min/session  
 30 m/min 
 Last week: 25 m/min 
 0º incline 
 
expression, VEGF mRNA 
expression and 
mitochondria complex V 
activity  
↓ RV ET-1 mRNA 
expression, serum levels of 
lactate and mitochondria 
complex V nitration 
= RV ATP synthase 
subunit β protein 
expression 
Early intervention: 
↓ RV beta/alpha MHC 
protein expression, TNF-
α/IL-10 and BNP mRNA 
expression 
Male Wistar rats with 
PAH induced by 
monocrotaline (60 mg/kg) 
 Treadmill running 
 8 weeks prior to MCT 
administration + 3 weeks 
after MCT injection 
 5 days/week 
 60 min/session  
 15-18 m/min 
= RV ryanodine receptor, 
phospholamban and 
SERCA2a mRNA 
expression 
[37] 
Legend: ↑, increase; ↓, decrease; =, no change; 6MWT, 6-minute walk test; CPET, cardiopulmonary exercise 
testing; CTEPH, chronic thromboembolic pulmonary hypertension; eNOS, endothelial nitric oxide synthase; 
ET-1, endothelin-1; GSK-3β, glycogen synthase kinase-3β; HR, heart rate; IL-10, interleukin-10; iNOS, 
inducible nitric oxide synthase; LV, left ventricle; MHC, myosin heavy chain; MMP, matrix 
metalloproteinase; MuRF1, muscle ring finger protein 1; NT-proBNP, N-terminal-pro brain natriuretic 
peptide; NYHA – FC, New York Heart Association functional class; PAH, pulmonary arterial hypertension; 
PDE, phosphodiesterase; p-GSK-3β, phosphorylated GSK-3β; PI3K, phosphoinositide 3-kinase; RV, right 
ventricle; SERCA2a, sarco(endo)plasmic reticulum calcium-ATPase; sGC, soluble guanylate cyclase; TNF-
α, tumor necrosis factor-α; TRAF6, TNF receptor-associated factor 6; TWEAK, TNF-related weak inducer of 
apoptosis; VEGF, vascular endothelial growth factor; VO2, oxygen uptake; WHO – FC, World Health 
Organization functional class. 
 
Skeletal muscle adaptations 
Several skeletal muscle abnormalities have been reported in PAH such as muscle atrophy, 
fiber type switching and impaired contractility. Muscle abnormalities appear to be very 
common and seem to contribute to dyspnea, fatigue, and exercise limitation in patients 
with PAH [38-40]. Skeletal muscle biopsies (vastus lateralis) were collected to evaluate 
the effects of exercise training on muscle function in two clinical studies (Table 1). 
Exercise training increased quadriceps strength by 13% and quadriceps endurance by 34%. 
This was accompanied by increased capillarisation and oxidative enzyme activity, 
especially of the type-I (slow) muscle fibers [24]. In another study, exercise training was 
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shown to decrease type-IIx fiber proportion [26]. No other molecular adaptations were 
reported. 
 
2.1.2. Experimental studies   
Comment on available studies 
There are several studies assessing the impact of exercise training in cardiac or pulmonary 
vessels remodelling in experimental PAH but only 9 studies have described the molecular 
changes promoted by exercise training (Table 1). The pre-clinical models of PAH used to 
characterize the effect of exercise training were chronic hypoxia (two studies) and 
monocrotaline (MCT; 60 mg/kg) (seven studies) models. In general, the exercise training 
protocols were conducted for 2-8 weeks, 5 sessions/week, 30-60 minutes/session, at a 
running speed ranging from 15 to 30 meters/minute. The acute effect of exercise training 
was analyzed in one study, consisting in a single session of treadmill running during 45 
minutes at 75% VO2 max [34]. Treadmill is the mode of exercise used in all the studies 
designed to assess the effect of exercise training in experimental PAH. Treadmill training 
allows controlling exercise intensity and duration, and the calculation of the total amount 
of external work done by the animal; however, it is a form of forced exercise and requires 
constant observation to prevent animal injuries [41]. To the best of our knowledge, only 
one study evaluated the effect of voluntary access to a running wheel, a protocol that took 
an average of 4 weeks (depending on rats’ health status), showing that exercise training 
improved animals’ survival and delayed the progression to right heart failure, but no 
molecular mechanisms were studied [42]. The majority of the experimental studies 
evaluated exercise training as a therapeutic approach once the exercise program was 
performed after disease implementation. However, in one study the preventive effect of 
exercise training was tested using a protocol consisting in 4 weeks of treadmill running 
before MCT injection followed by 4 weeks with animal movements confined to the cage´s 
space [35]. Recently, another study evaluated the preventive effect of exercise training 
using a protocol consisting in 8 weeks of treadmill running before MCT injection followed 
by 3 weeks of treadmill running [37]. Right ventricle and lung tissues were the samples 
more analyzed. Additionally, analysis of protein expression by western blotting, mRNA 
expression by PCR and also assessment of enzymatic activity are the most common 
methodologies used to evaluate the molecular changes associated with exercise training.  
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Cardiac adaptations 
In the majority of the studies, exercise training showed beneficial effects on cardiac 
remodelling [30-37, 42, 43]. Still, other reported no improvement [44] or aggravation [45]. 
From those that studied the molecular changes associated with exercise training, mediators 
related with proliferation, apoptosis, oxidative stress, inflammation and proteolysis were 
evaluated, given the relevance of these processes in RV adaptation to PAH [46, 47].  
An exercise-training program consisting in 3 weeks of treadmill running post-MCT 
injection revealed an improvement in RV function by invasive hemodynamic analysis. RV 
remodelling was related with the glycogen synthase kinase (GSK) signalling, with a 
decreased ratio between the phosphorylated (inactive protein with pro-hypertrophic 
function) and dephosphorylated (active protein with anti-hypertrophic function) form of 
the protein GSK-3β in the exercised MCT rats [31]. GSK-3β is implicated in cardiac 
growth and regulates the calcineurin/NFAT (nuclear factor of activated T-cells) signalling, 
phosphorylating NFAT that is dephosphorylated by calcineurin. NFAT phosphorylation 
prevents its nuclear translocation, thereby limiting access to target genes. However, in its 
phosphorylated form, this protein exerts a pro-hypertrophic role, through the decrease in 
NFAT phosphorylation and the consequent increase of its translocation to the nucleus, 
activating the transcription of hypertrophic response genes [48-50]. Using the same 
exercise training protocol, hydrogen peroxide concentration and apoptotic signalling was 
shown to be reduced in RV of exercised animals, paralleled by a decrease in RV caspase-3 
protein expression and an increase in phosphorylated (activated) Akt levels [33]. This 
serine/threonine kinase is involved in physiologic cardiac growth and cardiomyocyte 
survival [49, 51, 52]. Additionally, the systemic lipid peroxidation and activity of 
antioxidant enzymes was assessed in MCT rats submitted to treadmill running during 3, 4 
or 5 weeks post-MCT injection. Exercise training reduced oxidative stress given by 
decreased lipid peroxidation and increased superoxide dismutase and glutathione S-
transferase activities, which was related to prevention of RV hypertrophy and increased 
animals’ survival [30]. Oxidative stress is an important contributor to RV remodelling and 
dysfunction in PAH. High cellular levels of reactive oxygen species seem to be involved in 
the activation of pro-apoptotic pathways in the failing RV in PAH, cardiomyocyte 
hypertrophy, matrix remodelling and contractile dysfunction [53]. 
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The impact of exercise training performed in different stages of the disease was also 
evaluated. After 1 week of habituation, a group of animals ran during 4 weeks post-MCT 
injection (early exercise training) and other group ran during 2 weeks after 2 weeks of 
MCT injection (late exercise training). Both exercise interventions (early and late) 
improved cardiac function. These benefits of exercise training were associated with 
improvements in markers of cardiac remodelling (SERCA2a, beta/alfa MHC), 
neurohumoral activation (endothelin-1, BNP, vascular endothelial growth factor), 
metabolism and mitochondrial oxidative stress (complex V activity and nitration) and 
inflammation (TNF-α/IL-10). Alterations on cardiomyocyte and extracellular matrix, 
neurohumoral activation, inflammation, mitochondrial and metabolic disturbances and 
oxidative stress have been pointed out as key contributors to RV remodelling and 
dysfunction in PAH [46, 54]. Importantly, greater positive effects were observed when 
exercise training was initiated in an earlier time point of the disease [36].  
Four weeks of treadmill running before MCT injection followed by 4 weeks of sedentary 
behavior revealed that prior exercise training prevented cardiac dysfunction and 
maladaptative remodelling, by modulating inflammation and proteolysis. In fact, exercise 
training decreased the expression of the pro-inflammatory cytokine TWEAK and 
modulated the downstream regulators from the NF-κB pathway, prevented the increase of 
the ubiquitin ligase atrogin-1 expression and induced a shift of metalloproteinases (MMP) 
activity from MMP-9 to MMP-2 activity [35]. In another study, prior exercise training was 
also shown to exert cardioprotective effects by decreasing hypertrophy and improving 
heart function but without modifying calcium transport genes (ryanodine receptor, 
phospholamban and SERCA2a) in the RV [37].  
Acute exercise (45 minutes of treadmill run at 75% of VO2 max) was also shown to 
provide some benefit as it transitorily normalized the RV systolic pressure of MCT-
induced stable PAH (evaluation was performed 17 days after administration of 50 mg/kg 
of MCT), without evidence of acute right ventricular inflammation or myocyte apoptosis 
[34]. The effect of an acute exercise bout in advanced stage of the disease remains to be 
determined.  
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Pulmonary adaptations 
The impact of exercise training on pulmonary vasculature remodelling remains 
inconclusive, with experimental studies showing improvement [31, 32, 34, 35], no 
improvement [30, 33, 36, 43, 44] or aggravation [45]. However, only two studies explored 
the molecular mechanisms associated with exercise training effects, giving emphasis to 
pathways involved in the vasodilatation process. The mRNA expression of lung mediators 
involved in the nitric oxide synthase/soluble guanylate cyclase/phosphodiesterase 
(NOS/sGC/PDE) pathway was evaluated in mice with PAH induced by chronic exposure 
to hypoxia submitted to 3 weeks of treadmill running. No vasodilatory shift of the 
NOS/sGC/PDE enzyme expression was observed after exercise training, despite the 
improvement in pulmonary vascular remodelling (decrease in small pulmonary vessel 
muscularization) [32]. Curiously, an acute running bout was shown to induce a transitory 
acute reduction in pulmonary artery pressure that was associated with lung endothelial 
NOS (eNOS) activation, supporting a mechanism of acute NO-mediated pulmonary 
vasodilatation [34]. The NO pathway is impaired in several ways in PAH and is an 
important therapeutic target. Nitric oxide activates sGC, catalyzing cyclic guanosine 
monophosphate (cGMP) synthesis. cGMP causes vasodilation and inhibits smooth muscle 
cell proliferation and platelet aggregation. An induction of eNOS activity can increase NO 
production, contributing to promote vasodilatation [55, 56].   
 
Skeletal muscle adaptations 
The effect of exercise training on skeletal muscle in the pre-clinical settings of PAH 
remains poorly studied. The preventive effects of exercise training in PAH-related muscle 
wasting was evaluated in Wistar rats injected with MCT [57]. Four weeks of treadmill 
running before MCT injection followed by 4 weeks of sedentary behavior prevented the 
PAH-related decrease in cross-sectional area and MHC-I expression in gastrocnemius 
muscle. Additionally, the phosphorylated forms of Akt and mTOR protein levels increased 
in exercised groups. Akt is involved in protein synthesis stimulation by activating mTOR 
and its downstream effectors, being also associated with muscle atrophy prevention by 
inhibiting the activity of FoxOs, thereby supressing the expression of the E3 ubiquitin 
ligases atrogin-1 and MuRF1 [58-60]. Exercise training also prevented the increase in 
atrogin-1 expression in gastrocnemius muscle and the increase of C-reactive protein and 
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IL-1β serum levels. Thus, the preventive effect of exercise training in muscle wasting 
seems to be related with the modulation of proteolysis and inflammation. Exercise training 
performed during 4 weeks post-MCT injection also increased gastrocnemius muscle 
weight and fiber cross-sectional area. However, no molecular alterations related with the 
therapeutic effect of exercise training on PAH-induced muscle wasting were evaluated 
[36]. 
  
3. Conclusions 
Experimental and clinical evidences support exercise training as a beneficial and safe non-
pharmacological approach to be included in multimodal strategies for the clinical 
management of PAH. Indeed, exercise training seems to modulate diverse molecular 
mechanisms in varied target organs (overviewed in figure 1), associated with proliferation, 
apoptosis, oxidative stress, inflammation, proteolysis and vasodilatation.  
 
 
Figure 1 – Molecular changes underlying exercise training effects in clinical and experimental pulmonary 
arterial hypertension. Figure made with Servier Medical Art. Legend: ↑, increase; ↓, decrease; =, no change; 
6MWD, 6-minute walk distance; CHD, congenital heart disease; CRP; C-reactive protein; CTD, connective 
tissue disease; eNOS, endothelial nitric oxide synthase; ET-1, endothelin-1; GSK-3β, glycogen synthase 
kinase-3β; GST, glutathione S-transferase; IL, interleukin; MCT, monocrotaline; MHC, myosin heavy chain; 
MMP-2, matrix metalloproteinase-2; mTOR, mammalian target of rapamycin; NT-proBNP, N-terminal-pro 
CHAPTER I. STATE OF THE ART 
37 
brain natriuretic peptide; NYHA – FC, New York Heart Association functional class; PAH, pulmonary 
arterial hypertension; p-GSK-3β, phosphorylated GSK-3β; QOL, quality of life; SERCA2a, 
sarco(endo)plasmic reticulum calcium-ATPase; SOD, superoxide dismutase; TNF-α, tumor necrosis factor-α; 
TWEAK, TNF-related weak inducer of apoptosis; VEGF, vascular endothelial growth factor; WHO – FC, 
World Health Organization functional class. 
 
However, more studies are needed with different training programs and a better 
phenotyping of patients, envisioning the recommendation of exercise training for the 
clinical management of PAH and the identification of molecular therapeutic targets that 
mimic or potentiate the effect of exercise. 
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Aims 
Pulmonary arterial hypertension remains a devastating disease without a cure, with most of 
the patients being diagnosed at a very advanced stage. So, the general goal of the present 
thesis was to explore novel preventive and therapeutic approaches for the clinical 
management of PAH. To accomplish this, specific purposes were outlined in the original 
research articles (experimental studies I, II and III) that comprise chapter III: 
 
i) to better characterize the functional, structural and molecular adaptations induced by 
lifelong aerobic exercise training in the right ventricle (Study I). 
 
ii) to evaluate the preventive effects of exercise training on right ventricle dysfunction and 
remodeling secondary to MCT-induced PAH (Study II). 
 
iii) to explore the in vivo effects of terameprocol in the MCT model of PAH and the 
biological processes modulated by this drug in primary cultures of pulmonary artery 
smooth muscle cells (PASMCs) (Study III).  
 
List of studies – Original research papers: 
Paper I 
R. Nogueira-Ferreira, R. Ferreira, A. I. Padrão, P. Oliveira, M. Santos, A. N. Kavazis, R. 
Vitorino, D. Moreira-Gonçalves (2016). “Different susceptibility to metabolic adaptations 
in the right and left ventricle of rats following one year of moderate exercise training”, 
(submitted). 
Paper II 
R. Nogueira-Ferreira, D. Moreira-Gonçalves, A.F. Silva, J.A. Duarte, A. Leite-Moreira, R. 
Ferreira, T. Henriques-Coelho (2016). “Exercise preconditioning prevents MCT-induced 
right ventricle remodeling through the regulation of TNF superfamily cytokines”, 
International Journal of Cardiology 203: 858-866. 
Paper III 
R. Nogueira-Ferreira, M. J. Ferreira-Pinto, A. F. Silva, R. Vitorino, J. Justino, R. Costa, D. 
Moreira-Gonçalves, J. F. Quignard, T. Ducret, J. P. Savineau, A. F. Leite-Moreira, R. 
Ferreira, T. Henriques-Coelho (2016). “HMGB1 down-regulation mediates terameprocol 
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vascular anti-proliferative effect in experimental pulmonary hypertension”, Journal of 
Cellular Physiology (Epub ahead of print).  
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Abstract 
Aim: Aerobic exercise training induces a unique cardioprotective phenotype, but it does 
not promote the same structural and functional adaptations to the right ventricle and left 
ventricle. In the present study we aimed to better characterize the molecular pathways 
involved in right ventricle remodeling induced by aerobic exercise training. 
 
Methods: Sprague-Dawley rats were randomly assigned to control and exercise groups. 
Animals in exercise group were submitted to moderate treadmill exercise for 54 weeks. 
After the experimental period, hemodynamic analysis were performed and right and left 
ventricles were harvested for morphological and biochemical analysis. 
 
Results: Data showed that long-term moderate exercise training improves cardiac 
function, especially diastolic function. In right ventricle, long-term exercise training 
induced an increase of manganese superoxide dismutase and sirtuin 3, suggestive of 
improved antioxidant capacity. The content of connexin-43 and c-kit was not modulated by 
exercise training in right and left ventricles.  
 
Conclusion: Our results show that lifelong moderate aerobic exercise training enhances 
the right ventricle mitochondrial ability to produce ATP and so meet the energetic 
demands imposed by exercise, resulting in improved cardiac function.  
 
Keywords: cardiac adaptation, hemodynamics, metabolism, mitochondria, oxidative 
stress, treadmill exercise 
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Introduction 
Endurance exercise training is widely recognized to induce a unique cardioprotective 
phenotype, making it an useful intervention for the prevention and treatment of 
cardiovascular diseases [1]. Cardiac hypertrophy is one of the major adaptations promoted 
by aerobic exercise, which confers mechanical advantages as it normalizes wall stress, 
decreases oxygen consumption and increases work capacity [1]. Cross-sectional cardiac 
magnetic resonance imaging (cMRI) studies have consistently reported an increase in 
cardiac mass and volumes of both ventricles in endurance trained athletes compared to age 
and sex-matched sedentary subjects [2, 3]. Increase in cardiomyocyte length and width are 
considered the greater contributors to this physiologic cardiac growth but recent findings 
also support a role for the generation of new cardiomyocytes [4].  
Exercise-induced intrinsic changes in the LV have been well characterized, but data 
depicting the changes that occur in the RV following aerobic exercise training is scarcer. 
This is very important as there is growing body of evidence showing that adaptations of the 
RV do not always match those observed in the LV [5]. Indeed, for the same cardiac output, 
the RV has to deal with higher load and stroke work during endurance exercise as the 
pulmonary vascular bed can only reduce its resistance by 30–50% during exercise as 
compared with greater reductions in systemic vascular resistance (>75%). Moreover, RV 
wall stress at peak exercise intensities rises by 170% compared to rest, with only a 23% 
increase in the LV wall stress (reviewed by [5]). The greater hemodynamic overload 
imposed to the RV may justify distinct ventricular adaptations to exercise in the long term. 
In this sense, one year of endurance exercise training in previously untrained individuals 
was shown to result in a more pronounced increase in RV mass and volume than in the LV, 
paralleled with improved function [2]. Strenuous exercise was also associated with RV 
structural, electrical and functional changes that were related with pro-arrhythmogenic 
remodeling in some athletes [5, 6]. Evidence from animal studies further strengthens the 
notion that exercise differently impacts RV and LV by showing that long-term endurance 
exercise resulted in the development of myocardial fibrosis, myocardial stiffness and 
diastolic dysfunction in the RV, but not in LV [7, 8].  
Thus, while it is becoming clear that the structural and functional adaptations that occur in 
the RV following endurance exercise training may not parallel those observed in the LV, it 
is important to clarify exercise-related RV remodeling. So, the purpose of the present work 
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was to add new insights on the functional, structural and biochemical changes induced by 
lifelong aerobic exercise training of moderate intensity on RV using an animal model.  
 
Material and Methods  
Animals and experimental design 
Housing and experimental treatment were in accordance with the Guide for the Care and 
Use of Laboratory Animals from the Institute for Laboratory Animal Research (ILAR, 
2011). The experiments were approved by the local Ethics Committee for Animal 
Experimentation (licence number 008961) and performed in accordance to European 
Parliament Directive 2010/63/EU. Twenty female Sprague-Dawley rats (age: 5 weeks; 
weight: 130 ± 2.4 g at the beginning of the experiment, provided by Harlan Laboratories 
Models (Barcelona, Spain) were randomly assigned into the following two groups: 
sedentary (SED; n=10; with restricted movement to the cage space) and exercised (EX; 
n=10; submitted to treadmill exercise training). All animals were maintained in a 
controlled environment at a room temperature of 22 ºC, on a 12:12 h light-dark reverse 
cycle, and with food (standard diet 4RF21®, Mucedola, Italy) and water ad libitum. 
 
Exercise training program 
Animals in the exercise-training group were habituated to treadmill running for 2 weeks. 
During this period the running time and intensity were gradually increased until the 
animals were running 60 min/day at 20 m/min. After the habituation period, EX animals 
ran 5 days/week for 60 min/day at 20 m/min (~50% of VO2 max) [9] for 54 weeks. All EX 
animals completed the training program. 
 
Experimental preparations for hemodynamic evaluation 
Twenty-four hours after the end of the exercise training protocol, all animals were 
anesthetized by inhalation with a mixture of 4% sevoflurane with oxygen and placed over a 
heating pad, to maintain the body temperature at 37 ºC. Animals were tracheostomized for 
mechanical ventilation with oxygen-enriched air (60 cpm, tidal volume set at 1 ml/100 g, 
model 683: TOPO, Kent Scientific, Torrington, USA). The right jugular vein was 
cannulated under binocular surgical microscopy (Wild M651.MS-D; Leica, Herbugg, 
Switzerland) for administration of prewarmed 0.9% NaCl solution in order to balance the 
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perioperative fluid losses. The heart was exposed by a median sternotomy and the 
pericardium was extensively opened. Lastly, two-conductance catheters (SPR-324; Millar 
Instruments, Houston, USA) were positioned on the LV and RV to assess cardiac 
performance in baseline conditions. The animals were allowed to stabilize for 15 min 
before the collection of the hemodynamic data. 
 
Hemodynamic measurements 
Hemodynamic data collection was performed as previously described in detail [10]. 
Parameters were recorded and on-line converted to a digital data with a sample frequency 
of 1,000 Hz. Hemodynamic parameters included: Peak systolic pressure (Pmax), end-
diastolic (EDP) and end-systolic (ESP) pressure, peak rate of pressure rise (dP/dtmax) and 
peak rate of pressure decay (dP/dtmin). The tau (time constant of relaxation rate) was 
estimated by fitting the isovolumetric pressure fall to a monoexponential function. All 
animals completed the experimental protocol. Data were stored and analyzed with Millar 
conductance data acquisition and analysis software (PVAN3.5). 
 
Tissue collection 
After completing the acquisition of the hemodynamic data, all animals were sacrificed 
through exsanguination. The heart and lungs were excised and weighted. Under binocular 
magnification (×3.5) the LV free wall and RV free wall were dissected and weighted 
independently. Heart weight, LV and RV were normalized to tibia length. The left 
gastrocnemius was also removed and weighted. Samples from lungs, LV and RV from all 
animals were collected and fixed in a solution of 4% (v/v) buffered paraformaldehyde for 
latter histological analysis. Also, samples of LV and RV from all animals were collected 
for biochemical analysis. 
 
Histologic and immunohistochemical analysis  
Cubic pieces from cardiac muscle (RV and LV) and right lung were fixed [4% (v/v) 
buffered paraformaldehyde] by diffusion for 24 h and subsequently dehydrated with 
graded ethanol and included in paraffin blocks. Serial sections (5 μm of thickness) of 
paraffin blocks were cut by using a microtome and mounted on silane-coated slides. The 
slides were dewaxed in xylene and hydrated through graded alcohols finishing in 
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phosphate buffered saline solution. Deparaffinized sections of heart were stained for 
hematoxylin-eosin or Sirius Red for the analysis of cross sectional area and fibrosis, and 
sections of the lungs were stained with hematoxylin-eosin for the analysis of medial 
hypertrophy of pulmonary artery, as previously described by us [11]. Additional 
deparaffinized sections of cardiac tissue were prepared for immunohistochemical staining 
of connexin-43 (ab11370; Abcam, Cambridge, UK) and c-kit (sc-168; Santa Cruz, 
Heidelberg, Germany), as previously described by us [12].  
 
Analysis of myosin heavy chain (MHC) isoform content 
Right and left ventricle sections were weighted and homogenized (in the proportion of 
1:19) in 100 mM phosphate buffer, pH 7.4, containing 0.02% bovine serum albumin 
(BSA), with a tightly fitted Potter-Elvehjem homogenizer and Teflon pestle at 0-4 °C. 
Total protein concentration was spectrophotometrically assayed with the DC method (Bio-
Rad, California, USA). MHC isoforms content was evaluated as previously described [13]. 
 
Right and left ventricle muscle preparation for biochemical analysis 
A portion (~10 mg) of right and left ventricle muscle was homogenized in 100 mM 
phosphate buffer, pH 7.4, supplemented with protease inhibitor, using a Teflon pestle on a 
motor-driven Potter-Elvehjem glass homogenizer at 0-4 ºC (3-5 times for 5 s at low speed, 
with a final burst at a higher speed). The protein content of the cardiac muscle 
homogenates was assayed with the Bio-Rad DC method, following the instructions of the 
manufacturer, using BSA as a standard. 
 
Citrate synthase activity 
Citrate synthase activity was measured in RV and LV homogenates using the method 
described by Coore et al. [14]. In brief, the CoASH released from the reaction of acetyl-
CoA with oxaloacetate was measured by its reaction with 5, 5’-dithiobis-(2-nitrobenzoic 
acid) (DTNB) at 412 nm (molar extinction coefficient of 13.6 mM
-1
cm
-1
). 
 
Isolation of mitochondria from cardiac muscle 
Mitochondria isolation was performed as previously described [15]. In brief, samples from 
both ventricles were minced in an ice-cold isolation medium containing 250 mM sucrose, 
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0.5 mM EGTA, 10 mM HEPES-KOH (pH 7.4) and 0.1% defatted BSA. The minced 
blood-free tissue was resuspended in isolation medium containing subtilopeptidase A type 
VIII (1 mg/g tissue) and homogenized. The homogenate was centrifuged at 14,500g for 10 
min, and the pellet was gently resuspended in isolation medium. The suspension was 
centrifuged (750g, 10 min) and the resulting supernatant was centrifuged again (12,000g, 
10 min). The new pellet was resuspended and re-pelleted (12,000g, 10 min) in isolation 
medium minus the BSA. Finally, the pellet, containing the mitochondrial fraction, was 
resuspended in a medium containing 250 mM sucrose, 10 mM HEPES-KOH, pH 7.4. 
Phosphatase and protease inhibitors were added and all the procedures were performed at 4 
ºC. The protein content was assayed with the Bio-Rad DC assay using BSA as a standard. 
ATP synthase activity was evaluated in mitochondrial extracts as previously described 
[16]. 
 
Immunoblotting analysis 
Equivalent amounts of right and left ventricles protein or mitochondrial protein were 
electrophoresed on a 12.5% SDS-PAGE as described by Laemmli [17]. Gels were blotted 
onto nitrocellulose membranes (Whatman®, Protan®, Merck, Darmstadt, Germany) in 
transfer buffer (25 mM Tris, 192 mM glycine, pH 8.3 and 20% methanol) for 2 h (200 
mA). Then, nonspecific binding was blocked with 5% (w/v) nonfat dry milk in TBS-T 
(100 mM Tris, 1.5 mM NaCl, pH 8.0 and 0.5% Tween 20). Membranes were incubated 
with primary antibody solution diluted 1:1000 in 5% (w/v) nonfat dry milk in TBS-T 
(mouse anti-ATP synthase subunit beta, ab14730, Abcam; rabbit anti-GAPDH, ab9485, 
Abcam; rabbit anti-ETFDH, ab91508, Abcam; mouse anti-MnSOD, ALX-804-265-C100, 
Alexis, Farmingdale, New York.; rabbit anti-PGC1 alpha, ab54481, Abcam; rabbit anti-
mtTFA, sc-28200, Santa Cruz; mouse anti-total OXPHOS, ab110413, Abcam; rabbit anti-
c-kit, sc-168, Santa Cruz; rabbit anti-connexin-43, ab63851, Abcam; rabbit anti-SIRT3, 
#2627, Cell Signalling, Massachusetts, USA; rabbit anti-RAF1, ab32025, Abcam). After a 
2 h incubation at room temperature with agitation, membranes were washed with TBS-T 
and incubated, with agitation, with anti-mouse or anti-rabbit IgG peroxidase secondary 
antibody (Merck) diluted 1:1000 in 5% (w/v) nonfat dry milk in TBS-T.  
For the protein carbonyl derivative assay, a given volume (V) of the sample containing 
20 μg of protein was derivatized with 2,4-dinitrophenylhydrazine (DNPH). Briefly, the 
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sample was mixed with 1 V of 12% SDS, 2 V of 2 mM DNPH/10% trifluoroacetic acid, 
followed by 30 min of incubation in the dark, after which 1.5 V of 2 M Tris-base/18.3% of 
β-mercaptoethanol was added for neutralization. After diluting the derivatized proteins in 
TBS to obtain a final concentration of 0.001 μg/μL, a 100 μL volume was slot-blotted into 
a nitrocellulose membrane. For 3-nitrotyrosine expression, 30 μg of protein from RV and 
LV samples were diluted in TBS to obtain a final protein concentration of 0.001 μg/μL and 
a volume of 100 μL was slot-blotted into a nitrocellulose membrane. The slot-blot 
membranes were processed as above using anti-3-nitrotyrosine (MAB 5404, EMD 
Millipore, Merck, Darmstadt, Germany) or anti-DNP (MAB 2223, EMD Millipore) 
primary antibodies diluted 1:1000 in 5% w/v nonfat dry milk in TBS-T. 
Immunoreactive bands were detected with enhanced chemiluminescence reagents (ECL, 
Amersham Pharmacia Biotech, Uppsala, Sweden) according to the manufacturer’s 
procedure and images were recorded using X-ray films (Amersham Hyperfilm ECL, GE 
Healthcare). The films were scanned in Molecular Imager Gel Doc XR+System (Bio-Rad) 
and analyzed with Image Lab software (v4.1, Bio-Rad). Protein loading was controlled by 
Ponceau S staining once the expression of structural proteins as actin or tubulin was 
previously noticed to change with exercise training. 
 
Statistical analysis 
Values are given as mean ± standard deviation for all variables. Kolmogorov-Smirnov test 
was performed to check the normality of the data. When variables were normally 
distributed, significant differences between the groups were evaluated using an unpaired t-
test (data sets with 2 variables) or a two-way analysis of variance (data sets with 4 
variables) followed by the Bonferroni post hoc test. Kruskal-Wallis test followed by 
Dunn’s Multiple Comparison Test was used for non-parametric variables (histological 
data). Results were considered significantly different when P<0.05. Statistical analysis was 
performed with Graph Pad Prism software, version 5.0. 
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Results 
Impact of lifelong exercise training on morphometric parameters and cardiac 
hemodynamics 
Fifty-four weeks of endurance exercise training resulted in a significant increase of body 
weight (P<0.05), gastrocnemius mass (P<0.001) and a decrease in RV weight and RV/tibia 
ratio (P<0.01; Table 1). No significant alterations were observed for lungs mass, 
lungs/tibia, heart weight, LV weight, heart/tibia or LV/tibia length. 
 
Table 1 – Morphometric characterization. 
 
 Sedentary Exercise 
Body weight (Kg) 0.291 ± 0.031 0.323 ± 0.036* 
Gastrocnemius mass (g) 1.988 ± 0.120 2.230 ± 0.170*** 
Lungs mass (g) 1.946 ± 0.287 1.931 ± 0.356 
Lungs/tibia 0.501 ± 0.076 0.472 ± 0.101 
Heart mass (g) 1.051 ± 0.121 1.041 ± 0.120 
Heart/tibia 0.271 ± 0.030 0.264 ± 0.035 
Left ventricle (g) 0.572 ± 0.084 0.600 ± 0.109 
Left ventricle/tibia 0.147 ± 0.020 0.145 ± 0.030 
Right ventricle (g) 0.225 ± 0.068 0.170 ± 0.017** 
Right ventricle/tibia 0.058 ± 0.016 0.043 ± 0.004** 
Values are presented as mean ± standard deviation (n=10 per group). * P<0.05 vs. SED; ** P<0.01 vs. SED; 
*** P<0.001 vs. SED. 
 
Hemodynamic RV and LV profile at baseline conditions is presented in Table 2. Long-
term exercise training resulted in a significant decrease in resting heart rate (P<0.05). In 
comparison to the SED group, EX group had higher LV Pmax (P<0.01), ESP (P<0.01) and 
lower EDP (P<0.05). No significant alterations were detected in the remaining LV 
hemodynamic parameters between SED and EX.  
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Table 2 – Hemodynamic evaluation at basal conditions. 
 
 Sedentary Exercise 
HR (bpm) 313.10 ± 28.42 292.20 ± 17.83* 
 RV LV RV LV 
Pmax (mmHg) 32.48 ± 3.79 146.50 ± 16.92### 26.93 ± 1.43 160.40 ± 12.48**+++ 
Pmin (mmHg) 0.22 ± 0.04 1.83 ± 1.72# 0.25 ± 0.14 1.76 ± 1.59+ 
ESP (mmHg) 31.61 ± 4.56 143.00 ± 15.87### 25.75 ± 2.11 157.90 ± 12.06**+++ 
EDP (mmHg) 5.18 ± 0.73 8.74 ± 4.36# 4.13 ± 1.56 5.80 ± 1.97* 
dP/dtmax (mmHg/s) 1999.00 ± 118.70 9658.00 ± 1706.00### 1928.00 ± 224.00 9768.00 ± 764.80+++ 
dP/dtmin (mmHg/s) -1654.00 ± 391.30 -10550.00 ± 1950.00### -1211.00 ± 265.80 -11070.00 ± 376.70+++ 
Tau (ms) 11.62 ± 4.66 11.59 ± 1.39 11.53 ± 3.10 11.55 ± 0.95 
LV: left ventricle, RV: right ventricle, HR: heart rate, Pmax: maximum pressure, Pmin: minimum pressure, 
ESP: end systolic pressure, EDP: end diastolic pressure, dP/dtmax: maximum rate of pressure elevation, 
dP/dtmin: maximum rate of pressure decay, Tau: isovolumic relaxation constant. Values are presented as 
mean ± standard deviation (n=10 per group). * P<0.05 vs. respective SED group; ** P<0.01 vs. respective 
SED group; # P<0.05 vs. SEDRV; ### P<0.001 vs. SEDRV; + P<0.05 vs. EXRV; +++ P<0.001 vs. EXRV. 
 
Regarding the RV, no significant alterations were detected in the hemodynamic parameters 
between SED and EX. Comparing RV and LV hemodynamics within each condition (i.e., 
SED and EX), Pmax is significantly higher in LV (P<0.001) as well as Pmin (P<0.05), 
ESP (P<0.001), dP/dtmax (P<0.001) and dP/dtmin (P<0.001). 
 
Effect of lifelong exercise training on histological parameters 
Lifelong exercise training resulted in a significant increase of LV cardiomyocyte cross 
sectional area (CSA) when compared to SED animals (P<0.001; Figure 1). 
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Figure 1 – Effect of exercise training on LV and RV cardiomyocyte CSA and fibrosis. LV: left ventricle, 
RV: right ventricle. Values are presented as mean ± standard deviation (n=10 per group). *** P<0.001 vs. 
respective SED group; ### P<0.001 vs. SEDRV; +++ P<0.001 vs. EXRV. 
 
In exercised animals, higher cardiomyocyte CSA were observed in LV compared to RV 
(P<0.001). Exercise training prevented the accumulation of fibrosis in the RV (P<0.001). 
Accumulation of fibrosis was higher in the RV of SED animals (P<0.001 vs. LV). Medial 
hypertrophy of pulmonary artery was also significantly reduced in EX animals in 
comparison to SED (P<0.01; Figure 2). 
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Figure 2 – Effect of exercise training on pulmonary artery hypertrophy. Values are presented as mean ± 
standard deviation (n= 6 per group). ** P<0.01 vs. SED. 
 
To explore if lifelong exercise training has an impact in the cardiac conduction system, we 
determined the levels of connexin-43 (Cx43) and we also performed immunohistological 
analysis to assess its cellular location. No significant alterations of Cx43 content and 
cellular location were observed in both ventricles of trained animals (Figure 3a-b). 
However, the content of Cx43 was significantly higher in LV than in RV of EX animals 
(P<0.05; Figure 3a). 
Moreover, after 54 weeks of endurance training there were no signs of cardiac progenitor 
cells activation in both ventricles given by the expression levels of c-kit (Figure 3c), a 
marker of a major type of cardiac progenitor cells [18]. No differences in the pattern of 
immunostaining were observed among trained and sedentary animals (data not shown). No 
expression differences of c-kit were noticed among ventricles within each group. 
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Figure 3 – Effect of exercise training on connexin-43 content (a) and cell location in LV and RV (b), and on 
c-kit content (c). LV: left ventricle, RV: right ventricle. Values are presented as mean ± standard deviation 
(n=6 per group). + P<0.05 vs. EXRV. 
 
MHC isoform profiling of right and left ventricles 
Figure 4 shows MHC isoforms’ profile of RV and LV muscles from sedentary and 
exercised animals. Two isoforms were observed in the gel, with predominance of alpha-
MHC. Lifelong exercise training had no effect on beta/alpha MHC ratio in both ventricles, 
despite the significant lower levels of this ratio in LV (P<0.05).  
 
 
Figure 4 – Effect of exercise training on MHC isoform ratio in LV and RV.  LV: left ventricle, RV: right 
ventricle. Values are presented as mean ± standard deviation (n=6 per group). # P<0.05 vs. SEDRV; + 
P<0.05 vs. EXRV. 
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Effects of exercise training protocol in cardiac metabolic remodeling 
In order to evaluate the impact of 54 weeks of exercise training on heart metabolism, the 
levels of metabolic enzymes were evaluated by western blotting in RV and LV extracts. 
No changes were noted on the levels of ATP synthase while levels of the glycolytic 
enzyme glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were significantly lower in 
the RV of exercised animals in comparison to sedentary rats (P<0.01 vs. SED; Figure 5a 
and b). The ratio ATP synthase to GAPDH, a rough marker of oxidative metabolism, was 
also increased in RV of exercised animals though without statistical significance (Figure 
5c). As shown in Figure 5d, exercise training did not promote significant alterations in the 
cardiac levels of the subunits NDUFB8 from complex I, SDHB from complex II, 
UQCRC2 from complex III, MTCO1 from complex IV and ATP5A and ATP5B from 
complex V of oxidative phosphorylation (OXPHOS), respectively, in none of the 
ventricles. However, when the content of ATP5B was analyzed in mitochondria isolated 
from cardiac muscle (pool of both ventricles) it was noticed a significant increase of its 
content and of complex V activity in trained animals (P<0.01 vs SED; Figure 5f and 5g). 
These data suggest that despite no alterations in OXPHOS subunits levels in RV and LV, 
exercise increased mitochondrial ability to produce ATP. Moreover, the content of the 
electron transfer flavoprotein:ubiquinone oxidoreductase (ETFDH), which conducts 
electrons from nine different mitochondrial FAD-containing acyl-CoA dehydrogenases of 
fatty acid β-oxidation to the ubiquinone pool of the main respiratory chain [19], was not 
modulated by lifelong exercise training in none of the ventricles (Figure 5e), suggesting no 
alterations in fatty acid oxidation.  
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Figure 5 – Effect of exercise training on the levels of ATP synthase subunit β (a), GAPDH (b), ratio ATP 
synthase to GAPDH (c), OXPHOS subunits (d), ETFDH (e) in RV and LV and on the content of 
mitochondrial ATP synthase subunit β (f) and ATP synthase activity (g). LV: left ventricle, RV: right 
ventricle, OXPHOS: oxidative phosphorylation, GAPDH: glyceraldehyde 3-phosphate dehydrogenase, 
ETFDH: electron transfer flavoprotein:ubiquinone oxidoreductase. Values are presented as mean ± standard 
deviation (n=6 per group). ** P<0.01 vs. respective SED group. 
 
After 54 weeks of endurance training there were no significant differences of citrate 
synthase (CS) activity between RV or LV in SED and EX groups (Figure 6a). CS activity 
has been suggested as a marker of mitochondrial content [20], so data point to no 
alterations in the pool of mitochondria from each ventricle due to lifelong exercise training. 
However, LV presented a significantly higher density of mitochondria than RV (P<0.001 
vs. SEDRV and P<0.01 vs. EXRV). The levels of PGC-1α, a key player in the regulation 
of mitochondria biogenesis [21], were significantly lower in the LV of exercised animals in 
comparison to its RV (P<0.05) and in comparison to the LV of sedentary animals (P<0.01; 
Figure 6b). Differences between RV and LV of exercised animals were more expressive 
when the levels of PGC-1α were normalized to the number of mitochondria given by CS 
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activity (P<0.001; Figure 6c). So, data suggest that mitochondrial biogenesis is decreased 
in exercised LV. A similar trend of PGC-1α levels was noticed for the content of the 
mitochondrial transcription factor mtTFA, which was lower in exercised LV (P<0.05; 
Figure 6d).   
The levels of RAF-1 were measured since this kinase has been implicated in the control of 
mitochondrial ROS and Ca
2+
 [1]. However, no expression differences were noticed among 
trained and sedentary animals in both ventricles (Figure 6f), in opposition to the observed 
in isolated mitochondria (Supplementary Figure S1). 
 
Figure 6 – Effect of exercise training on CS activity (a), PGC-1α content (b), ratio PGC-1α to CS activity 
(c), mtTFA content (d), ratio mtTFA to CS activity (e), RAF-1 content (f) in RV and LV. LV: left ventricle, 
RV: right ventricle, CS: citrate synthase, PGC-1α: peroxisome proliferator-activated receptor-gamma 
coactivator-1 alpha, mtTFA: mitochondrial transcription factor A, RAF-1: RAF proto-oncogene 
serine/threonine-protein kinase. Values are presented as mean ± standard deviation (n=6 per group). * P<0.05 
vs. respective SED group; ** P<0.01 vs. respective SED group; ### P<0.001 vs. SEDRV; + P<0.05 vs. 
EXRV; ++ P<0.01 vs. EXRV; +++ P<0.001 vs. EXRV. 
 
The levels of the deacetylase SIRT3 were determined in LV and RV extracts (Figure 7a-b), 
considering its role in the regulation of mitochondrial metabolic pathways [22]. No 
expression differences were noticed in both ventricles due to lifelong exercise training. 
However, when data was normalized to CS activity, significant differences among 
ventricles were observed. Specifically, higher values were observed for RV compared to 
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LV (P<0.001), and exercise training promoted an increased content of SIRT3 per 
mitochondria in RV (P<0.05; Figure 7b). Data from the analysis of isolated mitochondria 
confirmed this exercise-related increase of SIRT3 levels (Supplementary Figure S1).  
Being a target of SIRT3 [22], it was expected that MnSOD showed an expression profile 
similar to SIRT3. Indeed, in RV from exercised animals there was a significant increase of 
MnSOD content (P<0.05; Figure 7c). Even more pronounced differences were detected 
when data was normalized to CS activity (P<0.001; Figure 7d). Moreover, the amount of 
this antioxidant enzyme per mitochondria was significantly higher in RV than in LV of 
exercised animals (P<0.001; Figure 7d).  
In order to evaluate the impact of 54-weeks of endurance training on oxidative stress, we 
analyzed the content of oxidized proteins. In the RV of trained animals it was observed a 
significant increase of nitrated proteins (P<0.01; Figure 7f). The content of carbonylated 
proteins was also higher in the RV of exercised animals, though not statistically significant 
(Figure 7e). In LV, no alterations in the content of nitrated or carbonylated proteins were 
observed among experimental groups (Figure 7e and 7f).  
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Figure 7 – Effect of exercise training on SIRT3 content (a) and on the ratio SIRT3 to CS activity (b), on 
MnSOD content (c), on the ratio MnSOD to CS activity (d), on carbonylated (e) and nitrated (f) proteins in 
RV and LV. LV: left ventricle, RV: right ventricle, CS: citrate synthase, MnSOD: manganese dependent 
superoxide dismutase, SIRT3: NAD-dependent deacetylase sirtuin-3. Values are presented as mean ± 
standard deviation (n=6 per group). * P<0.05 vs. respective SED group; ** P<0.01 vs. respective SED group; 
*** P<0.001 vs. respective SED group; # P<0.05 vs. SEDRV; ### P<0.001 vs. SEDRV; +++ P<0.001 vs. 
EXRV. 
 
Discussion 
Despite the well-documented benefits of endurance exercise training in promoting health, 
we are still searching for identifying novel molecular mechanisms underlying the long-
term functional and structural changes that occur in the heart. Studies on the effects of 
exercise training have traditionally focused on the LV, despite the fact that overall cardiac 
performance is determined by two pumps in series. Even in healthy individuals, exercise 
imposes a disproportionate load on the RV, which may promote RV dysfunction if exercise 
is sufficiently intense and prolonged [23]. This observation supports the notion that the 
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adaptations of the RV to exercise training are not necessarily similar to those reported for 
LV. To add new insights on this topic, we analyzed RV and LV functional, structural and 
molecular adaptations promoted by one year of endurance exercise training. Rats from EX 
group performed endurance training for 54-weeks, which in humans corresponds to 
approximately 35 years of training [24], one of the longest exercise training programs 
performed in animal models.  
In response to endurance exercise, the heart changes in size, shape, structure and 
physiology. Indeed, exercise training was reported to induce up to a 60% increase in LV 
mass, and up to 17–32% in cardiomyocyte size [4]. In the present study, no variation in the 
LV mass was observed in exercised animals, despite the 10% increase in cardiomyocyte 
size (Table 1 and Figure 1). This can be attributed in part to the maintenance of a low 
running intensity throughout the entire duration of the study as cardiac hypertrophy is 
known to be intensity-dependent [25]. Exercise-induced cardiomyocyte hypertrophy was 
related to significantly augmented systolic pressures, either maximum or at end-systole, 
which indicates a rescue from systolic function decline [26]. Regarding the diastolic 
proprieties, EX animals presented a lower EDP suggesting a less stiff myocardium. 
Because our histological data did not show any difference regarding collagen deposition, 
we believe that these differences could be explained in part by intrinsic changes to the 
cardiomyocytes [27]. In RV, we observed significantly less mass increase in exercised 
animals, which we attribute mainly to the prevention of fibrosis. The similar results of RV 
cardiomyocyte size between SED and EX were intriguing as exercise training was 
expected to cause hypertrophy. Thus, we believe that the RV of SED animals suffered 
some degree of hypertrophy secondary to RV afterload as suggested by a non-significant 
increase of 20% in RV Pmax and a significant increase of 10% in pulmonary artery 
hypertrophy, and exercise was able to prevent it. This interpretation is corroborated by 
clinical data from the general population showing that pulmonary artery pressures also 
increases with age [28]. As in the systemic circulation, the pulmonary vasculature may be 
affected by age-associated arterial remodeling, though in a lower magnitude, leading to 
pulmonary vascular stiffening and increases in pulmonary artery pressures [28-30]. 
Pulmonary artery pressure is also directly affected by downstream left heart filling 
pressures [28] and we observed that sedentary animals had a greater increase in LV EDP. 
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Besides hypertrophy of the pre-existing myocytes, it has been reported that exercise 
training induces the formation of new cardiomyocytes from progenitor/stem cells [18, 31, 
32]. These studies suggest that c-kit positive cardiac stem cells are necessary and sufficient 
for functional cardiac regeneration and repair [18, 32]. Data from the present study do not 
support the activation of c-kit positive cardiac stem cells in response to 54-weeks of 
moderate exercise training (Figure 3), in opposition to the reported for 4 weeks of treadmill 
exercise [32] or 21 days of swimming [18]. These apparent contradictory findings might be 
justified, at least in part, by the aging process. Indeed, the percentage of cardiomyocytes 
emerging from the c-kit positive lineage was reported to astonishingly decrease with aging, 
and so unlikely to impact cardiac function [31]. Another factor could be related to the 
moderate intensity of our exercise training protocol as it was shown that c-kit positive 
cardiac stem cells activation is exercise-intensity dependent [32]. 
Long-term endurance training has been associated with arrhythmogenic cardiac 
remodeling of the RV [6, 33]. In the current study, we observed a significant reduction of 
Cx43 expression in RV of exercised animals in comparison to their LV values. Cx43 is the 
main gap junctional cardiac protein responsible for the rapid conduction of the action 
potential across the heart and its disturbance was implicated in the induction of arrhythmia 
[34, 35]. Moreover, down-regulation of Cx43 expression was previously shown with the 
use of the nonspecific beta-blocker propranolol, indicating that sympathetic tone is 
involved in Cx43 regulation [36]. While we are not able to relate the susceptibility of the 
RV to arrhythmia with Cx43 expression, it could be possible that the lower expression of 
Cx43 is an adaptive response to the increased vagal tone observed in the trained animals. 
The main molecular adaptations of heart to long-term exercise training were seen at the 
metabolic level, mainly in the RV. The oxidative metabolism was increased in the RV of 
trained animals, mainly due to a significant reduction of glycolysis without a significant 
compensation by fatty acid oxidation (Figure 5). So, data from our study do not support the 
metabolic shift towards a reliance on glycolysis, as reported during cardiac hypertrophic 
growth [37, 38]. As a consequence of the metabolic adaptation of RV towards an oxidative 
phenotype, there was an increase of nitrated proteins, possibly due to augmented NO 
levels, and of MnSOD content. Increased generation of NO leads to the formation of 
peroxynitrite, which then reacts with proteins’ tyrosine residues [39].  The up-regulation of 
MnSOD and the increased production of NO associated with eNOS activity have been 
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pointed out as a cardioprotective mechanism induced by exercise training [1, 40]. Even 
when exercise was performed during aging, MnSOD activity was reported to significantly 
increase in heart [41].  
Despite the described effect of exercise training in endorsing mitochondrial biogenesis [1], 
our data do not support this cardiac adaptation. PGC-1α, which plays a key role in 
regulating genes involved in myocardial fuel metabolism and mitochondrial biogenesis 
[42], and the content of mitochondria, roughly assessed by CS activity [43], were not 
significantly modulated by 54-weeks of exercise (Figure 6). However, there is no 
consensus in the literature regarding the impact of exercise training on mitochondrial 
biogenesis in the heart. For instance, 6 weeks of swimming was shown to promote an up-
regulation of mitochondrial biogenesis in heart [38], whereas 3 months of running did not 
impact mitochondrial density in LV [42]. In the regulation of PGC-1α expression, the 
deacetylase activity of SIRT3 has a key role [42]. This deacetylase also regulates the 
activity of several metabolic pathways harbored in mitochondria, namely antioxidant 
enzymes [22], protecting the heart against oxidative stress [44]. Lifelong exercise training 
induced an up-regulation of SIRT3 per mitochondria in RV (Figure 7). Once the 
expression profile of SIRT3 was similar to its target MnSOD, we might speculate that this 
mitochondrial deacetylase has mainly an antioxidant role in trained RV. Altogether, data 
suggest that heart adaptation to lifelong exercise training occurs mainly at the mitochondria 
level, resulting in an increased ability of this organelle to produce ATP (Figure 5) to 
support the cardiomyocytes’ contractile apparatus. The lower mitochondrial density of RV 
compared to LV might explain, at least in part, the greater molecular alterations noticed in 
trained RV that could be considered a beneficial adaptation to meet the greater work 
requirements imposed by exercise [5].  
We believe that a more marked effect of exercise training would be detected if we 
progressively increased the training intensity throughout the entire duration of the training 
period. However, our emphasis was on duration and we clearly show that one year of low 
intensity protocol is able to induce changes at the functional, structural and molecular 
level. Future studies should address the impact of exercise intensity in the aging heart.  
In conclusion, findings from the present study show that lifelong moderate exercise 
training: i) improved the cardiac function, especially diastolic, with no apparent 
involvement of cardiac stem cells; ii) did not modulate the levels of Cx43; iii) increased 
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the antioxidant capacity of RV; iv) had no impact on mitochondrial biogenesis, but 
improved the mitochondrial ability to produce ATP and so meet the energetic demands 
imposed by exercise during the aging process.  
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HMGB1 down-regulation mediates terameprocol vascular anti-proliferative effect in 
experimental pulmonary hypertension 
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Abstract  
Pulmonary arterial hypertension (PAH) is a progressive disease with a poor prognosis. 
Pulmonary artery smooth muscle cells (PASMCs) play a crucial role in PAH 
pathophysiology, displaying a hyperproliferative and apoptotic-resistant phenotype. In the 
present study, we evaluated the potential therapeutic role of terameprocol (TMP), an 
inhibitor of cellular proliferation and promoter of apoptosis, in a well-established pre-
clinical model of PAH induced by monocrotaline (MCT) and studied the biological 
pathways modulated by TMP in PASMCs. Wistar rats injected with MCT or saline 
(SHAM group) were treated with TMP or vehicle. On day 21 after injection, we assessed 
bi-ventricular hemodynamics and cardiac and pulmonary morphometry. The effects of 
TMP on PASMCs were studied in a primary culture isolated from SHAM and MCT-
treated rats, using an iTRAQ-based proteomic approach to investigate the molecular 
pathways modulated by this drug. In vivo, TMP significantly reduced pulmonary and 
cardiac remodeling and improved cardiac function in PAH. In vitro, TMP inhibited 
proliferation and induced apoptosis of PASMCs. A total of 65 proteins were differentially 
expressed in PASMCs from MCT rats treated with TMP, some of which involved in the 
modulation of transforming growth factor beta pathway and DNA transcription. Anti-
proliferative effect of TMP seems to be explained, at least in part, by the down-regulation 
of the transcription factor HMGB1. Our findings support the beneficial role of TMP in 
PAH and suggest that it may be an effective therapeutic option to be considered in the 
clinical management of PAH.  
 
Keywords: monocrotaline, pulmonary arterial hypertension, terameprocol, vascular 
remodeling 
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Introduction 
Vascular remodeling is a central process in the pulmonary arterial hypertension (PAH) 
pathobiology. This process is associated with structural and functional alterations in the 
pulmonary artery wall, leading to muscularization of previously nonmuscular arteries, 
neointima formation, plexiform lesions development, which result in pulmonary artery 
obliteration. Hypertrophy, proliferation, migration and resistance to apoptosis are features 
of medial smooth muscle cells associated to the development of these changes [1-3]. 
Despite the increasing knowledge of PAH pathophysiology, this disease is characterized by 
a late diagnosis and a high mortality rate [4], justifying the urgent need for new and 
effective therapeutic strategies. Currently approved drugs do not revert nor halt the 
progression of the disease, have variable efficiency and frequent systemic side effects. 
Despite some of them exert slight anti-proliferative effects, their main mechanism of action 
is through the re-establishment of the balance between vasoconstrictors and vasodilators 
[5, 6]. Since proliferative vascular remodeling is a main feature in PAH, there is a growing 
interest in targeting proliferative and apoptotic pathways [6-8]. These features are shared 
by cancer cells [9, 10], therefore supporting the potential utility of anticancer agents with 
anti-proliferative and/or pro-apoptotic proprieties in the management of PAH [8]. 
Terameprocol (meso-tetra-O-methyl nordihydroguaiaretic acid, TMP) is reported to block 
cell cycle progression and promote apoptosis by inhibiting the transcription of genes that 
are dependent on the transcription factor Sp1, such as Cdc2 and survivin [11]. Previous 
studies demonstrated that TMP exhibits in vitro and in vivo anti-tumoral activity without 
relevant systemic toxicity [12-16]. Clinical trials are currently being conducted to assess 
the potential of TMP in several cancer types [17-19]. Given its described properties, we 
hypothesized that TMP might also be of value in the management of PAH. So, the present 
work explores the effects of TMP in an experimental model of PAH. We studied the in 
vivo effects of TMP in the monocrotaline (MCT) model and characterized the biological 
processes modulated by this drug in primary cultures of pulmonary artery smooth muscle 
cells (PASMCs). 
 
 
 
 
CHAPTER III. EXPERIMENTAL WORK 
134 
Materials and Methods 
Experimental Design 
Housing and experimental treatment were in accordance with the Guide for the Care and 
Use of Laboratory Animals from the Institute for Laboratory Animal Research (ILAR, NIH 
Pub. No. 85-23, Revised 2011) and with the European Parliament Directive 2010/63/EU. 
Adult male Wistar rats (Charles River Laboratories; Barcelona, Spain) weighting 180–200 
g were housed in a controlled environment under a 12:12 h light-dark cycle at room 
temperature of 22 ºC, with a free supply of food and water. Rats randomly received a 
subcutaneous injection of MCT (60 mg/kg body weight, Sigma-Aldrich) (MCT groups) or 
an equal volume of saline solution (2 mL/kg body weight) (SHAM groups). In the first 
protocol, we treated MCT and SHAM animals with TMP (166 mg/kg body weight, ip, 
Cayman Chemical) or an equal volume of vehicle (DMSO, Sigma-Aldrich) on days 7, 12 
and 17 after MCT/saline injection, thus creating four groups: SHAM+Vehicle, 
SHAM+TMP, MCT+Vehicle, MCT+TMP (n=9-14 rats per group). At day 21 after 
MCT/saline injection, invasive hemodynamic evaluation was performed. In a second 
protocol, rats injected with MCT or saline solution (n=5 rats per group) were sacrificed on 
day 21 in order to isolate and establish a primary culture of PASMCs for in vitro 
evaluation of TMP effects. 
 
Hemodynamic evaluation 
Animals were anesthetized by inhalation of a mixture of sevoflurane (8 % for induction 
and 2.5-3 % for maintenance) and oxygen, endotracheally intubated for mechanical 
ventilation (150 min
-1
, 100 % O2, 14–16 cm H2O inspiratory pressure, with tidal volume 
adjusted to animal weight, and 5 cm H2O end-expiratory pressure; TOPO Small Animal 
Ventilator - Kent Scientific, Dual Mode) and placed over a heating pad. Under binocular 
surgical microscopy (Leica, Wild 384000), the right jugular vein was cannulated for fluid 
administration (prewarmed 0.9 % NaCl solution, 32 mL/kg/h) to compensate for 
perioperative losses. The heart was exposed through a median sternotomy. Conductance 
catheters were placed in the right ventricle (RV) and left ventricle (LV) (PVR-1045 and 
PVR-1035, respectively, Millar Instruments). After complete instrumentation, the animal 
preparation was allowed to stabilize for 15 min. Hemodynamic recordings were made with 
respiration suspended at end-expiration under basal conditions. Data was continuously 
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acquired (MPVS 300, Millar Instruments), digitally recorded at 1000 Hz (ML880 
PowerLab 16/30, Millar TM Instruments), and analyzed (LabChart, ADInstruments, 
RRID:SCR_001620). 
 
Morphometric and histological analysis 
After complete hemodynamic assessment, animals were euthanized by exsanguination 
under anesthesia. The heart, lungs and gastrocnemius muscle were excised and weighted. 
The right tibia was also excised and its length was measured with a millimetric ruler. The 
RV free wall was dissected from the LV + septum (S), under binocular magnification 
(3.5x) and weighted separately. Heart, lungs, RV, and LV + S weights were normalized to 
body weight (BW) and gastrocnemius weight was normalized to tibial length. RV weight 
was also normalized to that of LV+S. For histological analysis, RV and lung samples were 
immersion fixed in 4 % paraformaldehyde and embedded in paraffin. Sections 4 μm thick 
were cut and stained with hematoxylin and eosin. RV free wall specimens were obtained 
from each heart at midway between the apex and base. Studied samples were observed at 
microscope, photographed with a digital camera and measured with a digital image 
analyzer (cell^B life science basic imaging software, Olympus). All the measurements 
were made directly at 400x magnification and only round to ovoid nucleated myocytes 
were considered for analysis. RV samples were divided into five sections and the area of 
fifty cardiomyocytes per sample was measured and averaged. On the pulmonary 
specimens, external diameter and medial wall thickness in small muscular arteries 
(diameter < 50 μm, 12-18 arteries/lung) were analyzed at 400x magnification. Orthogonal 
intercepts were used to generate eight random measurements of external diameter (distance 
between the external lamina) and sixteen random measurements of medial thickness 
(distance between the internal and external lamina). For each artery, medial hypertrophy 
was expressed as follows: %wall thickness = [(medial thickness x 2)/(external diameter)] x 
100. 
 
Isolation and primary culture of PASMCs 
A primary culture of PASMCs was established using an enzymatic dissociation process 
adapted from a previously described protocol [20]. Animals were euthanized with an 
intraperitoneal injection of pentobarbital (120 mg/kg body weight). The left upper lung 
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lobe was removed and placed in a calcium enriched Hank’s Buffered Salt Solution (HBSS, 
Invitrogen) (5.4 mM KCl, 137 mM NaCl, 0.44 mM KH2PO4, 4.2 mM NaHCO3, 0.25 mM 
NaH2PO4, 1 mM D-glucose, 0.2 mM phenol red, 2 mM CaCl2 and 1 mM MgCl2). First 
order intrapulmonary artery was dissected free of connective tissue under a 
stereomicroscope (Leica EZ4). After extraction from the lung, the adventitia was removed, 
the vessel was opened longitudinally and endothelium was removed by gently rubbing the 
inner surface with forceps tips. In order to release smooth muscle cells, the artery, mainly 
consisting of medial layer, was submitted to an enzymatic dissociation process with papain 
(Sigma-Aldrich) and collagenase type 1 (Worthington Biochemical Corp.), in a calcium-
poor HBSS solution (25 μM CaCl2 and 1 mg/mL BSA). Next, a mechanical dissociation 
process was performed with a fire polished, silicone coated glass pipette, in order to release 
the cells. The cell-free tissue was removed and the solution was centrifuged (250 g, 5 min, 
room temperature) in order to pellet the cells. Finally, cells were seeded in DMEM culture 
medium (PAN Biotech), supplemented with 1 % penicillin-streptomycin-amphotericin B 
(Invitrogen), 1 % sodium pyruvate (Sigma-Aldrich) and 1 % nonessential aminoacids 
(Sigma-Aldrich) containing 10 % FBS (fetal bovine serum, Sigma-Aldrich), in a 24-well 
culture plate (500 μL/well) and placed in an incubator (37 ºC, 5 % CO2). The medium was 
changed after 24 h and then every 48 h. Cell passage was performed when approximately 
80 % confluence was achieved and they were then detached with trypsin (PAN Biotech), 
passaged and cultured continuously. Cells between passages 2 and 4 were used for all 
experiments. Smooth muscle origin was confirmed by typical morphology (fusiform shape 
with hills and valleys) and detection of smooth muscle α-actin expression by 
immunocytochemistry (data not shown). 
 
Cell proliferation assay 
The effect of TMP in cell proliferation was evaluated using the 5’-bromodeoxyuridine 
(BrdU) immunoassay (Roche Diagnostics). BrdU is a thymidine analogue and its 
incorporation in the DNA is a measure of cell proliferation. For BrdU assay, cells were 
seeded in 24-well plates at a density of 1.5x10
4
 cells⁄mL. After 72 h, medium was removed 
and cells were incubated with different concentrations of TMP prepared in DMSO (0 μM, 
0.1 μM, 1 μM, 10 μM and 20 μM) for 24 h in medium without FBS. The BrdU assay was 
conducted following the 24 h incubation with TMP/vehicle. All protocol was followed 
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according to manufacturer’s instructions. Each condition (concentration) was tested in 
triplicate and in cells from three animals per group. 
 
Apoptosis assay 
For apoptosis evaluation, we performed the TUNEL (TdT-mediated dUTP Nick End 
Labelling) assay using the In Situ Cell Death Detection kit (Roche Diagnostics), according 
to the manufacturer’s instructions. For TUNEL assay, cells were seeded in 24-well plates, 
with glass coverslips, at a density of 1.5x10
4 
cells/mL. After 72 h, medium was removed 
and cells were incubated with different concentrations of TMP prepared in DMSO (0 μM, 
0.1 μM, 1 μM, 10 μM and 20 μM) for 24 h in medium without FBS. After 24 h incubation 
with TMP/vehicle, cells were stained with TUNEL and DAPI (4’,6-diamidino-2-
phenylindole, Roche Diagnostics). The percentage of apoptotic cells was calculated by 
dividing the number of cells stained with TUNEL (apoptotic cells) by the total number of 
nuclei stained with DAPI, in at least 10 different fields at 200x magnification. Each 
condition (concentration) was tested in triplicate and in cells from three animals per group. 
 
Preparation of protein extracts and peptide labelling with iTRAQ 
For iTRAQ (Isobaric tags for relative and absolute quantification) analysis, cells were 
seeded in 6-well plates at a concentration of 1.5x10
4 
cells⁄mL. Medium was changed after 
24 h and after 48 h cells were incubated for 24 h in medium without FBS, containing TMP 
10 μM or DMSO (CONT). This TMP concentration was chosen based on data from 
proliferative and apoptotic assays. Indeed, at this concentration, the proliferation of 
PASMCs was significantly inhibited whereas signs of apoptosis were not evident. So, a 
sufficient number of cells was obtained for proteomics at an effective anti-proliferative 
concentration of TMP. The medium was removed from the culture plates and after a wash 
in ice cold 1x PBS, cells were lysed in 1x RIPA buffer (50 mM Tris-HCl, pH 7.4, 150 mM 
NaCl, 0.25 % sodium deoxycholate, 1 % NP-40, 1 mM EDTA) supplemented with 
Phosphatase Inhibitor Cocktail (Sigma-Aldrich) and protease inhibitor (200 mM PMSF) 
and detached from the plates using cell scrapers. Samples were vortexed (5 min), sonicated 
and then centrifuged (12000 g, 5 min, 4 ºC). The supernatant was collected and the protein 
content of the cell homogenate was assayed with the RC-DC method (Bio-Rad), following 
the instructions of the manufacturer, using bovine serum albumin (BSA) as standard. 
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Two independent assays were performed, one for SHAM cells and other for MCT cells, 
using three animals per group. An in-solution digestion was performed for iTRAQ 
labelling, as previously described [21]. Brieﬂy, 100 μg of protein was precipitated with 9 
volumes of cold acetone at -20 ºC for 3 h. After samples centrifugation (20000 g, 30 min, 4 
ºC) and acetone removal, pellets were resuspended with 0.1 M TEAB (triethylammonium 
bicarbonate buffer, Sigma-Aldrich), pH 8.5 and 2 % SDS to achieve a final concentration 
of 0.05 %. Samples were then reduced with 50 mM TCEP (tris(2-carboxyethyl)phosphine, 
Sigma-Aldrich) for 1 h at 60 ºC with agitation. Then, samples were alkylated with 10 mM 
MMTS (S-methyl methanethiosulfonate, Sigma-Aldrich) for 10 min at room temperature 
with agitation. Trypsin was added to each sample and the digestion was performed for 18 h 
at 37 ºC. Digested sample peptides were subsequently labelled with the iTRAQ® reagent 
8-plex (ABSciex) following the protocol provided by the manufacturer. Briefly, labels 
were reconstituted in 60 % isopropanol, added to each sample peptides and incubated for 2 
h at room temperature with agitation. Labelled samples were then combined and dried in a 
SpeedVac. Then, labelled peptides were separated by a multidimensional LC approach, as 
described by Carvalhais et al. [21]. Sample loading was performed at 200 µL/min with 
buffers (A) 2 % ammonium hydroxide and 0.014 % formic acid in water, pH 10 and (B) 2 
% ammonium hydroxide and 90 % ACN (acetonitrile) in water, pH 10. After 5 min of 
sample loading and washing, peptide fractionation was performed with linear gradient to 
70 % B over 85 min. Sixty fractions were collected, dried in a SpeedVac and resuspended 
in 5 % ACN and 0.1 % TFA (trifluoroacetic acid). Collected fractions were then separated 
by LC. Brieﬂy, peptides loaded onto a C18 pre-column (5-mm particle size, 5 mm; 
Dionex) connected to an RP column PepMap100 C18 (150 mm x 75-mm i.d., 3-mm 
particle size). The ﬂow rate was set at 300 nL/min. The mobile phases A and B were 2 % 
ACN and 0.05 % TFA in water, and 90 % ACN with 0.045 % TFA in water, respectively. 
The gradient started at 10 min and ramped to 60 % B till 50 min and 100 % B at 55 min 
and retained at 100 % B till 65 min. The separation was monitored at 214 nm using a UV 
detector (Dionex/LC Packings). Using the micro-collector Probot (Dionex/LC Packings) 
and, after a lag time of 5 min, peptides eluting from the capillary column were mixed with 
a continuous ﬂow of α-CHCA matrix solution (in internal standard Glu-Fib) and were 
directly deposited onto the LC-MALDI plates. The spectra were generated and processed 
with 4800 MALDI-TOF/TOF. Protein identification based on MS/MS data were 
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performed with ProteinPilot
TM
 software (v.4.04, ABSciex) using Paragon search method. 
SwissProt from Rattus norvegicus (release date October 21, 2014) was used as protein 
database. Default search parameters used were as follows: trypsin as the digestion enzyme 
with 2 missed cleavages, 40-ppm tolerance, carbamidomethyl modification on cysteine 
residue, iTRAQ 8-plex modification of N-terminal and lysine peptide residues as fixed 
modification. Additionally, biological modiﬁcations with emphasis on methionine 
oxidation, deamidation and iTRAQ 8-plex modification of tyrosine residue and 
deamidation were considered variable modiﬁcations. Bias correction was applied, and 
proteins were identified with an unused ProtScore>1.3 with at least one peptide at a 
confidence level of 95 %. Proteins identified with one peptide were manually validated 
when MS/MS spectra presented at least 5 successive amino acids covered by b or y 
fragmentations. Only proteins identified with a minimum of 2 peptides at a confidence 
level of 95 % were included in the quantification. The quantification results were reviewed 
manually for all proteins found to be differentially expressed (p<0.05). 
 
Immunohistochemical analysis  
Cubic pieces from lung tissue were fixed [4 % (v/v) buffered paraformaldehyde] by 
diffusion during 24 h and subsequently dehydrated with graded ethanol and included in 
paraffin blocks. Serial sections (5 μm of thickness) of paraffin blocks were cut by a 
microtome and mounted on silane-coated slides. The slides were dewaxed in xylene and 
hydrated through graded alcohols finishing in PBS solution. Deparaffinized sections of 
lung tissue were stained for immunohistochemical staining of rabbit anti-HMGB1 (1:400 
dilution; Abcam, Cat# ab79823, RRID:AB_1603373), using the secondary antibody goat 
biotinylated anti-rabbit (1:200 dilution; Vector Laboratories, Cat# BA-1000, 
RRID:AB_2313606) and counterstained with hematoxylin-eosin, as previously described 
[22].  
 
Western blotting analysis  
Equivalent amounts of PASMC protein from each experimental group were 
electrophoresed on a 15 % SDS-PAGE as described by Laemmli [23]. Gels were blotted 
onto nitrocellulose membranes (Whatman®, Protan®) in transfer buffer (25 mM Tris, 192 
mM glycine, pH 8.3 and 20 % methanol) for 2 h (200 mA). Then, nonspecific binding was 
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blocked with 5 % (w/v) nonfat dry milk in TBS-T (100 mM Tris, 1.5 mM NaCl, pH 8.0 
and 0.5 % Tween 20). Membranes were incubated with primary antibody solution diluted 
1:10000 in 5 % (w/v) nonfat dry milk in TBS-T (rabbit anti-HMGB1, ab79823, Abcam). 
After 2 h incubation at room temperature with agitation, membranes were washed with 
TBS-T and incubated, with agitation, with anti-rabbit IgG peroxidase secondary antibody 
(Amersham, GE Healthcare) diluted 1:1000 in 5 % (w/v) nonfat dry milk in TBS-T. 
Immunoreactive bands were detected with enhanced chemiluminescence reagents (ECL, 
Amersham Pharmacia Biotech) according to the manufacturer’s procedure and images 
were recorded using X-ray films (Amersham Hyperfilm ECL, GE Healthcare). The films 
were scanned in Molecular Imager Gel Doc XR+System (Bio-Rad) and analyzed with 
Image Lab software (v4.1, Bio-Rad). Protein loading was confirmed by staining the 
membranes with Ponceau S and immunoblotting with a mouse anti-alpha tubulin antibody 
(ab7291, Abcam, Cat# ab7291, RRID:AB_2241126). 
 
Statistical analysis 
Statistical analysis was performed using Prism GraphPad v6 software 
(RRID:SCR_002798). Group data are presented as means ± SE (standard error) and were 
compared using an unpaired t-test (data sets with 2 variables) or a two-way ANOVA (data 
sets with 4 variables). When the normality test failed, the two-way ANOVA was preceded 
by a logarithmic transform to obtain a normal distribution. When treatments were 
significantly different, the Holm-Sidak test was selected to perform pairwise multiple 
comparisons. Statistical significance was set at p<0.05. 
 
Results 
Effects of terameprocol on cardiac hemodynamics 
The effects of TMP treatment in hemodynamics are summarized in table 1. Compared to 
the SHAM group, animals from the MCT+Vehicle group presented increased RV peak 
systolic pressure, dP/dtmax and absolute value of dP/dtmin, as well as a significant reduction 
in RV stroke volume, ejection fraction and cardiac output. 
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Table 1 – Hemodynamic effects of terameprocol. 
 
SHAM+Vehicle SHAM+TMP MCT+Vehicle MCT+TMP 
RV function 
HR (bpm) 381 ± 12 377 ± 12 365 ± 8 393 ± 10 
Stroke volume (μL) 154 ± 9 151 ± 7 71 ± 18 * 134 ± 15 ‡ 
Output (mL/min) 59 ± 4 57 ± 4 26 ± 6
 *
 52 ± 5
 ‡
 
EF (%) 65 ± 6 70 ± 4 29 ± 7
 *
 71 ± 5
 ‡
 
PSP (mmHg) 26.1 ± 0.7 26.4 ± 0.7 58.2 ± 8.9
 *
 35.2 ± 1.9
 ‡
 
dP/dtmax (mmHg/s) 1419 ± 56 1567 ± 81 2979 ± 365
 *
 2107 ± 83
 ‡
 
EDP (mmHg) 4.5 ± 0.8 4.7 ± 0.7 5.1 ± 0.9 4.2 ± 0.7 
dP/dtmin (mmHg/s) -1316 ± 152 -1217 ± 71 -2747 ± 212
 *
 -2000 ± 97
 ‡. †
 
LV function 
HR (bpm) 378 ± 15 383 ± 17 367 ± 8 392 ± 10 
Stroke volume (μL) 243 ± 25 212 ± 18 131 ± 16 * 177 ± 23 
Output (mL/min) 92 ± 8 81 ± 6 48 ± 6
 *
 69 ± 8 
EF (%) 74 ± 4 73 ± 4 71 ± 3 69 ± 4 
PSP (mmHg) 88.4 ± 6.0 98.1 ± 1.5 94.9 ± 4.9 94.4 ± 4.0 
dP/dtmax (mmHg/s) 5582 ± 461 6871 ± 293 5724 ± 218 6047 ± 428 
EDP (mmHg) 5.4 ± 1.5 4.4 ± 1.3 4.5 ± 0.7 6.6 ± 1.9 
dP/dtmin (mmHg/s) -6040 ± 828 -7691 ± 501 -5242 ± 458 -6831 ± 392 
SHAM+Vehicle, saline-injected, vehicle-treated group; SHAM+TMP, saline-injected, terameprocol-treated 
group; MCT+Vehicle, monocrotaline-injected, vehicle-treated group; MCT+TMP, monocrotaline-injected, 
terameprocol-treated group; RV, right ventricle; LV, left ventricle; HR, heart rate; EF, ejection fraction; PSP, 
peak systolic pressure; dP/dtmax, peak rate of pressure rise; EDP, end-diastolic pressure; dP/dtmin, peak rate of 
pressure fall. Data are presented as mean ± SE. *p < 0.05 vs SHAM+Vehicle; †p < 0.05 vs SHAM+TMP; ‡p 
< 0.05 vs MCT+Vehicle. 
 
TMP treatment improved cardiac function in MCT-induced PAH, normalizing RV peak 
systolic pressure, dP/dtmax, RV ejection fraction, stroke volume and cardiac output and 
attenuating the increase in the absolute value of dP/dtmin. Regarding LV, we found 
significant reduction in stroke volume and cardiac output in MCT+Vehicle, while these 
changes were prevented in MCT+TMP group. 
 
Effects of terameprocol on morphometric and histological characteristics 
MCT-induced RV hypertrophy was normalized by TMP treatment, as shown by 
RV/(LV+S) and RV cardiomyocyte cross-sectional area (Table 2 and Figure 1). 
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Table 2 – Morphometric effects of terameprocol. 
 
SHAM+Vehicle SHAM+TMP MCT+Vehicle MCT+TMP 
BW (g) 295 ± 8 265 ± 8 
*
 254 ± 7 
*
 247 ± 6 
HW/BW (g/Kg) 2.89 ± 0.05 2.68 ± 0.08 3.59 ± 0.24 
*
 2.92 ± 0.11 
‡
 
RV/(LV+S) (g/g) 0.30 ± 0.01 0.31 ± 0.02 0.49 ± 0.03 
*
 0.35 ± 0.02 
‡
 
RV/BW (g/Kg) 0.57 ± 0.02 0.59 ± 0.04 0.94 ± 0.09 
*
 0.68 ± 0.04 
‡
 
(LV+S)/BW (g/Kg) 1.33 ± 0.05 1.20 ± 0.05 1.41 ± 0.08 1.31 ± 0.05 
LuW/BW (g/Kg) 4.59 ± 0.30 4.34 ± 0.08 9.56 ± 1.01
 *
 5.88 ± 0.35 
‡
 
GW/tib (g/cm) 0.52 ± 0.01 0.49 ± 0.01 0.50 ± 0.01 0.47 ± 0.01 
SHAM+Vehicle, saline-injected, vehicle-treated group; SHAM+TMP, saline-injected, terameprocol-treated 
group; MCT+Vehicle, monocrotaline-injected, vehicle-treated group; MCT+TMP, monocrotaline-injected, 
terameprocol-treated group; BW, body weight; HW, heart weight; RV, right ventricle weight; LV + S, left 
ventricle plus septum weight; LuW, lung weight; GW, gastrocnemius weight; tib, tibial length. Data are 
presented as mean ± SE. *p < 0.05 vs SHAM+Vehicle; ‡p < 0.05 vs MCT+Vehicle. 
 
In the MCT group, small pulmonary arteries presented significant medial hypertrophy, 
which was significantly reduced by TMP. TMP treatment also normalized the lung/body 
weight ratio. No evidence of hepatic or renal histological damage was found in TMP 
treated animals (data not shown). 
 
 
Figure 1 – Effect of terameprocol on cardiomyocyte cross-sectional area and medial wall thickness of 
pulmonary arteries. A) Histological appearance of small pulmonary arteries (diameter <50 μm), stained with 
hematoxylin and eosin. B) Histological appearance of right ventricular cardiomyocytes, stained with 
hematoxylin and eosin. C) Pulmonary artery medial layer thickness expressed as percentage of wall 
thickness. D) Right ventricular cardiomyocyte cross-sectional area (μm2). RV, right ventricle; SHAM, saline-
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injected groups; MCT, monocrotaline-injected groups; TMP, terameprocol-treated groups; Vehicle, vehicle-
treated groups. Data are presented as mean ± SE. *p < 0.05 vs SHAM+Vehicle; †p < 0.05 vs SHAM+TMP; 
‡p < 0.05 vs MCT+Vehicle.  
 
Effects of terameprocol on pulmonary artery smooth muscle cell proliferation and 
apoptosis 
TMP treatment (10 and 20 μM) significantly inhibited the proliferation of PASMCs from 
SHAM and MCT-injected rats, in a dose dependent manner (Figure 2A). At a 20 μM 
concentration, the inhibitory effects of TMP in the proliferation of cells from the MCT 
group were less marked. TMP treatment (20 μM) induced apoptosis of PASMCs from both 
SHAM and MCT-treated rats (Figure 2B).  
 
 
Figure 2 – Effect of terameprocol in pulmonary artery smooth muscle cell proliferation and apoptosis. A) 
Cell proliferation is expressed as percentage of the absorbance of control (TMP 0 μM) from the same group. 
B) Apoptosis is expressed as percentage of apoptotic cells. TMP, terameprocol; SHAM, saline-injected 
group; MCT, monocrotaline-injected group. Data are presented as mean ± SE. *p < 0.05 vs. control of the 
same group; †p < 0.05 vs. 0.1 μM of the same group; ‡p < 0.05 vs. 1 μM of the same group; §p < 0.05 vs. 10 
μM of the same group; ||p < 0.05 vs. SHAM of the same TMP concentration. 
 
Analysis of terameprocol impact on the proteomic profile of pulmonary artery smooth 
muscle cells 
NanoLC-MS/MS analysis of PASMCs isolated from SHAM and MCT animals allowed the 
identification of a total of 560 distinct proteins (Supplementary Table S1). In order to 
detect variations in protein abundance induced by TMP treatment, iTRAQ-based 
quantification was performed. With this methodology, 18 and 65 proteins were found to be 
differentially expressed (p<0.05) between PASMCs treated with TMP (compared with 
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control), in cells from SHAM and MCT rats, respectively (Supplementary Tables S2 and 
S3 and Figures 3A and 3B). Nine proteins were found to be common to SHAM and MCT 
groups, namely brain acid soluble protein 1, moesin, non-muscle caldesmon, nucleoside 
diphosphate kinase B, protein disulfide-isomerase A1, protein S100-A6, tropomyosin 
alpha-1 chain, tropomyosin alpha-4 chain and tropomyosin beta chain. The majority of 
these proteins exert a role at the level of the cell’s structure.  
 
 
Figure 3 – Comparison of the log ratio of the relative intensity of the significantly regulated PASMC 
proteins among groups: (A) SHAM (TMP/CONT) and (B) MCT (TMP/CONT). Proteins are presented with 
the respective Gene ID showed in supplementary tables S2 and S3. 
 
Amongst the 18 proteins that we found to be differentially expressed in cells from SHAM 
animals, 6 were up-regulated and 12 were down-regulated. According to PANTHER 
(RRID:SCR_004869) [24], 42.9 % of the proteins are involved in structural integrity of the 
cell. Cellular (21.1 %) and developmental (17.5 %) processes are the biological processes 
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associated with the majority of the proteins. Furthermore, 47.4 % of the proteins belong to 
the cytoskeleton (Supplementary Figure S1). Between the 65 proteins differentially 
expressed in cells from MCT rats, 31 proteins were found to be up-regulated and 34 were 
down-regulated. According to PANTHER analysis [24], structural activity (32.9 %), 
catalytic activity (24.7 %) and binding (23.5 %) were the main molecular functions 
associated with the differentially expressed proteins. Metabolic (20.8 %) and cellular (18.5 
%) processes were the most prevalent biological processes. Regarding the protein class, the 
majority of the proteins differentially expressed were cytoskeletal proteins (21.4 %), 
followed by nucleic acid binding proteins (13.1 %) (Supplementary Figure S2). Although 
not being a major class, the protein class of transcription factors (3.6 %) was also 
highlighted from PANTHER analysis of PASMCs from the MCT group (but not in cells 
from SHAM animals). This cluster included the protein HMGB1, whose levels decreased 
with TMP treatment. Western blotting analysis confirmed the decreased expression of this 
protein in PASMCs from MCT rats treated with TMP (Figure 4A). Additionally, 
immunohistochemical analysis of HMGB1 in lung tissue from MCT+Vehicle and 
MCT+TMP groups evidenced the staining of this protein in PASMC nuclei in both groups 
(Figure 4B).  
 
Figure 4 – Effect of terameprocol on HMGB1 expression and staining profile in pulmonary arteries from 
MCT rats. A) HMGB1 expression evaluated by western blotting in PASMCs from MCT rats, treated with 
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vehicle or TMP. Representative immunoblot is shown above the correspondent graph. B) Staining prolife of 
HMGB1 evaluated by immunohistochemistry in lung tissue from MCT+Vehicle and MCT+TMP rats. TMP, 
terameprocol-treated group; Vehicle, vehicle-treated group. Data are expressed as mean ± SE. ‡p < 0.05 vs 
Vehicle.    
  
An integrated analysis of proteins that were found to be differentially expressed in cells 
from MCT rats treated with TMP was performed with Cytoscape (v3.1.1.) 
(RRID:SCR_003032) [25], plugins ClueGO+CluePedia [26, 27]. This analysis retrieved 
“positive regulation of protein binding”, “regulation of cell size”, “cellular response to IL-
4”, “cellular response to IL-1”, “response to endoplasmic reticulum (ER) stress” and 
“removal of superoxide radicals” as the biological processes up-regulated in PASMCs 
treated with TMP. The biological processes “response to transforming growth factor beta 
(TGF-beta)”, “regulation of ATPase activity”, “negative regulation of anoikis”, “negative 
regulation of mRNA metabolic process” and “DNA-templated transcription” were shown 
to be down-regulated by TMP (Figure 5).  
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Figure 5 – ClueGo+CluePedia analysis [26, 27] of protein-protein interactions considering the proteins identified as up- and down-regulated in PASMCs from MCT 
rats treated with TMP. Green nodes represent the over-represented biological processes, while red nodes refer to the ones under-represented. Release date: May 15, 
2015. 
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Finally, comparison of proteins identified experimentally with those predicted by 
SwissTargetPrediction tool as TMP targets (Supplementary Figures S3 and S4), evidenced 
common processes, such as regulation of cytoskeleton organization, cell mobility, 
migration and growth. So, our data suggest that the regulation of processes retrieved from 
proteomic analysis, such as DNA-templated transcription and response to TGF-beta, might 
be the specific of PASMCs treated with TMP in experimental PAH. 
 
Discussion 
The hyperproliferative and apoptotic-resistant phenotype of PASMCs constitutes an 
attractive target in the treatment of PAH. In order to study the potential beneficial effects 
of TMP in PAH, we evaluated its in vivo effects in MCT model of PAH and searched for 
the molecular mechanisms regulated by this drug in primary cultures of PASMCs using a 
quantitative proteomic approach. The MCT rat model has been extensively used to study 
the pathogenesis of PAH, as well as the effects of drug interventions. Although there are 
some differences between this experimental model and human PAH, MCT induces 
pulmonary artery medial layer remodeling [28-30], which was the focus of this study.  
TMP is being studied as an anticancer drug, reported to cause growth arrest in several 
cancer types, both in vitro and in vivo, showing no relevant toxicity [11, 15, 18]. TMP 
administration improved the hemodynamic features of MCT-induced PAH, such as RV 
peak systolic pressure and RV ejection fraction, stroke volume and cardiac output. 
Importantly, TMP did not change hemodynamic parameters in the SHAM animals, 
suggesting it has no adverse effects on cardiac function. Additionally, cardiac hypertrophy 
and pulmonary vascular remodeling decreased with TMP administration in MCT-induced 
PAH. TMP exerted anti-proliferative and pro-apoptotic effects in PASMCs, supported by 
the down-regulation of proteins involved in mRNA metabolism and DNA-templated 
transcription. It was reported that TMP reduces the transcription of genes controlled by 
Sp1 [31]. Our data highlighted the modulation of the transcription factors HMGB1, Fhl-1 
and Ptrf by TMP in PASMCs from PAH rats. The role of HMGB1 in PAH was already 
reported and implicated with pulmonary vascular remodeling by enhancing PASMC 
proliferation and migration [32-34]. The inhibition of HMGB1 by Glycyrrhizin was 
previously shown to attenuate the progression of MCT-induced PAH [35]. Therefore, our 
results suggest that the anti-proliferative effects of TMP on PAH can be mediated, at least 
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in part, by the down-regulation of HMGB1 in PASMCs. In cells from SHAM animals, 
TMP had no significant impact on HMGB1 levels or even on overall PASMC proteome, 
which presented only subtle expression differences, mainly for structural proteins, in 
opposition to the observed in cells from MCT rats treated with this drug.  
In addition to nucleic acid binding proteins, PANTHER analysis highlighted other major 
cluster of proteins modulated by TMP in PAH. Within this group we found collagen alpha-
1 (I) chain, collagen alpha-2 (I) chain and collagen alpha-1 (III) chain. Collagen deposition 
in pulmonary vessels is one of the main features of vascular remodeling seen in PAH and 
circulating markers of collagen metabolism have been associated with worse stages of 
PAH [36]. According to our data, TMP decreased the levels of these proteins, which could 
be mediated by TGF-beta signaling. Dysfunctional signaling of the TGF-beta pathway is 
associated with PAH pathogenesis, contributing to abnormal SMC proliferation [37, 38]. In 
addition, TGF-beta signaling inhibition was reported to prevent MCT-induced PAH 
development and progression, through the inhibition of PASMC proliferation [39-41]. 
Thus, TMP-related down-regulation of the response to TGF-beta might have contributed to 
the anti-proliferative effects of this drug on PASMCs from MCT rats. 
Interestingly, TMP also up-regulated the biological process “response to ER stress”. This is 
associated with the increased levels of HSP70 and HSP90 family of chaperones (heat 
shock protein HSP90-beta, 78 kDa glucose-regulated protein, hypoxia upregulated protein 
1 and stress-70 protein, mitochondrial) involved in the correct folding and degradation of 
misfolded proteins. ER stress was recently suggested as a new therapeutic target for the 
management of PAH. The use of some chemical chaperones in experimental PAH was 
shown to prevent and even reverse the disease, suppressing proliferation and inducing 
apoptosis of PASMCs [42].  
Taken together, our results suggest that TMP may be seen as an attractive therapeutic 
strategy for the management of PAH since it ameliorated the hemodynamic features and 
both cardiac and vascular remodeling. The regulation of DNA transcription and TGF-beta 
pathway seems to underlie these functional and morphological adaptations. 
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General Discussion 
Pulmonary arterial hypertension is a disease characterized by pulmonary vascular 
remodeling, vasoconstriction, inflammation and thrombosis. These vascular changes lead 
to a progressive increase in PVR, imposing a pressure overload to the RV. Initially, the RV 
adapts by developing hypertrophy but heart failure and premature death will eventually 
occur (Montani, Gunther et al. 2013; Baldi, Fuso et al. 2014; McLaughlin, Shah et al. 
2015). The symptoms of PAH are non-specific and mainly related to progressive RV 
dysfunction. Initial symptoms are typically induced by exertion while symptoms at rest 
occur only in advanced cases. They include shortness of breath, fatigue, syncope and 
dizziness, which negatively impact the functional capacity and quality of life (Matura, 
McDonough et al. 2012; Delcroix and Howard 2015; Galie, Humbert et al. 2016). Despite 
the advances in recent years in disease-targeted therapies, PAH remains an incurable 
disease with a high mortality rate (Humbert, Lau et al. 2014; McLaughlin, Shah et al. 
2015), justifying the need of novel preventive and therapeutic strategies. In this sense, we 
studied the potential application of a non-pharmacological (exercise training) and a 
pharmacological (TMP) strategy in the clinical management of this disease (Studies II and 
III from Chapter III).   
 
Despite the well-established health benefits of exercise training (Powers, Lennon et al. 
2002; La Gerche and Claessen 2015), the molecular mechanisms underlying its 
cardioprotective role need to be better clarified. The majority of the studies have focused 
on the LV, but RV function is a critical determinant of survival in pathological conditions 
such as PAH (La Gerche and Claessen 2015). Some reports suggest that exercise training 
induces distinct structural and functional adaptations in both ventricles (Benito, Gay-Jordi 
et al. 2011; Gay-Jordi, Guash et al. 2013; La Gerche, Roberts et al. 2014). However, the 
molecular pathways underlying these adaptations have not been explored. Aiming to add 
new insights on this issue, we analyzed LV and RV functional, structural and molecular 
adaptations promoted by one year of endurance exercise training in an animal model 
(Study I). Rats were submitted to endurance training for 54 weeks, one of the longest 
exercise training programs performed in animal models, and corresponds to approximately 
35 years of exercise in humans (Sengupta 2013). Our data showed that long-term, 
moderate exercise training improved bi-ventricular diastolic function, as shown by the 
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lower end-diastolic pressure (EDP). In RV, we observed a decrease in fibrosis in exercised 
animals, which can in part, explain the lower RV mass that we found in trained animals. 
Our data do not support the contribution of the formation of new cardiomyocytes from 
progenitor/stem cells, given by c-kit expression, to the cardiac growth induced by exercise 
training previously reported (Waring, Vicinanza et al. 2014; Xiao, Xu et al. 2014; Tao, Bei 
et al. 2015). C-kit positive cardiac stem cells are reported to be necessary and sufficient for 
the regeneration and repair of myocardial damage (Ellison, Vicinanza et al. 2013). The 
aging process can, at least in part, justify these contradictory results, once it was reported 
that the percentage of cardiomyocytes emerging from the c-kit positive lineage decreases 
with aging (van Berlo, Kanisicak et al. 2014). Also, the low-to-moderate intensity of our 
exercise training protocol could be a contributing factor as it was shown that c-kit positive 
cardiac stem cells activation is exercise-intensity dependent (Waring, Vicinanza et al. 
2014).  
The main molecular adaptations of the heart to 54 weeks of exercise training were seen at 
the metabolic level, mainly in the RV. A metabolic adaptation of RV towards an oxidative 
phenotype was observed, that can be related with the increase of nitrated proteins, due to 
augmented nitric oxide (NO) levels. Exercise training seems to generate greater levels of 
NO that reacted with superoxide anion with the formation of peroxynitrite, which may 
react with proteins’ tyrosine residues (van der Loo, Labugger et al. 2000). This exercise 
training-related oxidative phenotype was not directly related to increased mitochondrial 
biogenesis, as previously reported (Vettor, Valerio et al. 2014). Indeed, the content of 
mitochondria, roughly assessed by citrate synthase activity (Figueiredo, Ferreira et al. 
2008), did not increase in RV or LV from trained rats, as well as of peroxisome 
proliferator-activated receptor gamma coactivator-1 alpha (PGC-1α), a key regulator of 
genes involved in myocardial fuel metabolism and mitochondrial biogenesis (Li, Muhlfeld 
et al. 2011). Nevertheless, the impact of exercise training on mitochondrial biogenesis in 
the heart is not clear. For instance, 6 weeks of swimming was shown to promote an up-
regulation of mitochondrial biogenesis in heart (Vettor, Valerio et al. 2014), whereas 3 
months of running did not impact mitochondrial density in LV (Li, Muhlfeld et al. 2011). 
The effect of lifelong exercise training was mainly noticed in the up-regulation of sirtuin 3 
(SIRT3) and manganese-dependent superoxide dismutase (MnSOD) in RV. Activation of 
the deacetylase SIRT3 is important in the regulation of PGC-1α expression (Li, Muhlfeld 
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et al. 2011; Mann and Rosenzweig 2012). Additionally, it has been suggested that the 
deacetylation of MnSOD by SIRT3 increases the activity of MnSOD, contributing to 
protect the heart against oxidative stress (Amado, Barros et al. 2014; Powers, Smuder et al. 
2014; Bindu, Pillai et al. 2016). Indeed, a cardioprotective role has been attributed to 
SIRT3, once this deacetylase is related with the activation of many targets that, via 
modifying their respective signaling molecules, block cardiac hypertrophy, fibrosis and 
apoptosis and promote cardiomyocyte survival (Bindu, Pillai et al. 2016). 
Following these advantageous effects of long-term moderate exercise training on RV, we 
aimed to evaluate the potential preventive role of exercise training on RV dysfunction and 
remodeling underlying PAH (Study II). Recent studies support the benefit and safety of 
supervised exercise training programs in patients with stable PAH (Buys, Avila et al. 2015; 
Pandey, Garg et al. 2015; Yuan, Yuan et al. 2015; Ehlken, Lichtblau et al. 2016). However, 
it remains to be evaluated if exercise training has a preventive role in PAH, which is of 
great relevance if we consider that the majority of PAH patients are diagnosed at advanced 
stages of the disease, when RV impairment is already present. The comprehension of this 
crosstalk is even more important in the clinical set of familial form of PAH once exercise 
preconditioning might be seen as a measure to prevent the severity or early onset of the 
disease. To accomplish our aim we used an animal model of PAH induced by MCT 
administration. MCT is a pyrrolizidine alkaloid found in the plant Crotalaria spectabilis. 
After being bioactivated in the liver, its bioactive metabolite (MCT pyrrole) is transported 
by the circulatory system to the lungs, where it induces pulmonary artery molecular and 
structural changes, increasing PVR and PAP, leading to RV hypertrophy. In the dosage of 
60 mg/kg, RV hypertrophy is observed by the third week and progresses to failure and 
death around the fourth week (Schultze and Roth 1998; Henriques-Coelho, Correia-Pinto 
et al. 2004; Henriques-Coelho, Oliveira et al. 2008; Correia-Pinto, Henriques-Coelho et al. 
2009; Handoko, de Man et al. 2009). Thus, the preventive effect of exercise training was 
studied using a protocol consisting in 4 weeks of treadmill running before 
(preconditioning) disease development by MCT injection, followed by 4 weeks of 
sedentary behavior. 
In this study we focused on inflammatory pathways in the RV, given the recognized role of 
inflammation in RV dysfunction (Watts, Zagorski et al. 2006; Watts, Gellar et al. 2008; 
Rondelet, Dewachter et al. 2012; Belhaj, Dewachter et al. 2013; Vonk-Noordegraaf, 
CHAPTER IV. GENERAL DISCUSSION 
162 
Haddad et al. 2013). We studied the contribution of tumor necrosis factor (TNF) 
superfamily signaling, specifically TNF-α and TNF-related weak inducer of apoptosis 
(TWEAK) to RV remodeling. These pro-inflammatory cytokines seem to contribute 
differently to the RV dysfunction secondary to MCT-induced PAH. An increased 
expression of TNF-α and members from the nuclear factor kappa B (NF-κB) non-canonical 
pathway (NF-κB p100/p52 and Rel-B) was observed in the RV of sedentary MCT-treated 
rats. Exercise preconditioning did not affect the levels of TNF-α, but decreased TWEAK 
expression and modulated the expression of NF-κB p105/p50 and NF-κB p65 proteins 
(members of the canonical NF-κB pathway) in MCT-treated rats. This is in accordance 
with previous findings that TWEAK and NF-κB signaling regulate cardiac hypertrophy, 
fibrosis and heart failure (Van der Heiden, Cuhlmann et al. 2010; Novoyatleva, Sajjad et 
al. 2014). This shift from the non-canonical to the canonical NF-κB signaling seems to 
have cardioprotective effects. Indeed, activation of p65 subunit was previously related to 
myocyte survival and cardiac homeostasis while the p50 subunit seems to antagonize the 
development of cardiac hypertrophy and fibrosis (Gaspar-Pereira, Fullard et al. 2012).  
Concomitantly, exercise preconditioning prevented the MCT-related overexpression of the 
ubiquitin ligase atrogin-1 and increase of matrix metalloproteinase (MMP)-9 activity. 
Atrogin-1 inhibition was previously reported to prevent pressure overload-induced cardiac 
hypertrophy (Zaglia, Milan et al. 2014) whereas inactivation of metalloproteinases in the 
RV is expected to prevent cardiomyocyte hypertrophy and fibrosis (Okada, Kikuzuki et al. 
2008). Indeed, RV fibrosis was prevented in trained MCT rats as well as beta-myosin 
heavy chain (MHC) isoform overexpression, highlighting the role of exercise 
preconditioning in the prevention of contractile cardiac dysfunction, once both fibrosis and 
the shift to the beta-MHC isoform are related with an impaired contractile function (Barry, 
Davidson et al. 2008; Harvey and Leinwand 2011). However, the exercise preconditioning-
related decrease of MMP-9 activity in MCT-treated rats was paralleled by an increase of 
MMP-2 activity. This shift of MMP activity might have contributed to the decreased 
accumulation of fibrosis observed in the RV of trained MCT-treated rats. Different 
expression patterns of MMP-2 and MMP-9 to angiogenic-related mechanical stimuli 
induced by exercise training was already reported, and seem to be explained by their 
involvement in dissimilar cellular processes (Bellafiore, Battaglia et al. 2013). These 
molecular events were probably underlying the preventive effect of exercise training 
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against RV diastolic dysfunction, which is supported by the reduction of EDP. Exercise 
preconditioning also prevented pulmonary artery remodeling and led to a decrease in 
cardiac hypertrophy observed in MCT-treated rats. Of note, our data also support the 
notion that cardioprotection promoted by exercise training can be sustained for several 
weeks after the cessation of the exercise training protocol.  
Despite the experimental evidences of the therapeutic benefits of exercise training for the 
clinical management of PAH, most of the patients do not tolerate exercise at the time of 
diagnosis (Fowler, Gain et al. 2012; Babu, Arena et al. 2016). Given that the current 
guidelines support the use of exercise training only in clinically stable patients and 
considering that PAH is lacking from effective drugs (Gurtu and Michelakis 2015; Galie, 
Humbert et al. 2016), it was also our aim to test a pharmacological approach. Because of 
the role of proliferative and apoptotic pathways on the remodeling of the pulmonary 
vasculature, we searched for a drug with the potential to target these processes and decided 
to test TMP.  TMP is a methylated derivate of nordihydroguaiaretic acid, found in the plant 
Larrea tridentate, which is being studied as an anticancer drug and reported to cause 
growth arrest in several cancer types, both in vitro and in vivo, without relevant toxicity. 
TMP was reported to block cell cycle progression and promote apoptosis by competing 
with Sp1-DNA binding, decreasing the transcription of genes dependent from this 
transcription factor, such as Cdc2 and survivin (Chang, Heller et al. 2004; Ryan, 
O'Donovan et al. 2009; Lu, Nurko et al. 2010; Church and Talbot 2012). In order to 
evaluate the potential therapeutic effect of TMP in PAH, we searched for the molecular 
mechanisms regulated by this drug in primary cultures of PASMCs using a quantitative 
proteomic approach (Study III). To achieve this, we used the MCT experimental model. 
MCT administration induces changes in the medial layer characterized by hypertrophy and 
hyperplasia of smooth muscle, resistance of PASMCs to apoptosis and extension of 
smooth muscle to normally nonmuscular pulmonary arteries (Schultze and Roth 1998; 
Maarman, Lecour et al. 2013).  
In our study, TMP treatment was able to improve cardiac function of MCT-treated rats, 
and this was accompanied by a significant reduction of pulmonary and cardiac remodeling. 
TMP exerted anti-proliferative and pro-apoptotic effects in SMCs isolated from the 
pulmonary artery from MCT-treated rats. Aiming to explore the molecular mechanisms 
associated with these effects, a mass spectrometry-based approach was used for 
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quantitative comparison of proteome profiles of PASMCs isolated from MCT and saline 
treated rats, treated or not with TMP. To the best of our knowledge, this is the first study 
that characterized proteome alterations in PASMCs isolated from rats treated with MCT. 
TMP had no impact on overall PASMC proteome of saline-treated rats, presenting only 
subtle expression differences, mainly for structural proteins as tropomyosin beta chain, 
myosin light polypeptide 6 and moesin. However, in PASMCs from MCT-treated rats, 
TMP modulated the biological processes “regulation of cell size”, “response to 
endoplasmic reticulum (ER) stress”, “response to transforming growth factor beta (TGF-
beta)” and “DNA-templated transcription”. The biological process “DNA-templated 
transcription” was found down-regulated in these TMP-treated cells, which was related to 
the decrease of the transcription factor high mobility group box 1 (HMGB1). This 
chromatin-binding protein participates in maintaining nucleosome structure and regulating 
gene transcription. Several reports showed that HMGB1 plays a role in the pulmonary 
vascular remodeling underlying PAH by enhancing PASMC proliferation and migration 
(Bauer, Shapiro et al. 2012; Sadamura-Takenaka, Ito et al. 2014; Wang, Peng et al. 2014; 
Zabini, Crnkovic et al. 2015). Furthermore, the inhibition of HMGB1 was previously 
shown to attenuate the progression of MCT-induced PAH (Yang, Kim et al. 2014).  
TMP also modulated collagen alpha-1 (I) chain, collagen alpha-2 (I) chain and collagen 
alpha-1 (III) chain levels. Collagen deposition in pulmonary vessels is one of the main 
features of vascular remodeling observed in PAH and circulating markers of collagen 
metabolism have been associated with worse stages of PAH (Safdar, Tamez et al. 2014). 
According to our data, TMP decreased the levels of these proteins, which could be 
mediated by TGF-beta signaling. Dysfunctional signaling of the TGF-beta pathway is 
associated with PAH pathogenesis, contributing to abnormal SMC proliferation. In 
addition, TGF-beta signaling inhibition prevented MCT-induced PAH development and 
progression, involving PASMC proliferation decrease (Zaiman, Podowski et al. 2008; 
Long, Crosby et al. 2009; Thomas, Docx et al. 2009). Thus, TMP-related down-regulation 
of the response to TGF-beta can also contribute to the anti-proliferative effects on 
PASMCs from MCT-treated rats. Interestingly, TMP also up-regulated the biological 
process “response to ER stress”. This is associated with the increased levels of heat shock 
protein (HSP)70 and HSP90 family of chaperones (heat shock protein HSP90-beta, 78 kDa 
glucose-regulated protein, hypoxia up-regulated protein 1 and stress-70 protein, 
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mitochondrial) involved in the correct folding and degradation of misfolded proteins. ER 
stress has been described in the pulmonary arteries of PAH patients and it was recently 
suggested as a new therapeutic target. The use of some chemical chaperones in 
experimental PAH was shown to prevent and even reverse the disease, suppressing 
proliferation and inducing apoptosis of PASMCs (Dromparis, Paulin et al. 2013). So, the 
observed molecular alterations induced by TMP treatment may underlie our in vivo 
findings of significant attenuation of the increased pulmonary artery medial wall thickness, 
which may have contributed to decrease the RV dysfunction and hypertrophy associated to 
MCT-induced PAH.  
 
In overall, our data highlighted that both exercise training, as a non-pharmacological 
approach and TMP, as a pharmacological strategy, can positively interfere with the RV 
dysfunction and pulmonary vascular remodeling underlying PAH, supporting their clinical 
relevance in the management of this disease. The observed benefits are associated with the 
modulation of inflammation-related signaling pathways in both preventive and therapeutic 
strategies. 
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Conclusions 
Pulmonary arterial hypertension is a devastating disease associated with right heart failure 
and premature death. Although current therapies have allowed an increase on patient 
survival, this disease remains without a cure and PAH-related mortality is still enormously 
high. Aiming to find novel preventive and therapeutic strategies, three experimental studies 
were developed to assess the potential application of exercise training and the anticancer 
drug TMP in the management of PAH. Data obtained allowed to conclude that: 
 
i) One year of moderate exercise training improves the cardiac function by increasing 
RV antioxidant capacity and mitochondrial ability to produce ATP, though with no 
significant impact on mitochondrial biogenesis.  
 
ii) Prior exercise training prevents pulmonary artery remodeling and cardiac 
dysfunction, hypertrophy and fibrosis associated to MCT-induced PAH, supporting 
its beneficial role for the prevention of this disease. These functional and 
morphological alterations were related with reduced beta/alpha-MHC ratio, 
modulation of TWEAK/NF-B signaling and atrogin-1 levels and induction of a 
shift of MMPs activity from MMP-9 to MMP-2 activity in the RV.   
 
iii) TMP might be seen as a novel therapeutic strategy for the clinical management of 
PAH once promotes the reduction of the maladaptive vascular remodeling and 
attenuates RV dysfunction and hypertrophy associated to the disease. These effects 
were related to the modulation of the biological processes “regulation of cell size”, 
“response to endoplasmic reticulum stress”, “response to transforming growth 
factor beta” and “DNA-templated transcription” in PASMCs collected from MCT-
treated rats. The transcription factor HMGB1 seems to be a key target of TMP, 
whose down-regulation may justify, at least in part, its anti-proliferative effects in 
PASMCs.   
 
Taken together, data suggest that preconditioning exercise training and TMP treatment can 
be of clinical relevance in the management of PAH. Further studies describing the 
molecular mechanisms underlying exercise training effects on PAH, focusing not only in 
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the heart, but also in the pulmonary artery and skeletal muscle will assist in the 
recommendation of exercise training for the clinical management of PAH. Additionally, 
future work focused on the evaluation of TMP effects in other pulmonary artery cell types, 
such as endothelial cells, and also in the heart will contribute to propose this anticancer 
drug as a novel therapeutic alternative in PAH treatment. 
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REVIEW II – MECHANISMS UNDERLYING THE IMPACT OF EXERCISE TRAINING 
IN PULMONARY ARTERIAL HYPERTENSION 
 
Supplementary Table S1 – Summary of clinical studies assessing exercise training effects in pulmonary 
arterial hypertension. 
 
Patient characteristics Exercise training program 
Major 
findings 
References 
Control group 
 N=15 
 Age=53 ± 14 
 67% female 
 PAH (n=11) and 
CTEPH (n=4) 
 WHO – FC II-IV 
(80% III) 
 
Training Group 
 N=15 
 47 ± 12 
 67% female 
 PAH (n=13) and 
CTEPH (n=2) 
 WHO – FC II-IV 
(67% III) 
In hospital (3 weeks) 
 7 days/week of interval bicycle 
ergometer training at lower 
workload for 1⁄2 min and a higher 
workload for 1 min, for 10 to 25 
min/day, (60% to 80% of peak HR). 
 60 min of walking, 5 days/week 
(flat-ground and uphill walking).  
 Mental training, 5 days/week.  
 30 min of dumbbell training of 
single muscle groups with low 
weights (500 to 1000 g) and 30 min 
of respiratory training, 5 days/week. 
 
Home-based intervention (12 weeks) 
 Bicycle exercise training, once 
daily, 15-30 min, 5 days/week. 
 Respiratory exercise and dumbbell 
training every other day, 15-30 min. 
 Walking training twice a week. 
↑6MWD 
↑QOL 
↓WHO – FC 
↑VO2 (peak + 
AT) 
↑Workload 
(maximal + 
AT) 
= SPAP 
Adverse 
events: 
dizziness, 2 
patients 
[1] 
Training Group 
 N=2 
 50 and 57 years 
 50% female 
 Idiopathic PAH 
(1) and Associated 
PAH (CTD) (1) 
 NYHA – FC II 
(100% II) 
Institution based (6 weeks) 
 Cycle ergometry at workloads 
progressing from 50% to 80% of 
peak workload, 3 days/week. Each 
session consisted of 5 min of warm-
up, 35 min of loaded cycling, and 5 
min of cool down. 
↑6MWD 
↑QOL 
↓NYHA – FC  
↑VO2 (AT) 
↑Workload  
(AT) 
No adverse 
events 
[2] 
Training Group 
 N=19 
 42 ± 13 
 79% female 
 Idiopathic PAH 
(19) 
 NYHA – FC II-III 
(84% III) 
Institution based (12 weeks) 
 Bicycle training. 
 Quadriceps strength and endurance 
training. 
= 6MWD 
= Peak exercise 
capacity 
↑Endurance 
capacity 
↑Quadriceps 
strength and 
endurance 
↑Capillaries 
per muscle 
fiber (muscle 
biopsies) 
= CSA and 
fiber type 
distribution 
↑Oxidative 
enzyme 
activity 
[3] 
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= BNP levels 
Adverse 
events: 
dizziness, 2 
patients 
Control Group 
 N=4 
 33 ± 6 
 25% female 
 Associated PAH 
(CHD) (4) 
 NYHA – FC II-III 
(50% III) 
 
Training Group 
 N=4 
 23 ± 7 
 50% female 
 Associated PAH 
(CHD) (4) 
 NYHA – FC II-III 
(75% III) 
Institution based (3 months) 
2 days/week:  
 10 min warming up, with stretching 
of long muscles.  
 Resisted exercises (1–2 kg). 
 Aerobic interval training in a 
bicycle ergometer during 24 min 
with bases at 10–25W and 30-
second peaks of 20–50W (80% of 
HR reached in the 6MWT). 
 Education. 
 
From 3
rd
 to 12
th
  month: 
 Flat-ground walking daily. 
 Similar rehabilitation exercises as 
done in the rehabilitation sessions. 
↑6MWD 
↓NYHA – FC 
↑Ο2 saturation 
= Hand and leg 
strength 
= QOL 
= BNP levels 
No adverse 
events 
[4] 
Training Group 
 N=5 
 40 ± 15 
 80% female 
 Idiopathic PAH 
(5) 
 WHO – FC II-III 
(60% II) 
Institution based (12 weeks) 
3 days/week:  
 10 to 15 min of cycling exercise 
with workload initially set to 60% 
of the maximal workload achieved 
during incremental exercise test. 
 2 sets of 10 to 12 repetitions for 6 to 
8 different exercises involving 
single muscle groups (arms and 
quadriceps). 
 15 min of brisk walking on a 
treadmill (85% of the mean speed of 
6MWT). 
↑6MWD 
↓Minute 
ventilation 
↓Type IIx 
muscle fiber 
proportion 
No adverse 
events 
[5] 
Control Group 
 N=11 
 46 ± 5 
 45% female 
 Idiopathic PAH 
(7) and Associated 
PAH (CTD) (4) 
 NYHA – FC II-III 
(82% II) 
 
Training Group 
 N=11 
 57 ± 4 
 91% female 
 Idiopathic PAH 
(3), Associated 
PAH (CTD, CHD) 
(6) and CTEPH 
(2) 
 NYHA – FC II-III 
(64% III) 
Institution based (12 weeks) 
2 days/week  
1-hour sessions of exercise training, two 6-
week  blocks (60-80% of CPET HRmax): 
 first block: interval training with 
treadmill walking, cycling, and step 
climbing   
second block: longer periods of 
continuous aerobic exercise, with 
resistance training by step climbing, 
unsupported arm/leg exercises with 
and without dumbbells (500-1000 
g), and supporting body weight over 
a chair 
 daily home-based exercise with 
stair-climbing and brisk walking 
↑6MWD 
↑Peak VO2 
↑Peak work 
rate 
= BNP levels 
= SPAP 
= CO 
No adverse 
events 
[6] 
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Training Group 
 N=58 
 51 ± 12 
 72% female 
 Idiopathic PAH 
(37), Heritable 
PAH (3), 
Associated PAH 
(CTD, CHD, 
Portal 
Hypertension, 
HIV) (7), LD-PH 
(3), CTEPH (6) 
and Others (2) 
 WHO – FC II-IV 
(76% III) 
In hospital (3 weeks) + Home-based 
intervention (12 weeks) 
Same as [1]. 
24 ± 12 months follow-up 
↑6MWD 
↑QOL  
↓WHO – FC 
↓Rest heart rate 
↑VO2 (peak + 
AT) 
↑Workload 
(maximal + 
AT) 
Survival: 
1year, 100%; 2 
years, 95% 
Adverse 
events: 
dizziness, 2 
patients; 
respiratory 
infections, 7 
patients 
[7] 
Training Group 
 N=183 
 53 ± 15 
 69% female 
 Idiopathic PAH 
(83), Heritable 
PAH (4), Drug- 
and toxin-induced 
PAH (3), 
Associated PAH 
(CTD, CHD, 
Portal 
Hypertension, 
HIV) (43), LHD-
PH (8), LD-PH 
(11) and CTEPH 
(31) 
 WHO – FC I-IV 
(75% III)  
In hospital (3 weeks) + Home-based 
intervention (12 weeks) 
Same as [1]. 
↑6MWD (in all 
PH forms and 
FC, including 
IV) 
↑QOL  
↓WHO – FC 
↑VO2 (peak + 
AT) 
↓Rest heart rate 
↓SPAP 
↑Maximal 
workload 
Adverse 
events: 
respiratory 
infections, 14 
patients; 
syncope, 2 
patients; 
presyncope, 6 
patients 
[8] 
Training Group 
 N=21 
 52 ± 18 
 95% female 
 Associated PAH 
(CTD) (21) 
 WHO – FC II-IV 
(43% II) 
In hospital (3 weeks) + Home-based 
intervention (12 weeks) 
Same as [1]. 
2.9 ± 1.9 years follow-up 
↑6MWD 
↑QOL  
↑VO2 (peak + 
AT) 
↓Rest heart rate 
↑O2 saturation 
↑Maximal 
workload 
↓SPAP 
= BNP levels 
Survival: 1 
year, 100%; 2 
years, 100%; 3 
years,73% 
Adverse 
events: 
gastrointestinal 
infection with 
[9] 
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diarrhea, 1 
patient; 
respiratory 
infections, 2 
patients 
Control Group 
 N=10 
 54 ± 14 
 60% female 
 Idiopathic PAH 
(4), Heritable PAH 
(1), Associated 
PAH (CTD, Portal 
Hypertension) (2) 
and CTEPH (3) 
 WHO – FC II-III 
(90% III) 
 
Training Group 
 N=10 
 47 ± 8 
 80% female 
 Idiopathic PAH 
(7), Associated 
PAH (CTD, Portal 
Hypertension) (2) 
and CTEPH (1) 
 WHO – FC II-III 
(70% III) 
In hospital (3 weeks)  
Same as [1]. 
↑6MWD 
↑MRI flow 
peak velocity 
↑MRI 
perfusion 
(pulmonary 
blood volume) 
No adverse 
events 
[10] 
Training Group 
 N=20 
 48 ± 11 
 80% female 
 Associated PAH 
(CHD) (20) 
 WHO – FC II-III 
(70% III) 
In hospital (3 weeks) + Home-based 
intervention (12 weeks) 
Same as [1].  
21 ± 14 months follow-up 
↑6MWD 
↑QOL  
↑Peak VO2 
= SPAP 
↑Maximal 
workload 
↑BNP levels 
Survival: 1 
year, 100%; 2 
years, 100%; 3 
years, 95% 
Adverse 
events: 
respiratory 
infections, 4 
patients 
[11] 
Control Group 
 N=13 
 56 ± 9 
 100% female 
 Idiopathic PAH 
(3), Drug-induced 
PAH (1) and 
Associated PAH 
(CTD) (9) 
 WHO/NYHA – 
FC II-III (62% II) 
 
Institution based (10 weeks) 
 24-30 sessions of treadmill walking 
for 30-45 min per session at 70-
80% of heart rate reserve and 
education. 
↑6MWD 
↑QOL  
↑time to 
exercise 
intolerance 
↑Peak work 
rate 
No adverse 
events 
[12] 
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Training Group 
 N= 10 
 53 ± 13 
 100% female 
 Idiopathic PAH 
(2) and Associated 
PAH (CTD) (8) 
 WHO/NYHA – 
FC I-IV (40% 
II=III) 
Control Group 
 N=13 
 55 ± 9 
 100% female 
 Idiopathic PAH 
(4) and Associated 
PAH (CTD) (9) 
 WHO/NYHA – 
FC II-III (62% II) 
 
Training Group 
 N=11 
 53 ± 12 
 100% female 
 Idiopathic PAH 
(2) and Associated 
PAH (CTD) (9) 
 WHO/NYHA – 
FC I-IV (45% III) 
Institution based (10 weeks) 
 24-30 sessions of treadmill walking 
for 30-45 min per session at 70-
80% of heart rate reserve, 3 
days/week and education. 
↑ physical 
activity 
↓fatigue 
↑6MWD 
↑peak power 
output 
↑symptom 
limited 
treadmill 
exercise test 
duration 
No adverse 
events 
[13] 
Training Group 
 N=7 
 60 ± 11 
 57% female 
 Idiopathic PAH 
(5) and Associated 
PAH (CTD) (2) 
 WHO – FC III-IV 
(86% III) 
In hospital (3 weeks) + Home-based 
intervention (12 weeks) 
Same as [1]. 
↑6MWD 
↑respiratory 
muscle strength 
No adverse 
events 
[14] 
Control Group 
 N=46 
 53 ± 10 
 65% female 
 Idiopathic PAH 
(18), Associated 
PAH (CTD, CHD, 
Portal 
Hypertension, 
HIV) (12), LD-PH 
(5), CTEPH (8) 
and Others (3) 
 WHO – FC II-IV 
(70% III) 
 
Training Group 
 N=58 
 51 ± 12 
In hospital (3 weeks) + Home-based 
intervention (12 weeks)  
Same as [1].  
24 ± 12 months follow-up 
↑time to 
clinical 
worsening 
↑QOL  
↓healthcare 
costs 
Survival: 
1year, 100%; 2 
years, 95% 
No adverse 
events 
[15] 
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 72% female 
 Idiopathic PAH 
(37), Heritable 
PAH (3), 
Associated PAH 
(CTD, CHD, 
Portal 
Hypertension, 
HIV) (7), LD-PH 
(3), CTEPH (6) 
and Others (2) 
 WHO – FC II-IV 
(76% III) 
Training Group 
 N=17 
 62 ± 13 
 65% female 
 PAH (14) and 
CTEPH (3) 
 WHO – FC II-III 
(65% III) 
Institution based (10 months) 
 90 min once a month at low 
workloads (10 to 60 W): 30 min 
breathing exercises, 30 min 
moderate strengthening exercises 
and very moderate endurance 
training of orthostatic leg muscles 
with general coordination 
movements and 30 min education. 
 Repetition of respiratory and 
exercise training at home once daily 
for a total of 15-30 min, 5 
days/week. 
= 6MWD  
↑QOL 
No adverse 
events 
[16] 
Control Group 
 N=41 
 57 ± 15 
 51% female 
 PAH (26) and 
CTEPH (15) 
 WHO – FC II-IV 
(75% III) 
 
Training Group 
 N=46 
 55 ± 15 
 57% female 
 PAH (35) and 
CTEPH (11) 
 WHO – FC II-III 
(82% III) 
In hospital (3 weeks) + Home-based 
intervention (12 weeks) 
Same as [1]. 
↑6MWD  
↑QOL 
↑Peak VO2 
↑CI (rest and 
during 
exercise) 
↑CO (rest and 
during 
exercise) 
↓mPAP 
↓PVR 
↑Exercise 
capacity 
= BNP levels 
No adverse 
events 
[17] 
Legend: ↑, increase; ↓, decrease; =, no change; 6MWD, 6-minute walk distance; 6MWT, 6-minute walk test; 
AT, anaerobic threshold; BNP, brain natriuretic peptide; CHD, congenital heart disease; CI, cardiac index; 
CO, cardiac output; CPET, cardiopulmonary exercise testing; CSA, cross-sectional area; CTD, connective 
tissue disease; CTEPH, chronic thromboembolic pulmonary hypertension; HIV, human immunodeficiency 
virus; HR, heart rate; LD-PH, PH due to lung diseases; LHD-PH, PH due to left heart diseases; mPAP, mean 
pulmonary artery pressure; MRI, magnetic resonance imaging; NYHA – FC, New York Heart Association 
functional class; PAH, pulmonary arterial hypertension; PVR, pulmonary vascular resistance; QOL, quality 
of life; SPAP, systolic pulmonary artery pressure; VO2, oxygen uptake; WHO – FC, World Health 
Organization functional class.  
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STUDY I – DIFFERENT SUSCEPTIBILITY TO METABOLIC ADAPTATIONS IN THE 
RIGHT AND LEFT VENTRICLE OF RATS FOLLOWING ONE YEAR OF MODERATE 
EXERCISE TRAINING 
 
 
 
Supplementary Figure S1 – Effect of exercise training on RAF-1 and SIRT3 content in isolated 
mitochondria. *** P<0.001 vs. SED group. 
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STUDY III – HMGB1 DOWN-REGULATION MEDIATES TERAMEPROCOL VASCULAR ANTI-PROLIFERATIVE EFFECT IN 
EXPERIMENTAL PULMONARY HYPERTENSION 
 
Supplementary Table S1 – List of all PASMC proteins identified using LC-MS/MS. 
 
N Unused Total 
% 
Cov 
Accession # Name Species 
Peptides 
(95%) 
TMP10:CONT p value 
42 104,59 104,59 43,7 sp|Q62812|MYH9_RAT Myosin-9 OS=Rattus norvegicus GN=Myh9 PE=1 SV=3 RAT 53 0,8182 0,0001 
211 82,54 82,75 34,7 sp|D3ZHA0|FLNC_RAT Filamin-C OS=Rattus norvegicus GN=Flnc PE=1 SV=1 RAT 40 0,9849 0,6548 
53 69,8 69,8 81,1 sp|P31000|VIME_RAT Vimentin OS=Rattus norvegicus GN=Vim PE=1 SV=2 RAT 45 1,4669 0,0003 
307 68,43 68,43 64,4 sp|P06761|GRP78_RAT 
78 kDa glucose-regulated protein OS=Rattus norvegicus GN=Hspa5 PE=1 
SV=1 
RAT 35 1,3363 0 
108 57,06 57,06 56,2 sp|P48679|LMNA_RAT Prelamin-A/C OS=Rattus norvegicus GN=Lmna PE=1 SV=1 RAT 25 1,1141 0,1314 
441 55,6 56,57 32,4 sp|P16086|SPTN1_RAT 
Spectrin alpha chain, non-erythrocytic 1 OS=Rattus norvegicus GN=Sptan1 
PE=1 SV=2 
RAT 25 1,2167 0 
37 51,35 51,42 81,9 sp|P09495|TPM4_RAT Tropomyosin alpha-4 chain OS=Rattus norvegicus GN=Tpm4 PE=1 SV=3 RAT 28 0,9349 0,3553 
487 50,11 54,4 58,2 sp|P63018|HSP7C_RAT 
Heat shock cognate 71 kDa protein OS=Rattus norvegicus GN=Hspa8 PE=1 
SV=1 
RAT 30 1,184 0,1908 
241 49,43 49,82 72,8 sp|P60711|ACTB_RAT Actin, cytoplasmic 1 OS=Rattus norvegicus GN=Actb PE=1 SV=1 RAT 71 0,8454 
 
278 49,17 49,17 43,1 sp|Q9QXQ0|ACTN4_RAT Alpha-actinin-4 OS=Rattus norvegicus GN=Actn4 PE=1 SV=2 RAT 24 1,0369 0,7046 
368 48,71 50,65 20,7 sp|P30427|PLEC_RAT Plectin OS=Rattus norvegicus GN=Plec PE=1 SV=2 RAT 22 1,0905 0,1302 
282 42,68 43,77 37,9 sp|Q66HD0|ENPL_RAT Endoplasmin OS=Rattus norvegicus GN=Hsp90b1 PE=1 SV=2 RAT 19 1,0813 0,3144 
222 39,46 39,53 61,2 sp|P11980|KPYM_RAT Pyruvate kinase PKM OS=Rattus norvegicus GN=Pkm PE=1 SV=3 RAT 18 1,1723 0,0076 
76 38,55 42,79 43 sp|P34058|HS90B_RAT 
Heat shock protein HSP 90-beta OS=Rattus norvegicus GN=Hsp90ab1 PE=1 
SV=4 
RAT 20 1,2315 0,0195 
312 36,86 36,86 35,7 sp|P02454|CO1A1_RAT Collagen alpha-1(I) chain OS=Rattus norvegicus GN=Col1a1 PE=1 SV=5 RAT 27 0,498 0,0003 
393 32,63 32,83 30,9 sp|P05197|EF2_RAT Elongation factor 2 OS=Rattus norvegicus GN=Eef2 PE=1 SV=4 RAT 16 1,1923 0,0168 
401 31,77 31,77 64,8 sp|Q62736|CALD1_RAT Non-muscle caldesmon OS=Rattus norvegicus GN=Cald1 PE=1 SV=1 RAT 18 0,9377 0,0509 
399 31,38 31,38 56,5 sp|P04797|G3P_RAT 
Glyceraldehyde-3-phosphate dehydrogenase OS=Rattus norvegicus GN=Gapdh 
PE=1 SV=3 
RAT 17 1,1577 0,141 
491 30,96 30,96 60,7 sp|P07150|ANXA1_RAT Annexin A1 OS=Rattus norvegicus GN=Anxa1 PE=1 SV=2 RAT 17 0,9533 0,4697 
239 30,01 30,08 51,8 sp|P69897|TBB5_RAT Tubulin beta-5 chain OS=Rattus norvegicus GN=Tubb5 PE=1 SV=1 RAT 20 0,8058 0,1798 
162 29,4 48,89 47,2 sp|Q9Z1P2|ACTN1_RAT Alpha-actinin-1 OS=Rattus norvegicus GN=Actn1 PE=1 SV=1 RAT 22 1,2287 0,0779 
APPENDIX – SUPPLEMENTARY DATA 
194 
210 26,47 26,83 38,2 sp|P15999|ATPA_RAT 
ATP synthase subunit alpha, mitochondrial OS=Rattus norvegicus GN=Atp5a1 
PE=1 SV=2 
RAT 14 1,0003 0,9956 
83 26,4 26,45 39,4 sp|P48037|ANXA6_RAT Annexin A6 OS=Rattus norvegicus GN=Anxa6 PE=1 SV=2 RAT 11 1,0234 0,7643 
432 26,31 26,31 88,2 sp|Q05175|BASP1_RAT Brain acid soluble protein 1 OS=Rattus norvegicus GN=Basp1 PE=1 SV=2 RAT 15 1,0105 0,7913 
529 25,99 25,99 75,6 sp|P31232|TAGL_RAT Transgelin OS=Rattus norvegicus GN=Tagln PE=1 SV=2 RAT 16 1,0565 0,1876 
412 25,61 25,68 37 sp|P18418|CALR_RAT Calreticulin OS=Rattus norvegicus GN=Calr PE=1 SV=1 RAT 14 1,144 0,3526 
387 24,69 41,65 70,1 sp|P04692|TPM1_RAT Tropomyosin alpha-1 chain OS=Rattus norvegicus GN=Tpm1 PE=1 SV=3 RAT 30 0,8235 0,01 
244 24,68 24,87 64,9 sp|P63102|1433Z_RAT 14-3-3 protein zeta/delta OS=Rattus norvegicus GN=Ywhaz PE=1 SV=1 RAT 12 0,9172 0,8815 
103 23,38 23,68 39,4 sp|P63039|CH60_RAT 
60 kDa heat shock protein, mitochondrial OS=Rattus norvegicus GN=Hspd1 
PE=1 SV=1 
RAT 11 1,1562 0,1075 
66 23,25 23,43 39,8 sp|P16617|PGK1_RAT Phosphoglycerate kinase 1 OS=Rattus norvegicus GN=Pgk1 PE=1 SV=2 RAT 11 0,9794 0,7629 
374 22,98 23,12 54,8 sp|Q63716|PRDX1_RAT Peroxiredoxin-1 OS=Rattus norvegicus GN=Prdx1 PE=1 SV=1 RAT 14 1,1572 0,0138 
186 22,98 23,05 20,1 sp|Q5QD51|AKA12_RAT A-kinase anchor protein 12 OS=Rattus norvegicus GN=Akap12 PE=1 SV=1 RAT 11 0,7352 0,0047 
98 22,67 22,98 39 sp|P68370|TBA1A_RAT Tubulin alpha-1A chain OS=Rattus norvegicus GN=Tuba1a PE=1 SV=1 RAT 14 2,2037 
 
366 22,49 22,54 58,1 sp|P52944|PDLI1_RAT PDZ and LIM domain protein 1 OS=Rattus norvegicus GN=Pdlim1 PE=2 SV=4 RAT 11 1,0195 0,7973 
240 22,31 22,55 30,7 sp|P46462|TERA_RAT 
Transitional endoplasmic reticulum ATPase OS=Rattus norvegicus GN=Vcp 
PE=1 SV=3 
RAT 12 1,081 0,5236 
259 22,15 22,35 34,4 sp|Q63598|PLST_RAT Plastin-3 OS=Rattus norvegicus GN=Pls3 PE=2 SV=2 RAT 12 0,9222 0,1955 
62 22,12 22,12 40,8 sp|P63259|ACTG_RAT Actin, cytoplasmic 2 OS=Rattus norvegicus GN=Actg1 PE=1 SV=1 RAT 15 1,9656 0 
354 21,97 23,38 14,8 sp|P11442|CLH1_RAT Clathrin heavy chain 1 OS=Rattus norvegicus GN=Cltc PE=1 SV=3 RAT 11 1,2324 0,0009 
143 21,81 21,91 44,2 sp|P05982|NQO1_RAT 
NAD(P)H dehydrogenase [quinone] 1 OS=Rattus norvegicus GN=Nqo1 PE=1 
SV=4 
RAT 11 1,2422 0,0119 
377 21,3 21,51 46,4 sp|Q63081|PDIA6_RAT Protein disulfide-isomerase A6 OS=Rattus norvegicus GN=Pdia6 PE=1 SV=2 RAT 10 1,15 0,2451 
39 20,93 20,93 27,8 sp|P02466|CO1A2_RAT Collagen alpha-2(I) chain OS=Rattus norvegicus GN=Col1a2 PE=1 SV=3 RAT 13 0,5759 0,0011 
154 20,61 20,69 40,1 sp|P10719|ATPB_RAT 
ATP synthase subunit beta, mitochondrial OS=Rattus norvegicus GN=Atp5b 
PE=1 SV=2 
RAT 11 1,258 0,0958 
448 20,46 20,46 67,8 sp|Q5XFX0|TAGL2_RAT Transgelin-2 OS=Rattus norvegicus GN=Tagln2 PE=1 SV=1 RAT 17 1,0336 0,5085 
217 20,4 20,41 25,7 sp|Q5RKI0|WDR1_RAT WD repeat-containing protein 1 OS=Rattus norvegicus GN=Wdr1 PE=1 SV=3 RAT 11 0,9936 0,9412 
233 19,96 20,16 34,1 sp|Q68FR6|EF1G_RAT Elongation factor 1-gamma OS=Rattus norvegicus GN=Eef1g PE=1 SV=3 RAT 8 1,0872 0,0982 
306 19,8 20,01 79 sp|P15865|H14_RAT Histone H1.4 OS=Rattus norvegicus GN=Hist1h1e PE=1 SV=3 RAT 9 1,0364 0,7589 
177 19,67 19,76 30,7 sp|Q62952|DPYL3_RAT 
Dihydropyrimidinase-related protein 3 OS=Rattus norvegicus GN=Dpysl3 
PE=1 SV=2 
RAT 10 0,9539 0,6931 
88 19,46 19,74 45,3 sp|P04636|MDHM_RAT 
Malate dehydrogenase, mitochondrial OS=Rattus norvegicus GN=Mdh2 PE=1 
SV=2 
RAT 10 1,079 0,2762 
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353 19,44 19,54 61,3 sp|Q5XFX0|TAGL2_RAT Transgelin-2 OS=Rattus norvegicus GN=Tagln2 PE=2 SV=1 RAT 11 0,9383 0,659 
230 17,52 17,52 48,6 sp|P04764|ENOA_RAT Alpha-enolase OS=Rattus norvegicus GN=Eno1 PE=1 SV=4 RAT 10 1,2706 0,0006 
140 17,52 17,52 44,5 sp|P25113|PGAM1_RAT Phosphoglycerate mutase 1 OS=Rattus norvegicus GN=Pgam1 PE=1 SV=4 RAT 9 1,0181 0,8781 
256 17,34 17,52 31,7 sp|P10860|DHE3_RAT 
Glutamate dehydrogenase 1, mitochondrial OS=Rattus norvegicus GN=Glud1 
PE=1 SV=2 
RAT 10 1,0576 0,311 
85 17,28 17,28 47 sp|P49242|RS3A_RAT 40S ribosomal protein S3a OS=Rattus norvegicus GN=Rps3a PE=1 SV=2 RAT 9 1,4054 0,0265 
477 17,19 17,25 54,7 sp|P21533|RL6_RAT 60S ribosomal protein L6 OS=Rattus norvegicus GN=Rpl6 PE=1 SV=5 RAT 9 1,2032 0,0241 
109 17,18 17,51 27,3 sp|P07153|RPN1_RAT 
Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit 1 
OS=Rattus norvegicus GN=Rpn1 PE=2 SV=1 
RAT 8 1,2021 0,1348 
433 17,15 17,15 83,5 sp|P10111|PPIA_RAT 
Peptidyl-prolyl cis-trans isomerase A OS=Rattus norvegicus GN=Ppia PE=1 
SV=2 
RAT 8 1,0645 0,5375 
254 17,06 17,06 41,9 sp|P04642|LDHA_RAT L-lactate dehydrogenase A chain OS=Rattus norvegicus GN=Ldha PE=1 SV=1 RAT 8 1,2101 0,0316 
253 17,01 17,35 24,6 sp|P13941|CO3A1_RAT Collagen alpha-1(III) chain OS=Rattus norvegicus GN=Col3a1 PE=2 SV=3 RAT 12 0,4031 0 
100 16,93 17,19 45,5 sp|P14668|ANXA5_RAT Annexin A5 OS=Rattus norvegicus GN=Anxa5 PE=1 SV=3 RAT 12 1,218 0,1316 
119 16,78 16,93 18,3 sp|Q9ESN0|NIBAN_RAT Protein Niban OS=Rattus norvegicus GN=Fam129a PE=2 SV=2 RAT 9 0,9938 0,9383 
449 16,58 16,62 14,3 sp|P04937|FINC_RAT Fibronectin OS=Rattus norvegicus GN=Fn1 PE=1 SV=2 RAT 8 1,159 0,048 
310 16,5 16,58 24,4 sp|Q6P502|TCPG_RAT 
T-complex protein 1 subunit gamma OS=Rattus norvegicus GN=Cct3 PE=1 
SV=1 
RAT 9 1,1931 0,2574 
514 16,46 16,46 28,3 sp|P11884|ALDH2_RAT 
Aldehyde dehydrogenase, mitochondrial OS=Rattus norvegicus GN=Aldh2 
PE=1 SV=1 
RAT 9 0,9646 0,727 
336 16,27 16,36 97,7 sp|P62329|TYB4_RAT Thymosin beta-4 OS=Rattus norvegicus GN=Tmsb4x PE=2 SV=2 RAT 10 0,9313 0,693 
381 15,95 16,08 59,2 sp|P19804|NDKB_RAT 
Nucleoside diphosphate kinase B OS=Rattus norvegicus GN=Nme2 PE=1 
SV=1 
RAT 7 1,3715 0,0228 
470 15,81 15,87 47,5 sp|P18420|PSA1_RAT 
Proteasome subunit alpha type-1 OS=Rattus norvegicus GN=Psma1 PE=1 
SV=2 
RAT 9 0,9562 0,5502 
172 15,72 15,91 53,2 sp|P62982|RS27A_RAT 
Ubiquitin-40S ribosomal protein S27a OS=Rattus norvegicus GN=Rps27a 
PE=1 SV=2 
RAT 8 1,2402 0,0533 
207 15,63 15,71 24,1 sp|Q08163|CAP1_RAT 
Adenylyl cyclase-associated protein 1 OS=Rattus norvegicus GN=Cap1 PE=1 
SV=3 
RAT 8 1,0962 0,1371 
67 15,29 34,63 47,9 sp|P82995|HS90A_RAT 
Heat shock protein HSP 90-alpha OS=Rattus norvegicus GN=Hsp90aa1 PE=1 
SV=3 
RAT 15 1,0702 0,3891 
268 15,06 15,06 77,3 sp|P62329|TYB4_RAT Thymosin beta-4 OS=Rattus norvegicus GN=Tmsb4x PE=1 SV=2 RAT 11 1,0409 0,623 
128 14,66 15,37 28,5 sp|P07943|ALDR_RAT Aldose reductase OS=Rattus norvegicus GN=Akr1b1 PE=1 SV=3 RAT 7 1,1227 0,0966 
170 14,61 14,67 42,7 sp|P41123|RL13_RAT 60S ribosomal protein L13 OS=Rattus norvegicus GN=Rpl13 PE=1 SV=2 RAT 7 0,9786 0,7893 
521 14,58 14,85 50,6 sp|P14669|ANXA3_RAT Annexin A3 OS=Rattus norvegicus GN=Anxa3 PE=1 SV=4 RAT 7 1,0555 0,6127 
384 14,17 14,17 50,4 sp|P11762|LEG1_RAT Galectin-1 OS=Rattus norvegicus GN=Lgals1 PE=1 SV=2 RAT 10 1,1709 0,0549 
5 14,05 14,05 44,2 sp|P04785|PDIA1_RAT Protein disulfide-isomerase OS=Rattus norvegicus GN=P4hb PE=1 SV=2 RAT 10 1,2391 0,0013 
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536 13,66 13,85 26,2 sp|P50137|TKT_RAT Transketolase OS=Rattus norvegicus GN=Tkt PE=1 SV=1 RAT 8 0,9799 0,8694 
169 13,51 13,51 78,3 sp|P23928|CRYAB_RAT Alpha-crystallin B chain OS=Rattus norvegicus GN=Cryab PE=1 SV=1 RAT 11 1,2382 0,0524 
95 13,49 13,77 27,2 sp|P54001|P4HA1_RAT 
Prolyl 4-hydroxylase subunit alpha-1 OS=Rattus norvegicus GN=P4ha1 PE=2 
SV=2 
RAT 7 0,8847 0,0573 
102 13,41 13,43 55,4 sp|P45592|COF1_RAT Cofilin-1 OS=Rattus norvegicus GN=Cfl1 PE=1 SV=3 RAT 9 1,0957 0,1724 
12 13,3 13,87 21 sp|O88600|HSP74_RAT Heat shock 70 kDa protein 4 OS=Rattus norvegicus GN=Hspa4 PE=1 SV=1 RAT 7 1,1406 0,0304 
8 13,27 13,72 23,9 sp|Q9ER34|ACON_RAT 
Aconitate hydratase, mitochondrial OS=Rattus norvegicus GN=Aco2 PE=1 
SV=2 
RAT 6 1,0811 0,3053 
247 12,76 47,27 69,7 sp|P58775|TPM2_RAT Tropomyosin beta chain OS=Rattus norvegicus GN=Tpm2 PE=3 SV=1 RAT 28 0,7512 0,0133 
273 12,74 12,9 38,8 sp|P37397|CNN3_RAT Calponin-3 OS=Rattus norvegicus GN=Cnn3 PE=1 SV=1 RAT 7 0,8396 0,0805 
494 12,64 13,02 54,2 sp|P62755|RS6_RAT 40S ribosomal protein S6 OS=Rattus norvegicus GN=Rps6 PE=1 SV=1 RAT 7 1,2106 0,0808 
438 12,59 12,82 21,2 sp|Q63355|MYO1C_RAT Unconventional myosin-Ic OS=Rattus norvegicus GN=Myo1c PE=1 SV=2 RAT 8 0,9274 0,2627 
185 12,2 12,48 22 sp|Q5M7W5|MAP4_RAT Microtubule-associated protein 4 OS=Rattus norvegicus GN=Map4 PE=1 SV=1 RAT 6 1,023 0,8081 
152 12,1 38,31 63,4 sp|P62738|ACTA_RAT Actin, aortic smooth muscle OS=Rattus norvegicus GN=Acta2 PE=2 SV=1 RAT 48 0,8496 0,2494 
248 12,05 12,17 48,6 sp|P62909|RS3_RAT 40S ribosomal protein S3 OS=Rattus norvegicus GN=Rps3 PE=1 SV=1 RAT 6 1,1073 0,3016 
279 12,01 12,01 47,8 sp|P41350|CAV1_RAT Caveolin-1 OS=Rattus norvegicus GN=Cav1 PE=1 SV=3 RAT 6 0,8329 0,0857 
83 12 12,09 52,1 sp|P62963|PROF1_RAT Profilin-1 OS=Rattus norvegicus GN=Pfn1 PE=1 SV=2 RAT 9 1,1157 0,4877 
475 11,91 12,24 42,3 sp|P61980|HNRPK_RAT 
Heterogeneous nuclear ribonucleoprotein K OS=Rattus norvegicus GN=Hnrnpk 
PE=1 SV=1 
RAT 5 0,9453 0,6069 
262 11,74 12,11 59 sp|P62752|RL23A_RAT 60S ribosomal protein L23a OS=Rattus norvegicus GN=Rpl23a PE=2 SV=1 RAT 6 1,0687 0,6925 
468 11,74 18,58 51,4 sp|P61983|1433G_RAT 14-3-3 protein gamma OS=Rattus norvegicus GN=Ywhag PE=1 SV=2 RAT 9 1,0195 0,7653 
422 11,64 11,8 21,4 sp|P28480|TCPA_RAT 
T-complex protein 1 subunit alpha OS=Rattus norvegicus GN=Tcp1 PE=1 
SV=1 
RAT 7 1,1388 0,3719 
471 11,62 11,77 18,5 sp|Q811A3|PLOD2_RAT 
Procollagen-lysine,2-oxoglutarate 5-dioxygenase 2 OS=Rattus norvegicus 
GN=Plod2 PE=2 SV=1 
RAT 7 0,9269 0,511 
43 11,52 11,53 41,9 sp|P04906|GSTP1_RAT Glutathione S-transferase P OS=Rattus norvegicus GN=Gstp1 PE=1 SV=2 RAT 6 1,1574 0,2535 
392 11,45 12,85 46,1 sp|Q08290|CNN1_RAT Calponin-1 OS=Rattus norvegicus GN=Cnn1 PE=2 SV=1 RAT 7 0,927 0,4292 
188 11,41 17,7 36,7 sp|P47942|DPYL2_RAT 
Dihydropyrimidinase-related protein 2 OS=Rattus norvegicus GN=Dpysl2 
PE=1 SV=1 
RAT 10 0,9728 0,7505 
158 11,28 11,62 36,7 sp|Q9JI85|NUCB2_RAT Nucleobindin-2 OS=Rattus norvegicus GN=Nucb2 PE=2 SV=1 RAT 4 1,1212 0,2546 
77 11,06 11,2 26,7 sp|Q66X93|SND1_RAT 
Staphylococcal nuclease domain-containing protein 1 OS=Rattus norvegicus 
GN=Snd1 PE=2 SV=1 
RAT 5 1,0319 0,7029 
87 11,04 11,8 22,4 sp|P51583|PUR6_RAT Multifunctional protein ADE2 OS=Rattus norvegicus GN=Paics PE=2 SV=3 RAT 6 1,1171 0,1508 
275 10,91 11,17 26,3 sp|P21531|RL3_RAT 60S ribosomal protein L3 OS=Rattus norvegicus GN=Rpl3 PE=1 SV=3 RAT 6 1,0898 0,2136 
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28 10,84 12,88 31,8 sp|P35704|PRDX2_RAT Peroxiredoxin-2 OS=Rattus norvegicus GN=Prdx2 PE=1 SV=3 RAT 6 1,1022 0,2097 
14 10,79 10,79 25,2 sp|Q6AYC4|CAPG_RAT Macrophage-capping protein OS=Rattus norvegicus GN=Capg PE=1 SV=1 RAT 6 0,9626 0,5721 
447 10,65 10,65 39,5 sp|Q6NYB7|RAB1A_RAT Ras-related protein Rab-1A OS=Rattus norvegicus GN=Rab1A PE=1 SV=3 RAT 4 1,4589 0,0046 
234 10,62 32,2 76,2 sp|Q63610|TPM3_RAT Tropomyosin alpha-3 chain OS=Rattus norvegicus GN=Tpm3 PE=1 SV=2 RAT 24 0,9162 0,1066 
92 10,59 10,59 34,3 sp|P10888|COX41_RAT 
Cytochrome c oxidase subunit 4 isoform 1, mitochondrial OS=Rattus 
norvegicus GN=Cox4i1 PE=1 SV=1 
RAT 5 1,0886 0,6403 
11 10,41 10,41 20,2 sp|P05370|G6PD_RAT 
Glucose-6-phosphate 1-dehydrogenase OS=Rattus norvegicus GN=G6pdx 
PE=1 SV=3 
RAT 5 1,0003 0,9975 
531 10,4 10,53 26,8 sp|Q6AXS5|PAIRB_RAT 
Plasminogen activator inhibitor 1 RNA-binding protein OS=Rattus norvegicus 
GN=Serbp1 PE=1 SV=2 
RAT 5 1,0874 0,3491 
411 10,36 10,6 33,8 sp|P62425|RL7A_RAT 60S ribosomal protein L7a OS=Rattus norvegicus GN=Rpl7a PE=1 SV=2 RAT 3 1,0781 0,386 
139 10,33 10,36 51,6 sp|P62961|YBOX1_RAT 
Nuclease-sensitive element-binding protein 1 OS=Rattus norvegicus GN=Ybx1 
PE=1 SV=3 
RAT 5 1,0714 0,9363 
450 10,33 10,33 26,1 sp|Q9WUH4|FHL1_RAT 
Four and a half LIM domains protein 1 OS=Rattus norvegicus GN=Fhl1 PE=2 
SV=1 
RAT 5 0,7936 0,0109 
43 10,28 10,68 26,4 sp|Q9WVC0|SEPT7_RAT Septin-7 OS=Rattus norvegicus GN=Sept7 PE=1 SV=1 RAT 5 0,9379 0,4371 
274 10,07 10,11 32,4 sp|Q3MIE4|VAT1_RAT 
Synaptic vesicle membrane protein VAT-1 homolog OS=Rattus norvegicus 
GN=Vat1 PE=1 SV=1 
RAT 5 0,9667 0,8154 
24 10,01 10,01 17,7 sp|Q9Z1Z9|PDLI7_RAT PDZ and LIM domain protein 7 OS=Rattus norvegicus GN=Pdlim7 PE=1 SV=1 RAT 5 0,9482 0,5718 
73 9,95 10,08 27,5 sp|Q5RKI1|IF4A2_RAT 
Eukaryotic initiation factor 4A-II OS=Rattus norvegicus GN=Eif4a2 PE=1 
SV=1 
RAT 5 0,9833 0,9066 
89 9,88 9,98 16 sp|Q68FP1|GELS_RAT Gelsolin OS=Rattus norvegicus GN=Gsn PE=1 SV=1 RAT 5 1,1362 0,4397 
161 9,87 9,96 49,5 sp|P62898|CYC_RAT Cytochrome c, somatic OS=Rattus norvegicus GN=Cycs PE=1 SV=2 RAT 5 0,9278 0,4643 
72 9,85 10,12 23,5 sp|P38659|PDIA4_RAT Protein disulfide-isomerase A4 OS=Rattus norvegicus GN=Pdia4 PE=1 SV=2 RAT 4 1,31 0,0037 
33 9,81 9,91 54,9 sp|P07483|FABPH_RAT Fatty acid-binding protein, heart OS=Rattus norvegicus GN=Fabp3 PE=1 SV=2 RAT 6 1,1531 0,1693 
258 9,67 10,34 16,4 sp|P21396|AOFA_RAT 
Amine oxidase [flavin-containing] A OS=Rattus norvegicus GN=Maoa PE=1 
SV=1 
RAT 5 1,1026 0,386 
349 9,61 9,76 42 sp|P12001|RL18_RAT 60S ribosomal protein L18 OS=Rattus norvegicus GN=Rpl18 PE=2 SV=2 RAT 5 1,4028 0,0891 
483 9,51 9,74 22,8 sp|Q5RJR8|LRC59_RAT 
Leucine-rich repeat-containing protein 59 OS=Rattus norvegicus GN=Lrrc59 
PE=1 SV=1 
RAT 4 1,308 0,1765 
530 9,49 9,7 15,3 sp|P49134|ITB1_RAT Integrin beta-1 OS=Rattus norvegicus GN=Itgb1 PE=2 SV=1 RAT 4 0,8252 0,152 
405 9,46 41,91 76,1 sp|P58775|TPM2_RAT Tropomyosin beta chain OS=Rattus norvegicus GN=Tpm2 PE=2 SV=1 RAT 30 0,8019 0,0088 
243 9,4 9,51 19,2 sp|Q9JLJ3|AL9A1_RAT 
4-trimethylaminobutyraldehyde dehydrogenase OS=Rattus norvegicus 
GN=Aldh9a1 PE=1 SV=1 
RAT 4 1,1508 0,1132 
324 9,36 9,44 19,4 sp|Q5XIM9|TCPB_RAT T-complex protein 1 subunit beta OS=Rattus norvegicus GN=Cct2 PE=1 SV=3 RAT 5 1,1102 0,5186 
388 9,31 9,75 14,2 sp|Q9JK11|RTN4_RAT Reticulon-4 OS=Rattus norvegicus GN=Rtn4 PE=1 SV=1 RAT 5 0,9947 0,9819 
32 9,27 9,27 25,9 sp|Q9EPH8|PABP1_RAT Polyadenylate-binding protein 1 OS=Rattus norvegicus GN=Pabpc1 PE=1 RAT 5 1,1391 0,0463 
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SV=1 
53 9,21 9,36 15,7 sp|P06685|AT1A1_RAT 
Sodium/potassium-transporting ATPase subunit alpha-1 OS=Rattus norvegicus 
GN=Atp1a1 PE=1 SV=1 
RAT 4 0,9446 0,442 
301 9,17 11,21 11,2 sp|P38650|DYHC1_RAT 
Cytoplasmic dynein 1 heavy chain 1 OS=Rattus norvegicus GN=Dync1h1 PE=1 
SV=1 
RAT 4 1,1142 0,141 
473 8,99 10,97 67,1 sp|P24368|PPIB_RAT 
Peptidyl-prolyl cis-trans isomerase B OS=Rattus norvegicus GN=Ppib PE=1 
SV=3 
RAT 5 1,1527 0,1074 
507 8,95 9,6 50,6 sp|P11030|ACBP_RAT Acyl-CoA-binding protein OS=Rattus norvegicus GN=Dbi PE=1 SV=3 RAT 5 1,25 0,0675 
395 8,82 9,04 25,2 sp|P19945|RLA0_RAT 60S acidic ribosomal protein P0 OS=Rattus norvegicus GN=Rplp0 PE=1 SV=2 RAT 4 1,0425 0,7447 
389 8,79 8,79 72,5 sp|P62161|CALM_RAT Calmodulin OS=Rattus norvegicus GN=Calm1 PE=1 SV=2 RAT 8 
  
97 8,78 10,75 61,8 sp|Q7M0E3|DEST_RAT Destrin OS=Rattus norvegicus GN=Dstn PE=1 SV=3 RAT 7 0,9026 0,2954 
303 8,69 8,74 39,2 sp|Q8VHK7|HDGF_RAT Hepatoma-derived growth factor OS=Rattus norvegicus GN=Hdgf PE=1 SV=2 RAT 4 0,8914 0,0929 
485 8,58 8,58 25,3 sp|P48500|TPIS_RAT Triosephosphate isomerase OS=Rattus norvegicus GN=Tpi1 PE=1 SV=2 RAT 4 0,9727 0,6686 
297 8,5 8,5 37,5 sp|P51635|AK1A1_RAT 
Alcohol dehydrogenase [NADP(+)] OS=Rattus norvegicus GN=Akr1a1 PE=1 
SV=2 
RAT 4 1,1046 0,1905 
165 8,48 8,58 43,6 sp|Q5XI73|GDIR1_RAT 
Rho GDP-dissociation inhibitor 1 OS=Rattus norvegicus GN=Arhgdia PE=1 
SV=1 
RAT 5 1,1072 0,668 
3 8,41 8,54 15,9 sp|Q63617|HYOU1_RAT Hypoxia up-regulated protein 1 OS=Rattus norvegicus GN=Hyou1 PE=1 SV=1 RAT 4 1,2071 0,0451 
26 8,4 8,52 19,4 sp|P55260|ANXA4_RAT Annexin A4 OS=Rattus norvegicus GN=Anxa4 PE=1 SV=3 RAT 4 1,1144 0,2153 
99 8,34 8,47 45,5 sp|P17074|RS19_RAT 40S ribosomal protein S19 OS=Rattus norvegicus GN=Rps19 PE=2 SV=3 RAT 4 1,2417 0,1005 
197 8,24 8,34 28,9 sp|O35987|NSF1C_RAT NSFL1 cofactor p47 OS=Rattus norvegicus GN=Nsfl1c PE=1 SV=1 RAT 4 0,9983 0,9792 
420 8,13 8,13 20,2 sp|Q99NA5|IDH3A_RAT 
Isocitrate dehydrogenase [NAD] subunit alpha, mitochondrial OS=Rattus 
norvegicus GN=Idh3a PE=1 SV=1 
RAT 4 1,0955 0,4157 
406 8,11 8,22 15,4 sp|O35567|PUR9_RAT 
Bifunctional purine biosynthesis protein PURH OS=Rattus norvegicus GN=Atic 
PE=1 SV=2 
RAT 4 1,2789 0,2662 
114 8,1 8,24 19 sp|Q68FQ0|TCPE_RAT 
T-complex protein 1 subunit epsilon OS=Rattus norvegicus GN=Cct5 PE=1 
SV=1 
RAT 4 0,9954 0,9386 
97 8,04 8,11 14,6 sp|P16036|MPCP_RAT 
Phosphate carrier protein, mitochondrial OS=Rattus norvegicus GN=Slc25a3 
PE=1 SV=1 
RAT 4 1,0951 0,4432 
36 8,03 8,1 42,9 sp|Q3T1J1|IF5A1_RAT 
Eukaryotic translation initiation factor 5A-1 OS=Rattus norvegicus GN=Eif5a 
PE=1 SV=3 
RAT 4 1,1998 0,5932 
214 8 8,27 20,8 sp|P17764|THIL_RAT 
Acetyl-CoA acetyltransferase, mitochondrial OS=Rattus norvegicus GN=Acat1 
PE=1 SV=1 
RAT 4 0,905 0,3589 
352 7,94 8,02 27,6 sp|P62919|RL8_RAT 60S ribosomal protein L8 OS=Rattus norvegicus GN=Rpl8 PE=2 SV=2 RAT 3 1,0701 0,3094 
318 7,9 7,98 28,4 sp|P08082|CLCB_RAT Clathrin light chain B OS=Rattus norvegicus GN=Cltb PE=1 SV=1 RAT 4 0,9787 0,8795 
291 7,79 8,17 32,3 sp|P50878|RL4_RAT 60S ribosomal protein L4 OS=Rattus norvegicus GN=Rpl4 PE=1 SV=3 RAT 4 1,0238 0,849 
415 7,72 7,81 48,9 sp|P67779|PHB_RAT Prohibitin OS=Rattus norvegicus GN=Phb PE=1 SV=1 RAT 4 0,9962 0,9372 
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213 7,69 7,76 23,8 sp|Q91Y81|SEPT2_RAT Septin-2 OS=Rattus norvegicus GN=Sept2 PE=1 SV=1 RAT 4 0,9689 0,6653 
104 7,68 7,83 10,8 sp|Q62940|NEDD4_RAT 
E3 ubiquitin-protein ligase NEDD4 OS=Rattus norvegicus GN=Nedd4 PE=1 
SV=1 
RAT 4 1,1661 0,3919 
294 7,66 7,8 16,9 sp|Q99PF5|FUBP2_RAT 
Far upstream element-binding protein 2 OS=Rattus norvegicus GN=Khsrp 
PE=1 SV=1 
RAT 4 0,9741 0,7924 
218 7,63 7,73 53,9 sp|P23358|RL12_RAT 60S ribosomal protein L12 OS=Rattus norvegicus GN=Rpl12 PE=2 SV=1 RAT 3 0,9371 0,6015 
461 7,57 7,74 49,6 sp|Q00715|H2B1_RAT Histone H2B type 1 OS=Rattus norvegicus PE=1 SV=2 RAT 4 0,8608 0,1788 
376 7,4 7,44 23,8 sp|P63029|TCTP_RAT 
Translationally-controlled tumor protein OS=Rattus norvegicus GN=Tpt1 PE=1 
SV=1 
RAT 4 2,0437 0,0756 
219 7,39 7,48 39,2 sp|Q68FU3|ETFB_RAT 
Electron transfer flavoprotein subunit beta OS=Rattus norvegicus GN=Etfb 
PE=2 SV=3 
RAT 4 1,1999 0,1073 
404 7,29 7,45 21,6 sp|P50399|GDIB_RAT 
Rab GDP dissociation inhibitor beta OS=Rattus norvegicus GN=Gdi2 PE=1 
SV=2 
RAT 4 1,0769 0,385 
48 7,18 7,18 36,1 sp|P18666|ML12B_RAT 
Myosin regulatory light chain 12B OS=Rattus norvegicus GN=Myl12b PE=1 
SV=3 
RAT 5 0,7447 0,0549 
293 7,12 9,7 22,3 sp|P70615|LMNB1_RAT Lamin-B1 OS=Rattus norvegicus GN=Lmnb1 PE=1 SV=3 RAT 5 1,1913 0,0969 
171 7,08 7,16 23,9 sp|Q4V7C7|ARP3_RAT Actin-related protein 3 OS=Rattus norvegicus GN=Actr3 PE=1 SV=1 RAT 4 1,242 0,1816 
369 7,05 7,07 29,4 sp|P24050|RS5_RAT 40S ribosomal protein S5 OS=Rattus norvegicus GN=Rps5 PE=1 SV=3 RAT 3 1,2387 0,0621 
212 6,98 7,17 21,5 sp|Q794E4|HNRPF_RAT 
Heterogeneous nuclear ribonucleoprotein F OS=Rattus norvegicus GN=Hnrnpf 
PE=1 SV=3 
RAT 4 1,0388 0,7978 
277 6,91 6,91 20,5 sp|Q3KRE8|TBB2B_RAT Tubulin beta-2B chain OS=Rattus norvegicus GN=Tubb2b PE=1 SV=1 RAT 5 1,6101 0,0067 
17 6,86 6,98 7,4 sp|P50475|SYAC_RAT 
Alanine--tRNA ligase, cytoplasmic OS=Rattus norvegicus GN=Aars PE=1 
SV=3 
RAT 3 1,2731 0,1138 
20 6,8 6,94 31,7 sp|O88989|MDHC_RAT 
Malate dehydrogenase, cytoplasmic OS=Rattus norvegicus GN=Mdh1 PE=1 
SV=3 
RAT 3 1,09 0,1526 
71 6,79 6,94 31,5 sp|Q62920|PDLI5_RAT PDZ and LIM domain protein 5 OS=Rattus norvegicus GN=Pdlim5 PE=1 SV=2 RAT 3 0,9061 0,092 
52 6,77 6,87 19,6 sp|Q62826|HNRPM_RAT 
Heterogeneous nuclear ribonucleoprotein M OS=Rattus norvegicus 
GN=Hnrnpm PE=1 SV=4 
RAT 4 0,9746 0,7746 
80 6,67 6,69 30,3 sp|P04904|GSTA3_RAT 
Glutathione S-transferase alpha-3 OS=Rattus norvegicus GN=Gsta3 PE=1 
SV=3 
RAT 4 1,343 0,2004 
499 6,64 6,64 15,6 sp|P16975|SPRC_RAT SPARC OS=Rattus norvegicus GN=Sparc PE=1 SV=4 RAT 4 1,0003 0,9981 
481 6,64 6,77 28,4 sp|Q63945|SET_RAT Protein SET OS=Rattus norvegicus GN=Set PE=2 SV=2 RAT 3 0,9522 0,8056 
535 6,53 6,6 15,9 sp|P25235|RPN2_RAT 
Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit 2 
OS=Rattus norvegicus GN=Rpn2 PE=2 SV=2 
RAT 3 0,9659 0,829 
495 6,47 6,61 13,4 sp|Q6P6V0|G6PI_RAT Glucose-6-phosphate isomerase OS=Rattus norvegicus GN=Gpi PE=1 SV=1 RAT 3 1,0954 0,5136 
403 6,42 6,56 14 sp|P35565|CALX_RAT Calnexin OS=Rattus norvegicus GN=Canx PE=1 SV=1 RAT 3 1,2065 0,4642 
304 6,39 6,39 43,8 sp|P11232|THIO_RAT Thioredoxin OS=Rattus norvegicus GN=Txn PE=1 SV=2 RAT 4 1,029 0,7545 
322 6,36 16,7 28,5 sp|P31977|EZRI_RAT Ezrin OS=Rattus norvegicus GN=Ezr PE=1 SV=3 RAT 8 1,0347 0,6468 
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84 6,31 6,57 17,8 sp|Q9Z1A6|VIGLN_RAT Vigilin OS=Rattus norvegicus GN=Hdlbp PE=2 SV=1 RAT 3 1,0187 0,7631 
236 6,2 28,28 50,8 sp|Q6P9T8|TBB4B_RAT Tubulin beta-4B chain OS=Rattus norvegicus GN=Tubb4b PE=1 SV=1 RAT 19 0,8982 0,7004 
335 6,14 6,19 24,2 sp|P52555|ERP29_RAT 
Endoplasmic reticulum resident protein 29 OS=Rattus norvegicus GN=Erp29 
PE=1 SV=2 
RAT 3 1,4325 0,147 
311 6,13 6,22 31,9 sp|P41562|IDHC_RAT 
Isocitrate dehydrogenase [NADP] cytoplasmic OS=Rattus norvegicus GN=Idh1 
PE=1 SV=1 
RAT 2 1,173 0,1857 
124 6,12 6,12 15,7 sp|P70490|MFGM_RAT Lactadherin OS=Rattus norvegicus GN=Mfge8 PE=2 SV=1 RAT 3 0,8873 0,4977 
86 6,11 6,41 24,5 sp|P04897|GNAI2_RAT 
Guanine nucleotide-binding protein G(i) subunit alpha-2 OS=Rattus norvegicus 
GN=Gnai2 PE=1 SV=3 
RAT 3 1,0763 0,4804 
334 6,04 6,12 26,9 sp|P62494|RB11A_RAT Ras-related protein Rab-11A OS=Rattus norvegicus GN=Rab11a PE=1 SV=3 RAT 3 1,3189 0,0382 
398 6,04 6,25 27,6 sp|P09895|RL5_RAT 60S ribosomal protein L5 OS=Rattus norvegicus GN=Rpl5 PE=1 SV=3 RAT 3 1,2515 0,2452 
136 6 6 18,1 sp|P30009|MARCS_RAT 
Myristoylated alanine-rich C-kinase substrate OS=Rattus norvegicus 
GN=Marcks PE=1 SV=2 
RAT 5 0,9826 0,854 
371 6 10,78 79,6 sp|P63312|TYB10_RAT Thymosin beta-10 OS=Rattus norvegicus GN=Tmsb10 PE=2 SV=2 RAT 7 0,9093 
 
149 6 6 27,2 sp|Q64119|MYL6_RAT Myosin light polypeptide 6 OS=Rattus norvegicus GN=Myl6 PE=1 SV=3 RAT 4 0,8682 0,2797 
305 5,96 6,09 19,9 sp|Q7TPB1|TCPD_RAT T-complex protein 1 subunit delta OS=Rattus norvegicus GN=Cct4 PE=1 SV=3 RAT 4 1,1828 0,586 
260 5,94 6,11 28 sp|P27952|RS2_RAT 40S ribosomal protein S2 OS=Rattus norvegicus GN=Rps2 PE=1 SV=1 RAT 3 1,2187 0,0441 
326 5,9 14,5 52,9 sp|P35213|1433B_RAT 14-3-3 protein beta/alpha OS=Rattus norvegicus GN=Ywhab PE=1 SV=3 RAT 7 0,8101 0,3045 
226 5,88 6,1 11,1 sp|O35142|COPB2_RAT Coatomer subunit beta' OS=Rattus norvegicus GN=Copb2 PE=1 SV=3 RAT 3 1,2577 0,0473 
309 5,86 5,86 32,5 sp|P07632|SODC_RAT Superoxide dismutase [Cu-Zn] OS=Rattus norvegicus GN=Sod1 PE=1 SV=2 RAT 7 1,1152 0,2254 
155 5,78 5,9 12,3 sp|P24268|CATD_RAT Cathepsin D OS=Rattus norvegicus GN=Ctsd PE=1 SV=1 RAT 3 0,9738 0,7585 
245 5,7 5,86 29,8 sp|O35783|CALU_RAT Calumenin OS=Rattus norvegicus GN=Calu PE=1 SV=1 RAT 3 1,1106 0,6721 
338 5,68 5,68 30,5 sp|Q9R063|PRDX5_RAT Peroxiredoxin-5, mitochondrial OS=Rattus norvegicus GN=Prdx5 PE=1 SV=1 RAT 3 1,2283 0,156 
348 5,65 5,74 64,4 sp|P02401|RLA2_RAT 60S acidic ribosomal protein P2 OS=Rattus norvegicus GN=Rplp2 PE=1 SV=2 RAT 3 1,2513 0,1356 
115 5,61 5,71 26,7 sp|Q8CFN2|CDC42_RAT 
Cell division control protein 42 homolog OS=Rattus norvegicus GN=Cdc42 
PE=1 SV=2 
RAT 3 0,9784 0,7851 
58 5,6 5,73 22,9 sp|Q9Z0W7|CLIC4_RAT 
Chloride intracellular channel protein 4 OS=Rattus norvegicus GN=Clic4 PE=1 
SV=3 
RAT 3 1,265 0,0525 
497 5,6 5,6 32,9 sp|P13084|NPM_RAT Nucleophosmin OS=Rattus norvegicus GN=Npm1 PE=1 SV=1 RAT 5 1,0373 0,7789 
375 5,58 5,6 23,8 sp|A7VJC2|ROA2_RAT 
Heterogeneous nuclear ribonucleoproteins A2/B1 OS=Rattus norvegicus 
GN=Hnrnpa2b1 PE=1 SV=1 
RAT 4 0,9834 0,8396 
516 5,57 5,97 15,8 sp|Q2PQA9|KINH_RAT Kinesin-1 heavy chain OS=Rattus norvegicus GN=Kif5b PE=1 SV=1 RAT 3 1,0956 0,275 
68 5,52 7,88 29,5 sp|B3GNI6|SEP11_RAT Septin-11 OS=Rattus norvegicus GN=Sept11 PE=1 SV=1 RAT 4 0,8896 0,1133 
195 5,44 5,46 19,8 sp|P21775|THIKA_RAT 
3-ketoacyl-CoA thiolase A, peroxisomal OS=Rattus norvegicus GN=Acaa1a 
PE=1 SV=2 
RAT 3 1,1221 0,6456 
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339 5,42 8,04 25,4 sp|O35814|STIP1_RAT Stress-induced-phosphoprotein 1 OS=Rattus norvegicus GN=Stip1 PE=1 SV=1 RAT 4 1,0941 0,3388 
423 5,37 5,37 24,2 sp|Q4KM74|SC22B_RAT 
Vesicle-trafficking protein SEC22b OS=Rattus norvegicus GN=Sec22b PE=1 
SV=3 
RAT 3 1,1387 0,5741 
478 5,32 5,32 11 sp|Q00438|PTBP1_RAT 
Polypyrimidine tract-binding protein 1 OS=Rattus norvegicus GN=Ptbp1 PE=1 
SV=1 
RAT 3 0,8943 0,1318 
175 5,29 5,31 10,7 sp|O08651|SERA_RAT 
D-3-phosphoglycerate dehydrogenase OS=Rattus norvegicus GN=Phgdh PE=1 
SV=3 
RAT 3 1,3174 0,0156 
451 5,27 5,27 21,1 sp|O35763|MOES_RAT Moesin OS=Rattus norvegicus GN=Msn PE=1 SV=3 RAT 3 1,3645 0,0041 
508 5,22 5,24 10,3 sp|Q5BJK8|GOLI4_RAT 
Golgi integral membrane protein 4 OS=Rattus norvegicus GN=Golim4 PE=1 
SV=2 
RAT 3 1,1966 0,1999 
464 5,18 5,3 9,9 sp|P52296|IMB1_RAT Importin subunit beta-1 OS=Rattus norvegicus GN=Kpnb1 PE=1 SV=1 RAT 3 1,2654 0,2065 
235 5,14 5,31 20,7 sp|P97584|PTGR1_RAT Prostaglandin reductase 1 OS=Rattus norvegicus GN=Ptgr1 PE=2 SV=3 RAT 2 1,3517 0,1651 
181 5,09 5,09 55,9 sp|P26772|CH10_RAT 
10 kDa heat shock protein, mitochondrial OS=Rattus norvegicus GN=Hspe1 
PE=1 SV=3 
RAT 4 1,1707 0,0727 
63 5,05 5,05 29,4 sp|P61314|RL15_RAT 60S ribosomal protein L15 OS=Rattus norvegicus GN=Rpl15 PE=1 SV=2 RAT 2 0,9625 0,7784 
88 4,94 5 27,5 sp|O88767|PARK7_RAT Protein DJ-1 OS=Rattus norvegicus GN=Park7 PE=1 SV=1 RAT 2 0,9033 0,2657 
56 4,92 7,17 18,5 sp|Q8VHV7|HNRH1_RAT 
Heterogeneous nuclear ribonucleoprotein H OS=Rattus norvegicus 
GN=Hnrnph1 PE=1 SV=2 
RAT 3 0,9885 0,8706 
22 4,91 5,09 48,9 sp|P62907|RL10A_RAT 60S ribosomal protein L10a OS=Rattus norvegicus GN=Rpl10a PE=1 SV=2 RAT 2 0,8884 0,1157 
276 4,9 5,03 21 sp|P85515|ACTZ_RAT Alpha-centractin OS=Rattus norvegicus GN=Actr1a PE=1 SV=1 RAT 3 1,2653 0,2653 
300 4,88 4,88 24,7 sp|P63255|CRIP1_RAT Cysteine-rich protein 1 OS=Rattus norvegicus GN=Crip1 PE=1 SV=2 RAT 3 1,1025 0,664 
202 4,88 4,93 16,2 sp|P13803|ETFA_RAT 
Electron transfer flavoprotein subunit alpha, mitochondrial OS=Rattus 
norvegicus GN=Etfa PE=1 SV=4 
RAT 2 1,0715 0,8251 
17 4,87 4,9 41,6 sp|P05964|S10A6_RAT Protein S100-A6 OS=Rattus norvegicus GN=S100a6 PE=1 SV=3 RAT 3 1,2379 0,4442 
458 4,73 4,73 63,8 sp|P62271|RS18_RAT 40S ribosomal protein S18 OS=Rattus norvegicus GN=Rps18 PE=1 SV=3 RAT 3 1,2997 0,0339 
134 4,69 4,83 43,3 sp|P62243|RS8_RAT 40S ribosomal protein S8 OS=Rattus norvegicus GN=Rps8 PE=1 SV=2 RAT 2 1,0033 0,9891 
91 4,68 4,78 15,7 sp|Q63347|PRS7_RAT 
26S protease regulatory subunit 7 OS=Rattus norvegicus GN=Psmc2 PE=1 
SV=3 
RAT 2 1,1168 0,4532 
426 4,63 4,63 73,9 sp|P62859|RS28_RAT 40S ribosomal protein S28 OS=Rattus norvegicus GN=Rps28 PE=1 SV=1 RAT 2 1,2194 0,2264 
357 4,63 4,69 50,8 sp|P31044|PEBP1_RAT 
Phosphatidylethanolamine-binding protein 1 OS=Rattus norvegicus GN=Pebp1 
PE=1 SV=3 
RAT 2 1,0829 0,4898 
538 4,63 4,63 20,5 sp|P00507|AATM_RAT 
Aspartate aminotransferase, mitochondrial OS=Rattus norvegicus GN=Got2 
PE=1 SV=2 
RAT 2 1,0656 0,6353 
288 4,6 4,61 9 sp|Q6P6R2|DLDH_RAT 
Dihydrolipoyl dehydrogenase, mitochondrial OS=Rattus norvegicus GN=Dld 
PE=1 SV=1 
RAT 2 1,1203 0,4694 
356 4,57 4,78 15,6 sp|Q9QZA2|PDC6I_RAT 
Programmed cell death 6-interacting protein OS=Rattus norvegicus 
GN=Pdcd6ip PE=1 SV=2 
RAT 2 1,0471 0,6965 
101 4,53 4,53 37,2 sp|P36972|APT_RAT 
Adenine phosphoribosyltransferase OS=Rattus norvegicus GN=Aprt PE=1 
SV=1 
RAT 2 1,3582 0,0865 
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168 4,53 4,75 12,7 sp|Q5M7U6|ARP2_RAT Actin-related protein 2 OS=Rattus norvegicus GN=Actr2 PE=1 SV=1 RAT 2 0,9875 0,9114 
198 4,52 4,72 22,1 sp|Q6P799|SYSC_RAT Serine--tRNA ligase, cytoplasmic OS=Rattus norvegicus GN=Sars PE=1 SV=3 RAT 3 1,28 0,324 
296 4,5 8,06 41,8 sp|P10536|RAB1B_RAT Ras-related protein Rab-1B OS=Rattus norvegicus GN=Rab1b PE=1 SV=1 RAT 3 1,0803 0,3746 
292 4,47 4,47 9,8 sp|P00762|TRY1_RAT Anionic trypsin-1 OS=Rattus norvegicus GN=Prss1 PE=1 SV=1 RAT 4 0,9618 
 
176 4,46 4,61 22,8 sp|Q3KR86|MIC60_RAT 
MICOS complex subunit Mic60 (Fragment) OS=Rattus norvegicus GN=Immt 
PE=1 SV=1 
RAT 3 0,9492 0,6208 
337 4,45 4,46 14,3 sp|Q5XIU9|PGRC2_RAT 
Membrane-associated progesterone receptor component 2 OS=Rattus 
norvegicus GN=Pgrmc2 PE=2 SV=1 
RAT 2 1,3831 0,0575 
269 4,44 4,57 38,2 sp|P61354|RL27_RAT 60S ribosomal protein L27 OS=Rattus norvegicus GN=Rpl27 PE=2 SV=2 RAT 2 1,2236 0,0379 
138 4,44 4,44 29,7 sp|P12749|RL26_RAT 60S ribosomal protein L26 OS=Rattus norvegicus GN=Rpl26 PE=1 SV=1 RAT 2 1,0859 0,5654 
413 4,43 4,54 10 sp|Q5U300|UBA1_RAT 
Ubiquitin-like modifier-activating enzyme 1 OS=Rattus norvegicus GN=Uba1 
PE=1 SV=1 
RAT 2 1,2332 0,3446 
74 4,38 4,45 32,3 sp|Q925G0|RBM3_RAT Putative RNA-binding protein 3 OS=Rattus norvegicus GN=Rbm3 PE=1 SV=2 RAT 2 0,9793 0,7902 
3 4,38 4,65 37,8 sp|P84100|RL19_RAT 60S ribosomal protein L19 OS=Rattus norvegicus GN=Rpl19 PE=1 SV=1 RAT 3 0,9724 0,782 
130 4,36 4,36 29,5 sp|P06302|PTMA_RAT Prothymosin alpha OS=Rattus norvegicus GN=Ptma PE=1 SV=2 RAT 3 1,158 
 
79 4,36 4,44 40,2 sp|P29314|RS9_RAT 40S ribosomal protein S9 OS=Rattus norvegicus GN=Rps9 PE=1 SV=4 RAT 2 1,0951 0,486 
15 4,36 4,6 9,8 sp|P18484|AP2A2_RAT AP-2 complex subunit alpha-2 OS=Rattus norvegicus GN=Ap2a2 PE=1 SV=3 RAT 2 0,8246 0,4719 
135 4,35 5,38 14,6 sp|Q68FS4|AMPL_RAT Cytosol aminopeptidase OS=Rattus norvegicus GN=Lap3 PE=1 SV=1 RAT 2 1,1528 0,7075 
397 4,35 4,56 12,5 sp|Q63377|AT1B3_RAT 
Sodium/potassium-transporting ATPase subunit beta-3 OS=Rattus norvegicus 
GN=Atp1b3 PE=2 SV=1 
RAT 3 0,8593 0,2329 
126 4,33 4,43 18,5 sp|Q05962|ADT1_RAT ADP/ATP translocase 1 OS=Rattus norvegicus GN=Slc25a4 PE=1 SV=3 RAT 4 1,8074 0,282 
196 4,32 4,32 39,8 sp|Q62658|FKB1A_RAT 
Peptidyl-prolyl cis-trans isomerase FKBP1A OS=Rattus norvegicus 
GN=Fkbp1a PE=1 SV=3 
RAT 2 1,1842 0,2001 
65 4,29 4,29 9,6 sp|Q4KMA2|RD23B_RAT 
UV excision repair protein RAD23 homolog B OS=Rattus norvegicus 
GN=Rad23b PE=1 SV=1 
RAT 2 1,1483 0,3601 
460 4,26 4,26 42,6 sp|P05942|S10A4_RAT Protein S100-A4 OS=Rattus norvegicus GN=S100a4 PE=2 SV=1 RAT 2 1,1133 0,2824 
360 4,24 4,3 36,4 sp|Q9Z2L0|VDAC1_RAT 
Voltage-dependent anion-selective channel protein 1 OS=Rattus norvegicus 
GN=Vdac1 PE=1 SV=4 
RAT 2 1,1362 0,1884 
192 4,22 4,35 42,3 sp|P05426|RL7_RAT 60S ribosomal protein L7 OS=Rattus norvegicus GN=Rpl7 PE=1 SV=2 RAT 2 1,3891 0,1504 
112 4,2 4,23 13,8 sp|P85845|FSCN1_RAT Fascin OS=Rattus norvegicus GN=Fscn1 PE=1 SV=2 RAT 2 0,9954 0,9914 
502 4,19 4,19 20,2 sp|P11598|PDIA3_RAT Protein disulfide-isomerase A3 OS=Rattus norvegicus GN=Pdia3 PE=1 SV=2 RAT 4 1,2231 0,2911 
23 4,19 6,68 66,7 sp|D3ZBN0|H15_RAT Histone H1.5 OS=Rattus norvegicus GN=Hist1h1b PE=3 SV=1 RAT 3 0,8455 0,1066 
281 4,16 4,16 15,6 sp|P16391|HA12_RAT 
RT1 class I histocompatibility antigen, AA alpha chain OS=Rattus norvegicus 
PE=1 SV=2 
RAT 2 1,0346 0,7251 
512 4,12 18,3 17,8 sp|Q9JLT0|MYH10_RAT Myosin-10 OS=Rattus norvegicus GN=Myh10 PE=2 SV=1 RAT 7 1,1158 0,7127 
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227 4,11 4,11 30,9 sp|P29457|SERPH_RAT Serpin H1 OS=Rattus norvegicus GN=Serpinh1 PE=1 SV=1 RAT 3 1,4447 0,122 
378 4,11 4,11 14,6 sp|P16290|PGAM2_RAT Phosphoglycerate mutase 2 OS=Rattus norvegicus GN=Pgam2 PE=2 SV=2 RAT 3 1,1888 0,5921 
323 4,11 5,2 14,8 sp|O88656|ARC1B_RAT 
Actin-related protein 2/3 complex subunit 1B OS=Rattus norvegicus 
GN=Arpc1b PE=2 SV=3 
RAT 3 1,1072 0,6165 
520 4,09 4,09 29,1 sp|P42930|HSPB1_RAT Heat shock protein beta-1 OS=Rattus norvegicus GN=Hspb1 PE=1 SV=1 RAT 3 1,3457 0,2085 
205 4,09 4,15 18,7 sp|P00763|TRY2_RAT Anionic trypsin-2 OS=Rattus norvegicus GN=Prss2 PE=1 SV=2 RAT 4 0,9676 
 
492 4,02 6,93 26,9 sp|Q5RJP0|ALD1_RAT 
Aldose reductase-related protein 1 OS=Rattus norvegicus GN=Akr1b7 PE=1 
SV=1 
RAT 3 1,1955 0,3246 
308 4,02 4,06 10,5 sp|Q4AEF8|COPG1_RAT Coatomer subunit gamma-1 OS=Rattus norvegicus GN=Copg1 PE=2 SV=1 RAT 2 1,1228 0,5888 
94 4,02 4,29 19,3 sp|P85834|EFTU_RAT 
Elongation factor Tu, mitochondrial OS=Rattus norvegicus GN=Tufm PE=1 
SV=1 
RAT 2 0,8274 0,5065 
11 4,01 4,17 16,1 sp|F1LMZ8|PSD11_RAT 
26S proteasome non-ATPase regulatory subunit 11 OS=Rattus norvegicus 
GN=Psmd11 PE=3 SV=2 
RAT 2 1,0964 0,6415 
48 4 4 4,7 sp|P11980|KPYM_RAT Pyruvate kinase isozymes M1/M2 OS=Rattus norvegicus GN=Pkm PE=1 SV=3 RAT 2 1,337 0,2125 
85 4 4 25,5 sp|Q7M767|UB2V2_RAT 
Ubiquitin-conjugating enzyme E2 variant 2 OS=Rattus norvegicus GN=Ube2v2 
PE=1 SV=3 
RAT 2 1,2958 0,3498 
19 4 4,09 9,7 sp|P10760|SAHH_RAT Adenosylhomocysteinase OS=Rattus norvegicus GN=Ahcy PE=1 SV=3 RAT 2 1,0771 0,6152 
501 4 4 14,3 sp|P13383|NUCL_RAT Nucleolin OS=Rattus norvegicus GN=Ncl PE=1 SV=3 RAT 2 1,0133 0,922 
316 4 4 14,9 sp|P62260|1433E_RAT 14-3-3 protein epsilon OS=Rattus norvegicus GN=Ywhae PE=1 SV=1 RAT 3 0,9994 
 
431 3,97 4,07 13,2 sp|Q5I0G4|SYG_RAT Glycine--tRNA ligase (Fragment) OS=Rattus norvegicus GN=Gars PE=1 SV=1 RAT 4 1,3534 0,0574 
156 3,96 3,98 27,6 sp|Q62785|HAP28_RAT 
28 kDa heat- and acid-stable phosphoprotein OS=Rattus norvegicus GN=Pdap1 
PE=1 SV=1 
RAT 2 1,0594 0,6721 
90 3,95 4,46 10,3 sp|Q62902|LMAN1_RAT Protein ERGIC-53 OS=Rattus norvegicus GN=Lman1 PE=1 SV=1 RAT 2 0,9237 0,6677 
96 3,92 3,92 19,8 sp|P09527|RAB7A_RAT Ras-related protein Rab-7a OS=Rattus norvegicus GN=Rab7a PE=1 SV=2 RAT 2 1,2015 0,5741 
345 3,9 3,93 46,9 sp|Q64598|H2A1F_RAT Histone H2A type 1-F OS=Rattus norvegicus PE=3 SV=3 RAT 2 1,0461 0,9553 
187 3,9 3,96 18,3 sp|Q920J4|TXNL1_RAT Thioredoxin-like protein 1 OS=Rattus norvegicus GN=Txnl1 PE=1 SV=3 RAT 2 1,0282 0,733 
232 3,89 3,89 9,4 sp|P48721|GRP75_RAT Stress-70 protein, mitochondrial OS=Rattus norvegicus GN=Hspa9 PE=1 SV=3 RAT 2 1,2941 0,2603 
107 3,88 3,96 9,7 sp|Q641X8|EIF3E_RAT 
Eukaryotic translation initiation factor 3 subunit E OS=Rattus norvegicus 
GN=Eif3e PE=2 SV=1 
RAT 2 1,2775 0,0946 
191 3,85 3,86 25,8 sp|P18421|PSB1_RAT Proteasome subunit beta type-1 OS=Rattus norvegicus GN=Psmb1 PE=1 SV=3 RAT 2 1,2445 0,2667 
40 3,84 3,86 12,5 sp|P04762|CATA_RAT Catalase OS=Rattus norvegicus GN=Cat PE=1 SV=3 RAT 2 1,2924 0,1867 
383 3,83 3,97 33,5 sp|Q5XI32|CAPZB_RAT 
F-actin-capping protein subunit beta OS=Rattus norvegicus GN=Capzb PE=1 
SV=1 
RAT 3 1,2225 0,3164 
68 3,8 4,33 22,6 sp|P08081|CLCA_RAT Clathrin light chain A OS=Rattus norvegicus GN=Clta PE=1 SV=1 RAT 2 1,0795 
 
343 3,79 3,83 6,8 sp|P26051|CD44_RAT CD44 antigen OS=Rattus norvegicus GN=Cd44 PE=1 SV=2 RAT 2 1,1068 0,3993 
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82 3,73 3,89 13,8 sp|P21670|PSA4_RAT 
Proteasome subunit alpha type-4 OS=Rattus norvegicus GN=Psma4 PE=1 
SV=1 
RAT 2 0,8307 0,5121 
57 3,72 3,83 17,8 sp|B2GUZ5|CAZA1_RAT 
F-actin-capping protein subunit alpha-1 OS=Rattus norvegicus GN=Capza1 
PE=1 SV=1 
RAT 2 0,8969 0,5568 
270 3,71 3,71 20,8 sp|Q6RUV5|RAC1_RAT 
Ras-related C3 botulinum toxin substrate 1 OS=Rattus norvegicus GN=Rac1 
PE=1 SV=1 
RAT 2 0,8871 0,3523 
287 3,71 4,07 10 sp|Q641Y8|DDX1_RAT 
ATP-dependent RNA helicase DDX1 OS=Rattus norvegicus GN=Ddx1 PE=2 
SV=1 
RAT 2 0,8845 0,5635 
178 3,7 3,7 39,8 sp|Q6B345|S10AB_RAT Protein S100-A11 OS=Rattus norvegicus GN=S100a11 PE=2 SV=1 RAT 3 1,275 0,2542 
367 3,69 3,69 28,1 sp|Q63190|EMD_RAT Emerin OS=Rattus norvegicus GN=Emd PE=2 SV=1 RAT 2 1,4905 
 
331 3,69 3,77 15,5 sp|Q6AYT3|RTCB_RAT 
tRNA-splicing ligase RtcB homolog OS=Rattus norvegicus GN=Rtcb PE=2 
SV=1 
RAT 2 1,0847 0,5637 
436 3,68 3,68 20,8 sp|P35434|ATPD_RAT 
ATP synthase subunit delta, mitochondrial OS=Rattus norvegicus GN=Atp5d 
PE=1 SV=2 
RAT 2 1,0382 0,8024 
325 3,67 3,68 43,9 sp|Q03344|ATIF1_RAT ATPase inhibitor, mitochondrial OS=Rattus norvegicus GN=Atpif1 PE=3 SV=2 RAT 2 1,2339 0,4014 
410 3,67 16,77 27,9 sp|Q5XIF6|TBA4A_RAT Tubulin alpha-4A chain OS=Rattus norvegicus GN=Tuba4a PE=2 SV=1 RAT 11 1,1526 0,5334 
350 3,65 3,72 13,3 sp|Q62871|DC1I2_RAT 
Cytoplasmic dynein 1 intermediate chain 2 OS=Rattus norvegicus GN=Dync1i2 
PE=1 SV=1 
RAT 2 1,0069 0,9579 
160 3,65 3,95 8,2 sp|P97536|CAND1_RAT 
Cullin-associated NEDD8-dissociated protein 1 OS=Rattus norvegicus 
GN=Cand1 PE=1 SV=1 
RAT 2 0,9793 0,8884 
228 3,64 3,73 25,3 sp|P62914|RL11_RAT 60S ribosomal protein L11 OS=Rattus norvegicus GN=Rpl11 PE=1 SV=2 RAT 2 0,9529 0,8086 
359 3,63 14,44 43,1 sp|P68511|1433F_RAT 14-3-3 protein eta OS=Rattus norvegicus GN=Ywhah PE=1 SV=2 RAT 7 0,9694 0,7156 
519 3,62 3,64 13,3 sp|P63245|GBLP_RAT 
Guanine nucleotide-binding protein subunit beta-2-like 1 OS=Rattus norvegicus 
GN=Gnb2l1 PE=1 SV=3 
RAT 2 1,0064 0,9298 
142 3,59 3,59 27,5 sp|Q9QX67|DAP1_RAT Death-associated protein 1 OS=Rattus norvegicus GN=Dap PE=3 SV=3 RAT 2 0,99 0,9365 
164 3,58 3,65 33,6 sp|P62902|RL31_RAT 60S ribosomal protein L31 OS=Rattus norvegicus GN=Rpl31 PE=2 SV=1 RAT 2 1,177 0,6177 
203 3,57 3,57 13,5 sp|P32551|QCR2_RAT 
Cytochrome b-c1 complex subunit 2, mitochondrial OS=Rattus norvegicus 
GN=Uqcrc2 PE=1 SV=2 
RAT 2 1,1699 0,2163 
98 3,55 3,73 39,4 sp|P63324|RS12_RAT 40S ribosomal protein S12 OS=Rattus norvegicus GN=Rps12 PE=1 SV=2 RAT 3 1,453 0,5181 
220 3,55 3,65 16,9 sp|P20070|NB5R3_RAT 
NADH-cytochrome b5 reductase 3 OS=Rattus norvegicus GN=Cyb5r3 PE=1 
SV=2 
RAT 2 1,1557 0,4671 
204 3,53 4,48 14,3 sp|Q62667|MVP_RAT Major vault protein OS=Rattus norvegicus GN=Mvp PE=1 SV=4 RAT 3 1,7867 0,2131 
361 3,45 3,45 10,6 sp|P01946|HBA_RAT Hemoglobin subunit alpha-1/2 OS=Rattus norvegicus GN=Hba1 PE=1 SV=3 RAT 2 1,5238 0,1792 
184 3,44 3,44 24,6 sp|O35244|PRDX6_RAT Peroxiredoxin-6 OS=Rattus norvegicus GN=Prdx6 PE=1 SV=3 RAT 2 1,0856 0,4352 
504 3,43 3,43 16,5 sp|Q498E0|TXD12_RAT 
Thioredoxin domain-containing protein 12 OS=Rattus norvegicus GN=Txndc12 
PE=2 SV=2 
RAT 2 1,1262 0,5814 
362 3,42 3,59 10,6 sp|Q6IRK9|CBPQ_RAT Carboxypeptidase Q OS=Rattus norvegicus GN=Cpq PE=1 SV=1 RAT 2 1,1764 0,2689 
523 3,42 3,44 34 sp|P63025|VAMP3_RAT 
Vesicle-associated membrane protein 3 OS=Rattus norvegicus GN=Vamp3 
PE=1 SV=1 
RAT 2 1,098 0,6314 
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141 3,37 3,5 24,1 sp|Q5XIH7|PHB2_RAT Prohibitin-2 OS=Rattus norvegicus GN=Phb2 PE=1 SV=1 RAT 2 1,0518 0,655 
67 3,35 3,38 13,8 sp|B4F7E8|NIBL1_RAT Niban-like protein 1 OS=Rattus norvegicus GN=Fam129b PE=2 SV=1 RAT 2 0,8786 0,2109 
435 3,31 3,32 39,8 sp|P01041|CYTB_RAT Cystatin-B OS=Rattus norvegicus GN=Cstb PE=1 SV=1 RAT 2 1,1925 0,2065 
70 3,3 3,34 35,2 sp|P62828|RAN_RAT GTP-binding nuclear protein Ran OS=Rattus norvegicus GN=Ran PE=1 SV=3 RAT 2 1,11 0,7512 
382 3,3 3,3 17,7 sp|Q5U318|PEA15_RAT 
Astrocytic phosphoprotein PEA-15 OS=Rattus norvegicus GN=Pea15 PE=1 
SV=1 
RAT 2 0,8651 0,4043 
418 3,28 3,36 16 sp|P50503|F10A1_RAT Hsc70-interacting protein OS=Rattus norvegicus GN=St13 PE=1 SV=1 RAT 2 1,2131 0,3175 
121 3,24 3,28 10,5 sp|Q6Q0N1|CNDP2_RAT 
Cytosolic non-specific dipeptidase OS=Rattus norvegicus GN=Cndp2 PE=1 
SV=1 
RAT 2 1,2849 0,219 
474 3,19 3,25 16,8 sp|Q5FVQ4|MLEC_RAT Malectin OS=Rattus norvegicus GN=Mlec PE=2 SV=1 RAT 2 1,1019 0,826 
314 3,17 3,17 20 sp|P38983|RSSA_RAT 40S ribosomal protein SA OS=Rattus norvegicus GN=Rpsa PE=1 SV=3 RAT 3 1,2684 0,2652 
189 3,14 3,41 10,5 sp|Q5PQX1|TOIP1_RAT 
Torsin-1A-interacting protein 1 OS=Rattus norvegicus GN=Tor1aip1 PE=1 
SV=1 
RAT 2 0,9141 0,6366 
59 3,14 3,32 19,7 sp|Q66H98|SDPR_RAT 
Serum deprivation-response protein OS=Rattus norvegicus GN=Sdpr PE=1 
SV=3 
RAT 2 0,7825 0,0972 
327 3,11 3,11 16,9 sp|P62630|EF1A1_RAT Elongation factor 1-alpha 1 OS=Rattus norvegicus GN=Eef1a1 PE=1 SV=1 RAT 3 1,2295 0,1545 
480 3,1 3,1 28,4 sp|P05943|S10AA_RAT Protein S100-A10 OS=Rattus norvegicus GN=S100a10 PE=1 SV=2 RAT 2 1,5162 0,3655 
445 3,1 3,1 29,1 sp|P62804|H4_RAT Histone H4 OS=Rattus norvegicus GN=Hist1h4b PE=1 SV=2 RAT 2 1,0042 0,9974 
252 3,09 3,09 11,6 sp|Q6AY84|SCRN1_RAT Secernin-1 OS=Rattus norvegicus GN=Scrn1 PE=1 SV=1 RAT 2 1,1886 0,3412 
251 3,08 3,23 22,8 sp|Q63584|TMEDA_RAT 
Transmembrane emp24 domain-containing protein 10 OS=Rattus norvegicus 
GN=Tmed10 PE=1 SV=2 
RAT 2 1,1247 0,5954 
101 3,06 3,06 35,7 sp|P12075|COX5B_RAT 
Cytochrome c oxidase subunit 5B, mitochondrial OS=Rattus norvegicus 
GN=Cox5b PE=1 SV=2 
RAT 2 1,4063 
 
358 3,04 3,04 42,3 sp|P36201|CRIP2_RAT Cysteine-rich protein 2 OS=Rattus norvegicus GN=Crip2 PE=2 SV=1 RAT 1 0,8666 0,647 
465 3,02 3,02 26,5 sp|P11250|RL34_RAT 60S ribosomal protein L34 OS=Rattus norvegicus GN=Rpl34 PE=1 SV=3 RAT 2 1,0426 0,7692 
506 2,98 3,03 14,5 sp|P05369|FPPS_RAT Farnesyl pyrophosphate synthase OS=Rattus norvegicus GN=Fdps PE=2 SV=2 RAT 2 1,0137 0,9472 
41 2,96 2,97 6,8 sp|P08461|ODP2_RAT 
Dihydrolipoyllysine-residue acetyltransferase component of pyruvate 
dehydrogenase complex, mitochondrial OS=Rattus norvegicus GN=Dlat PE=1 
SV=3 
RAT 2 1,0749 0,6159 
402 2,92 2,92 49,1 sp|P24368|PPIB_RAT 
Peptidyl-prolyl cis-trans isomerase B OS=Rattus norvegicus GN=Ppib PE=2 
SV=3 
RAT 5 1,0334 0,7294 
118 2,87 2,96 15,9 sp|Q6AYH5|DCTN2_RAT Dynactin subunit 2 OS=Rattus norvegicus GN=Dctn2 PE=1 SV=1 RAT 2 1,2569 0,2637 
36 2,81 2,93 9,7 sp|P11507|AT2A2_RAT 
Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 OS=Rattus norvegicus 
GN=Atp2a2 PE=1 SV=1 
RAT 1 1,199 0,3847 
32 2,81 3,02 21,2 sp|B2RZ37|REEP5_RAT 
Receptor expression-enhancing protein 5 OS=Rattus norvegicus GN=Reep5 
PE=1 SV=1 
RAT 1 1,1736 0,1196 
272 2,76 2,86 16,5 sp|P48004|PSA7_RAT 
Proteasome subunit alpha type-7 OS=Rattus norvegicus GN=Psma7 PE=1 
SV=1 
RAT 2 1,2877 0,2486 
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1 2,74 3,05 7,4 sp|P52873|PYC_RAT Pyruvate carboxylase, mitochondrial OS=Rattus norvegicus GN=Pc PE=1 SV=2 RAT 1 1,3528 0,1328 
490 2,74 2,77 11,6 sp|Q9JJ54|HNRPD_RAT 
Heterogeneous nuclear ribonucleoprotein D0 OS=Rattus norvegicus 
GN=Hnrnpd PE=1 SV=1 
RAT 1 0,9677 0,8068 
37 2,74 3,16 32,9 sp|P52925|HMGB2_RAT 
High mobility group protein B2 OS=Rattus norvegicus GN=Hmgb2 PE=2 
SV=2 
RAT 2 0,7864 0,1145 
513 2,73 2,73 7,4 sp|Q8VIF7|SBP1_RAT Selenium-binding protein 1 OS=Rattus norvegicus GN=Selenbp1 PE=1 SV=1 RAT 1 1,1746 0,4674 
532 2,7 2,74 13,2 sp|Q01205|ODO2_RAT 
Dihydrolipoyllysine-residue succinyltransferase component of 2-oxoglutarate 
dehydrogenase complex, mitochondrial OS=Rattus norvegicus GN=Dlst PE=1 
SV=2 
RAT 2 1,1722 0,3577 
49 2,69 2,81 8,1 sp|P62944|AP2B1_RAT AP-2 complex subunit beta OS=Rattus norvegicus GN=Ap2b1 PE=1 SV=1 RAT 1 0,9691 0,69 
484 2,68 2,77 21,2 sp|P34064|PSA5_RAT 
Proteasome subunit alpha type-5 OS=Rattus norvegicus GN=Psma5 PE=2 
SV=1 
RAT 1 1,4924 0,1583 
313 2,68 2,79 18,8 sp|P27605|HPRT_RAT 
Hypoxanthine-guanine phosphoribosyltransferase OS=Rattus norvegicus 
GN=Hprt1 PE=1 SV=1 
RAT 1 1,0364 0,7953 
427 2,67 2,76 26,7 sp|P47727|CBR1_RAT Carbonyl reductase [NADPH] 1 OS=Rattus norvegicus GN=Cbr1 PE=1 SV=2 RAT 1 1,0695 0,509 
87 2,65 2,81 38,3 sp|Q63507|RL14_RAT 60S ribosomal protein L14 OS=Rattus norvegicus GN=Rpl14 PE=1 SV=3 RAT 1 1,1468 0,3873 
459 2,63 3,25 16,7 sp|Q794F9|4F2_RAT 
4F2 cell-surface antigen heavy chain OS=Rattus norvegicus GN=Slc3a2 PE=1 
SV=1 
RAT 1 1,2679 0,2698 
429 2,63 2,64 14,9 sp|Q63965|SFXN1_RAT Sideroflexin-1 OS=Rattus norvegicus GN=Sfxn1 PE=2 SV=4 RAT 1 1,1683 0,2996 
321 2,58 2,65 15,3 sp|Q5EAJ6|IKIP_RAT 
Inhibitor of nuclear factor kappa-B kinase-interacting protein OS=Rattus 
norvegicus GN=Ikbip PE=2 SV=1 
RAT 1 1,2202 0,1536 
2 2,58 2,86 22 sp|A0JPM9|EIF3J_RAT 
Eukaryotic translation initiation factor 3 subunit J OS=Rattus norvegicus 
GN=Eif3j PE=2 SV=1 
RAT 2 1,1615 0,3731 
390 2,58 2,68 21,3 sp|Q66HR2|MARE1_RAT 
Microtubule-associated protein RP/EB family member 1 OS=Rattus norvegicus 
GN=Mapre1 PE=1 SV=3 
RAT 1 1,1305 0,4655 
456 2,58 2,79 11,8 sp|Q1JU68|EIF3A_RAT 
Eukaryotic translation initiation factor 3 subunit A OS=Rattus norvegicus 
GN=Eif3a PE=2 SV=2 
RAT 2 1,0227 0,7739 
163 2,57 2,66 18,4 sp|Q9JLZ1|GLRX3_RAT Glutaredoxin-3 OS=Rattus norvegicus GN=Glrx3 PE=1 SV=2 RAT 1 1,2487 0,296 
482 2,57 2,57 37,3 sp|P04550|PTMS_RAT Parathymosin OS=Rattus norvegicus GN=Ptms PE=1 SV=2 RAT 2 1,0176 0,8919 
94 2,53 2,55 8,1 sp|Q64361|LXN_RAT Latexin OS=Rattus norvegicus GN=Lxn PE=1 SV=1 RAT 1 1,2318 0,2985 
129 2,53 2,59 6,4 sp|Q62733|LAP2_RAT 
Lamina-associated polypeptide 2, isoform beta OS=Rattus norvegicus 
GN=Tmpo PE=1 SV=3 
RAT 2 1,019 0,9246 
496 2,52 2,52 13,7 sp|Q68A21|PURB_RAT 
Transcriptional activator protein Pur-beta OS=Rattus norvegicus GN=Purb 
PE=1 SV=3 
RAT 1 0,9662 0,8492 
116 2,47 2,59 27,8 sp|P05712|RAB2A_RAT Ras-related protein Rab-2A OS=Rattus norvegicus GN=Rab2a PE=1 SV=1 RAT 1 1,3138 0,2286 
51 2,45 2,45 18,3 sp|O35264|PA1B2_RAT 
Platelet-activating factor acetylhydrolase IB subunit beta OS=Rattus norvegicus 
GN=Pafah1b2 PE=1 SV=1 
RAT 1 1,2961 
 
39 2,44 2,46 17 sp|P62083|RS7_RAT 40S ribosomal protein S7 OS=Rattus norvegicus GN=Rps7 PE=1 SV=1 RAT 1 1,2344 0,3168 
79 2,43 2,43 14,7 sp|Q6LED0|H31_RAT Histone H3.1 OS=Rattus norvegicus PE=1 SV=3 RAT 2 0,8591 0,3769 
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66 2,4 2,4 11,3 sp|B0BNA5|COTL1_RAT Coactosin-like protein OS=Rattus norvegicus GN=Cotl1 PE=1 SV=1 RAT 1 1,3199 0,3781 
45 2,4 2,45 7,6 sp|Q4FZT9|PSMD2_RAT 
26S proteasome non-ATPase regulatory subunit 2 OS=Rattus norvegicus 
GN=Psmd2 PE=2 SV=1 
RAT 2 1,1792 0,7915 
524 2,38 2,4 14,6 sp|Q08013|SSRG_RAT 
Translocon-associated protein subunit gamma OS=Rattus norvegicus GN=Ssr3 
PE=2 SV=2 
RAT 2 0,9558 0,9207 
190 2,37 2,44 6,6 sp|Q64678|CP1B1_RAT Cytochrome P450 1B1 OS=Rattus norvegicus GN=Cyp1b1 PE=1 SV=1 RAT 1 1,2306 0,6404 
133 2,36 2,72 14 sp|Q10728|MYPT1_RAT 
Protein phosphatase 1 regulatory subunit 12A OS=Rattus norvegicus 
GN=Ppp1r12a PE=1 SV=2 
RAT 1 0,9787 0,9061 
69 2,35 3,87 8,8 sp|P81155|VDAC2_RAT 
Voltage-dependent anion-selective channel protein 2 OS=Rattus norvegicus 
GN=Vdac2 PE=1 SV=2 
RAT 2 0,9538 0,7224 
150 2,34 2,45 13,7 sp|P62703|RS4X_RAT 
40S ribosomal protein S4, X isoform OS=Rattus norvegicus GN=Rps4x PE=2 
SV=2 
RAT 1 1,2358 0,2877 
64 2,29 2,32 14 sp|O55096|DPP3_RAT Dipeptidyl peptidase 3 OS=Rattus norvegicus GN=Dpp3 PE=1 SV=2 RAT 2 1,2709 
 
263 2,26 3,3 20,8 sp|Q6MG61|CLIC1_RAT 
Chloride intracellular channel protein 1 OS=Rattus norvegicus GN=Clic1 PE=1 
SV=1 
RAT 2 0,9425 
 
42 2,25 2,32 7,1 sp|P21588|5NTD_RAT 5'-nucleotidase OS=Rattus norvegicus GN=Nt5e PE=1 SV=1 RAT 1 2,0382 0,1062 
120 2,22 2,22 17,2 sp|P29411|KAD3_RAT 
GTP:AMP phosphotransferase AK3, mitochondrial OS=Rattus norvegicus 
GN=Ak3 PE=2 SV=2 
RAT 1 1,0676 0,6291 
216 2,21 2,25 9,7 sp|P70566|TMOD2_RAT Tropomodulin-2 OS=Rattus norvegicus GN=Tmod2 PE=1 SV=1 RAT 2 2,439 
 
59 2,21 2,22 9,7 sp|Q64428|ECHA_RAT 
Trifunctional enzyme subunit alpha, mitochondrial OS=Rattus norvegicus 
GN=Hadha PE=1 SV=2 
RAT 1 0,9896 0,9328 
525 2,2 2,96 56,1 sp|P17078|RL35_RAT 60S ribosomal protein L35 OS=Rattus norvegicus GN=Rpl35 PE=1 SV=3 RAT 1 1,0676 0,7544 
167 2,2 2,24 6,6 sp|P14562|LAMP1_RAT 
Lysosome-associated membrane glycoprotein 1 OS=Rattus norvegicus 
GN=Lamp1 PE=1 SV=1 
RAT 2 1,0389 
 
242 2,19 2,19 14,1 sp|Q99MZ8|LASP1_RAT LIM and SH3 domain protein 1 OS=Rattus norvegicus GN=Lasp1 PE=1 SV=1 RAT 3 1,2794 0,2433 
40 2,19 2,31 18,6 sp|P85968|6PGD_RAT 
6-phosphogluconate dehydrogenase, decarboxylating OS=Rattus norvegicus 
GN=Pgd PE=1 SV=1 
RAT 1 1,0227 0,8278 
64 2,19 2,31 12 sp|P05708|HXK1_RAT Hexokinase-1 OS=Rattus norvegicus GN=Hk1 PE=1 SV=4 RAT 1 0,9462 0,6592 
47 2,18 2,34 12,8 sp|O70199|UGDH_RAT UDP-glucose 6-dehydrogenase OS=Rattus norvegicus GN=Ugdh PE=2 SV=1 RAT 1 1,067 0,7735 
127 2,18 2,38 7,8 sp|Q04462|SYVC_RAT Valine--tRNA ligase OS=Rattus norvegicus GN=Vars PE=2 SV=2 RAT 1 0,9148 0,8729 
47 2,15 2,2 31,2 sp|P62853|RS25_RAT 40S ribosomal protein S25 OS=Rattus norvegicus GN=Rps25 PE=2 SV=1 RAT 1 1,1775 0,321 
365 2,13 2,13 29,6 sp|P21571|ATP5J_RAT 
ATP synthase-coupling factor 6, mitochondrial OS=Rattus norvegicus 
GN=Atp5j PE=1 SV=1 
RAT 1 1,2827 0,2459 
416 2,13 2,13 22,3 sp|P19511|AT5F1_RAT 
ATP synthase F(0) complex subunit B1, mitochondrial OS=Rattus norvegicus 
GN=Atp5f1 PE=1 SV=1 
RAT 1 1,1849 0,096 
15 2,12 2,12 17,2 sp|P13471|RS14_RAT 40S ribosomal protein S14 OS=Rattus norvegicus GN=Rps14 PE=2 SV=3 RAT 1 1,4469 0,1682 
147 2,12 2,19 12,8 sp|Q5FVM4|NONO_RAT 
Non-POU domain-containing octamer-binding protein OS=Rattus norvegicus 
GN=Nono PE=1 SV=3 
RAT 1 1,049 0,775 
92 2,12 2,15 7,2 sp|Q5U301|AKAP2_RAT A-kinase anchor protein 2 OS=Rattus norvegicus GN=Akap2 PE=1 SV=1 RAT 1 1,048 0,785 
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225 2,12 2,16 9,1 sp|Q9R1J8|P3H1_RAT Prolyl 3-hydroxylase 1 OS=Rattus norvegicus GN=Lepre1 PE=1 SV=1 RAT 1 1,0118 0,9261 
540 2,11 2,35 9,2 sp|P02770|ALBU_RAT Serum albumin OS=Rattus norvegicus GN=Alb PE=1 SV=2 RAT 1 1,038 0,7716 
421 2,11 2,29 19,3 sp|Q06647|ATPO_RAT 
ATP synthase subunit O, mitochondrial OS=Rattus norvegicus GN=Atp5o 
PE=1 SV=1 
RAT 1 1,0085 0,9673 
8 2,1 2,1 32,9 sp|P62250|RS16_RAT 40S ribosomal protein S16 OS=Rattus norvegicus GN=Rps16 PE=1 SV=2 RAT 1 1,3315 0,227 
479 2,1 2,26 11,3 sp|Q63228|GMFB_RAT Glia maturation factor beta OS=Rattus norvegicus GN=Gmfb PE=1 SV=2 RAT 1 1,3232 
 
111 2,1 2,64 13,3 sp|P34067|PSB4_RAT Proteasome subunit beta type-4 OS=Rattus norvegicus GN=Psmb4 PE=1 SV=2 RAT 1 1,1122 0,4869 
424 2,1 2,14 47,4 sp|P11951|CX6C2_RAT 
Cytochrome c oxidase subunit 6C-2 OS=Rattus norvegicus GN=Cox6c2 PE=1 
SV=3 
RAT 1 0,8517 0,4079 
105 2,09 2,09 10,8 sp|P62246|RS15A_RAT 40S ribosomal protein S15a OS=Rattus norvegicus GN=Rps15a PE=1 SV=2 RAT 1 1,1691 0,4795 
246 2,09 2,15 10,3 sp|P29315|RINI_RAT Ribonuclease inhibitor OS=Rattus norvegicus GN=Rnh1 PE=1 SV=2 RAT 1 0,8555 0,2035 
173 2,08 2,1 5,2 sp|P07335|KCRB_RAT Creatine kinase B-type OS=Rattus norvegicus GN=Ckb PE=1 SV=2 RAT 1 1,1998 0,4392 
320 2,08 2,16 12,7 sp|P84025|SMAD3_RAT 
Mothers against decapentaplegic homolog 3 OS=Rattus norvegicus GN=Smad3 
PE=1 SV=1 
RAT 1 0,9665 
 
391 2,07 2,13 16,3 sp|Q8VHF5|CISY_RAT Citrate synthase, mitochondrial OS=Rattus norvegicus GN=Cs PE=1 SV=1 RAT 2 1,1936 0,1057 
93 2,06 2,12 17,3 sp|P49432|ODPB_RAT 
Pyruvate dehydrogenase E1 component subunit beta, mitochondrial OS=Rattus 
norvegicus GN=Pdhb PE=1 SV=2 
RAT 1 1,4925 0,1702 
518 2,06 2,24 19,1 sp|Q5RJR2|TWF1_RAT Twinfilin-1 OS=Rattus norvegicus GN=Twf1 PE=2 SV=1 RAT 1 1,0832 0,5689 
539 2,06 3,32 13,6 sp|P40329|SYRC_RAT 
Arginine--tRNA ligase, cytoplasmic OS=Rattus norvegicus GN=Rars PE=1 
SV=2 
RAT 2 1,009 0,9527 
229 2,06 2,33 17,8 sp|P27321|ICAL_RAT Calpastatin OS=Rattus norvegicus GN=Cast PE=1 SV=3 RAT 1 0,9333 0,5639 
81 2,05 2,1 23,5 sp|P02793|FRIL1_RAT Ferritin light chain 1 OS=Rattus norvegicus GN=Ftl1 PE=1 SV=3 RAT 1 1,7245 0,1279 
295 2,05 2,05 10,5 sp|Q9Z0V6|PRDX3_RAT 
Thioredoxin-dependent peroxide reductase, mitochondrial OS=Rattus 
norvegicus GN=Prdx3 PE=1 SV=2 
RAT 1 1,3433 0,5617 
351 2,05 2,12 21,1 sp|P62850|RS24_RAT 40S ribosomal protein S24 OS=Rattus norvegicus GN=Rps24 PE=2 SV=1 RAT 1 1,283 0,3191 
511 2,05 2,27 8,1 sp|Q9HB97|PARVA_RAT Alpha-parvin OS=Rattus norvegicus GN=Parva PE=1 SV=2 RAT 1 0,9155 
 
342 2,05 2,37 13,2 sp|Q63692|CDC37_RAT Hsp90 co-chaperone Cdc37 OS=Rattus norvegicus GN=Cdc37 PE=1 SV=2 RAT 1 0,9109 0,5389 
290 2,04 2,11 5,8 sp|Q05030|PGFRB_RAT 
Platelet-derived growth factor receptor beta OS=Rattus norvegicus GN=Pdgfrb 
PE=2 SV=2 
RAT 1 1,4277 0,1885 
396 2,04 2,04 24,2 sp|P63159|HMGB1_RAT 
High mobility group protein B1 OS=Rattus norvegicus GN=Hmgb1 PE=1 
SV=2 
RAT 1 1,1613 0,3725 
527 2,04 2,04 5,4 sp|P17046|LAMP2_RAT 
Lysosome-associated membrane glycoprotein 2 OS=Rattus norvegicus 
GN=Lamp2 PE=1 SV=2 
RAT 1 0,9781 0,8658 
45 2,04 2,22 4,6 sp|Q9WU82|CTNB1_RAT Catenin beta-1 OS=Rattus norvegicus GN=Ctnnb1 PE=1 SV=1 RAT 1 0,9666 0,803 
137 2,04 2,1 6,5 sp|Q9QZK5|HTRA1_RAT Serine protease HTRA1 OS=Rattus norvegicus GN=Htra1 PE=2 SV=1 RAT 1 
  
51 2,03 2,32 14,1 sp|Q07009|CAN2_RAT Calpain-2 catalytic subunit OS=Rattus norvegicus GN=Capn2 PE=1 SV=3 RAT 1 1,4086 0,3179 
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16 2,03 2,56 12,6 sp|B2RYG6|OTUB1_RAT Ubiquitin thioesterase OTUB1 OS=Rattus norvegicus GN=Otub1 PE=1 SV=1 RAT 1 1,0782 
 
231 2,03 2,04 17,5 sp|B0BN18|PFD2_RAT Prefoldin subunit 2 OS=Rattus norvegicus GN=Pfdn2 PE=2 SV=1 RAT 1 1,0275 
 
283 2,03 2,03 11,1 sp|P84083|ARF5_RAT ADP-ribosylation factor 5 OS=Rattus norvegicus GN=Arf5 PE=1 SV=2 RAT 1 0,9607 
 
453 2,02 2,02 5,6 sp|P97546|NPTN_RAT Neuroplastin OS=Rattus norvegicus GN=Nptn PE=1 SV=2 RAT 1 3,3469 
 
73 2,02 2,1 5,4 sp|P13697|MAOX_RAT NADP-dependent malic enzyme OS=Rattus norvegicus GN=Me1 PE=1 SV=2 RAT 1 1,7751 
 
372 2,02 2,12 6,5 sp|D3ZBP4|MICA1_RAT 
Protein-methionine sulfoxide oxidase MICAL1 OS=Rattus norvegicus 
GN=Mical1 PE=3 SV=1 
RAT 1 1,3364 
 
330 2,02 2,02 7,1 sp|O54975|XPP1_RAT Xaa-Pro aminopeptidase 1 OS=Rattus norvegicus GN=Xpnpep1 PE=1 SV=1 RAT 1 1,1917 0,3283 
57 2,02 2,22 7,3 sp|Q5U367|PLOD3_RAT 
Procollagen-lysine,2-oxoglutarate 5-dioxygenase 3 OS=Rattus norvegicus 
GN=Plod3 PE=2 SV=1 
RAT 1 1,1068 0,5139 
266 2,02 2,1 9,5 sp|P68101|IF2A_RAT 
Eukaryotic translation initiation factor 2 subunit 1 OS=Rattus norvegicus 
GN=Eif2s1 PE=1 SV=2 
RAT 1 0,9607 0,7554 
237 2,02 2,39 31,5 sp|P63170|DYL1_RAT 
Dynein light chain 1, cytoplasmic OS=Rattus norvegicus GN=Dynll1 PE=1 
SV=1 
RAT 1 0,9476 0,8625 
75 2,01 2,75 26,5 sp|P11517|HBB2_RAT Hemoglobin subunit beta-2 OS=Rattus norvegicus PE=1 SV=2 RAT 2 4,1219 
 
193 2,01 2,04 14,5 sp|Q4FZX7|SRPRB_RAT 
Signal recognition particle receptor subunit beta OS=Rattus norvegicus 
GN=Srprb PE=2 SV=1 
RAT 1 2,5725 
 
534 2,01 2,15 39,5 sp|P83732|RL24_RAT 60S ribosomal protein L24 OS=Rattus norvegicus GN=Rpl24 PE=2 SV=1 RAT 1 1,6162 0,0195 
425 2,01 2,04 7,8 sp|Q9Z2X5|HOME3_RAT Homer protein homolog 3 OS=Rattus norvegicus GN=Homer3 PE=2 SV=2 RAT 1 1,3407 
 
44 2,01 2,01 35,1 sp|Q4KLF8|ARPC5_RAT 
Actin-related protein 2/3 complex subunit 5 OS=Rattus norvegicus GN=Arpc5 
PE=1 SV=3 
RAT 1 1,3001 
 
472 2,01 2,05 2,6 sp|A1L1J9|LMF2_RAT Lipase maturation factor 2 OS=Rattus norvegicus GN=Lmf2 PE=2 SV=1 RAT 1 1,0827 
 
257 2,01 21,14 43,6 sp|P85108|TBB2A_RAT Tubulin beta-2A chain OS=Rattus norvegicus GN=Tubb2a PE=1 SV=1 RAT 14 1,0575 
 
344 2,01 2,01 27,4 sp|P61959|SUMO2_RAT 
Small ubiquitin-related modifier 2 OS=Rattus norvegicus GN=Sumo2 PE=1 
SV=1 
RAT 1 0,9712 
 
408 2,01 2,06 6,7 sp|Q9Z327|SYNPO_RAT Synaptopodin OS=Rattus norvegicus GN=Synpo PE=2 SV=2 RAT 1 0,7934 
 
54 2,01 2,28 45,8 sp|P05765|RS21_RAT 40S ribosomal protein S21 OS=Rattus norvegicus GN=Rps21 PE=1 SV=1 RAT 1 
  
18 2 2,04 3,6 sp|P10960|SAP_RAT Sulfated glycoprotein 1 OS=Rattus norvegicus GN=Psap PE=1 SV=1 RAT 1 2,1259 
 
182 2 2,17 19,3 sp|P19944|RLA1_RAT 60S acidic ribosomal protein P1 OS=Rattus norvegicus GN=Rplp1 PE=3 SV=1 RAT 1 1,916 
 
298 2 2,03 23,2 sp|Q6GQP4|RAB31_RAT Ras-related protein Rab-31 OS=Rattus norvegicus GN=Rab31 PE=1 SV=2 RAT 1 1,9015 
 
208 2 2,03 8,7 sp|Q62636|RAP1B_RAT Ras-related protein Rap-1b OS=Rattus norvegicus GN=Rap1b PE=2 SV=2 RAT 1 1,8404 
 
123 2 2 11,8 sp|Q07936|ANXA2_RAT Annexin A2 OS=Rattus norvegicus GN=Anxa2 PE=1 SV=2 RAT 1 1,8369 
 
250 2 8,07 15,5 sp|Q62764|YBOX3_RAT Y-box-binding protein 3 OS=Rattus norvegicus GN=Ybx3 PE=2 SV=1 RAT 4 1,8171 
 
364 2 2 6,8 sp|P85972|VINC_RAT Vinculin OS=Rattus norvegicus GN=Vcl PE=1 SV=1 RAT 1 1,7995 
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466 2 2,67 8,2 sp|P43244|MATR3_RAT Matrin-3 OS=Rattus norvegicus GN=Matr3 PE=1 SV=2 RAT 1 1,7774 
 
443 2 2,07 7,4 sp|B5DEH2|ERLN2_RAT Erlin-2 OS=Rattus norvegicus GN=Erlin2 PE=1 SV=1 RAT 1 1,7388 
 
285 2 2 6,3 sp|P05065|ALDOA_RAT 
Fructose-bisphosphate aldolase A OS=Rattus norvegicus GN=Aldoa PE=1 
SV=2 
RAT 1 1,7318 
 
444 2 2 4,3 sp|Q7TP48|APMAP_RAT 
Adipocyte plasma membrane-associated protein OS=Rattus norvegicus 
GN=Apmap PE=2 SV=2 
RAT 1 1,5779 
 
467 2 2 21,9 sp|P62628|DLRB1_RAT 
Dynein light chain roadblock-type 1 OS=Rattus norvegicus GN=Dynlrb1 PE=1 
SV=3 
RAT 1 1,4635 
 
340 2 3,93 15,5 sp|P35280|RAB8A_RAT Ras-related protein Rab-8A OS=Rattus norvegicus GN=Rab8a PE=1 SV=2 RAT 2 1,4633 
 
146 2 2 22,9 sp|P62832|RL23_RAT 60S ribosomal protein L23 OS=Rattus norvegicus GN=Rpl23 PE=2 SV=1 RAT 1 1,4473 
 
159 2 2 6,9 sp|Q6VV72|IF1A_RAT 
Eukaryotic translation initiation factor 1A OS=Rattus norvegicus GN=Eif1a 
PE=2 SV=3 
RAT 1 1,4395 
 
400 2 2,02 23,6 sp|P83883|RL36A_RAT 60S ribosomal protein L36a OS=Rattus norvegicus GN=Rpl36a PE=1 SV=2 RAT 1 1,4183 
 
505 2 2,4 15,1 sp|Q9EQX9|UBE2N_RAT 
Ubiquitin-conjugating enzyme E2 N OS=Rattus norvegicus GN=Ube2n PE=1 
SV=1 
RAT 1 1,3887 
 
271 2 2,07 5,7 sp|P11915|NLTP_RAT 
Non-specific lipid-transfer protein OS=Rattus norvegicus GN=Scp2 PE=1 
SV=3 
RAT 1 1,3808 
 
341 2 2 11,4 sp|P13668|STMN1_RAT Stathmin OS=Rattus norvegicus GN=Stmn1 PE=1 SV=2 RAT 1 1,3785 
 
332 2 2,14 6 sp|P15684|AMPN_RAT Aminopeptidase N OS=Rattus norvegicus GN=Anpep PE=1 SV=2 RAT 2 1,3446 
 
347 2 2 6,1 sp|Q68FR9|EF1D_RAT Elongation factor 1-delta OS=Rattus norvegicus GN=Eef1d PE=1 SV=2 RAT 1 1,2869 
 
221 2 22,97 37,2 sp|Q6AYZ1|TBA1C_RAT Tubulin alpha-1C chain OS=Rattus norvegicus GN=Tuba1c PE=1 SV=1 RAT 14 1,2612 
 
174 2 2 9,8 sp|Q07984|SSRD_RAT 
Translocon-associated protein subunit delta OS=Rattus norvegicus GN=Ssr4 
PE=2 SV=1 
RAT 1 1,2417 
 
131 2 2,05 10,7 sp|P62634|CNBP_RAT 
Cellular nucleic acid-binding protein OS=Rattus norvegicus GN=Cnbp PE=2 
SV=1 
RAT 1 1,2212 
 
515 2 2,03 8,9 sp|P61751|ARF4_RAT ADP-ribosylation factor 4 OS=Rattus norvegicus GN=Arf4 PE=2 SV=2 RAT 1 1,2076 
 
417 2 2,02 8,7 sp|Q6P7B0|SYWC_RAT 
Tryptophan--tRNA ligase, cytoplasmic OS=Rattus norvegicus GN=Wars PE=1 
SV=2 
RAT 1 1,1975 
 
93 2 2,16 13,9 sp|P62890|RL30_RAT 60S ribosomal protein L30 OS=Rattus norvegicus GN=Rpl30 PE=3 SV=2 RAT 1 1,189 
 
249 2 2 15,4 sp|O35796|C1QBP_RAT 
Complement component 1 Q subcomponent-binding protein, mitochondrial 
OS=Rattus norvegicus GN=C1qbp PE=1 SV=2 
RAT 1 1,1838 
 
46 2 2,02 8,8 sp|P37996|ARL3_RAT 
ADP-ribosylation factor-like protein 3 OS=Rattus norvegicus GN=Arl3 PE=1 
SV=2 
RAT 1 1,1676 
 
394 2 2,13 8,2 sp|Q9Z269|VAPB_RAT 
Vesicle-associated membrane protein-associated protein B OS=Rattus 
norvegicus GN=Vapb PE=1 SV=3 
RAT 1 1,1671 
 
329 2 2 22,7 sp|P47198|RL22_RAT 60S ribosomal protein L22 OS=Rattus norvegicus GN=Rpl22 PE=2 SV=2 RAT 1 1,1659 
 
355 2 2 20,2 sp|P60868|RS20_RAT 40S ribosomal protein S20 OS=Rattus norvegicus GN=Rps20 PE=3 SV=1 RAT 1 1,1606 
 
455 2 2 22,4 sp|P63326|RS10_RAT 40S ribosomal protein S10 OS=Rattus norvegicus GN=Rps10 PE=2 SV=1 RAT 1 1,1302 0,6757 
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437 2 2 17,3 sp|Q63945|SET_RAT Protein SET OS=Rattus norvegicus GN=Set PE=1 SV=2 RAT 1 1,1246 
 
71 2 2 5,5 sp|P13852|PRIO_RAT Major prion protein OS=Rattus norvegicus GN=Prnp PE=1 SV=2 RAT 1 1,1016 
 
148 2 2,08 14,3 sp|Q9JHY2|SFXN3_RAT Sideroflexin-3 OS=Rattus norvegicus GN=Sfxn3 PE=2 SV=1 RAT 1 1,0871 
 
261 2 2 18,3 sp|P62959|HINT1_RAT 
Histidine triad nucleotide-binding protein 1 OS=Rattus norvegicus GN=Hint1 
PE=1 SV=5 
RAT 1 1,076 
 
194 2 2 13 sp|P47875|CSRP1_RAT 
Cysteine and glycine-rich protein 1 OS=Rattus norvegicus GN=Csrp1 PE=2 
SV=2 
RAT 1 1,0654 
 
9 2 2,24 9,4 sp|Q63028|ADDA_RAT Alpha-adducin OS=Rattus norvegicus GN=Add1 PE=2 SV=2 RAT 1 1,0329 
 
117 2 9,84 30,6 sp|P68255|1433T_RAT 14-3-3 protein theta OS=Rattus norvegicus GN=Ywhaq PE=1 SV=1 RAT 5 1,0305 
 
89 2 2 20,6 sp|P11240|COX5A_RAT 
Cytochrome c oxidase subunit 5A, mitochondrial OS=Rattus norvegicus 
GN=Cox5a PE=1 SV=1 
RAT 1 1,0224 
 
55 2 2 49,3 sp|P29419|ATP5I_RAT 
ATP synthase subunit e, mitochondrial OS=Rattus norvegicus GN=Atp5i PE=1 
SV=3 
RAT 1 1,0185 
 
223 2 2 22,2 sp|Q71UE8|NEDD8_RAT NEDD8 OS=Rattus norvegicus GN=Nedd8 PE=1 SV=1 RAT 1 1,0178 
 
463 2 3,96 18,4 sp|Q5U316|RAB35_RAT Ras-related protein Rab-35 OS=Rattus norvegicus GN=Rab35 PE=1 SV=1 RAT 2 1,0036 
 
38 2 2 7,2 sp|P04256|ROA1_RAT 
Heterogeneous nuclear ribonucleoprotein A1 OS=Rattus norvegicus 
GN=Hnrnpa1 PE=1 SV=3 
RAT 1 0,9945 
 
509 2 2,07 24,1 sp|P83941|ELOC_RAT 
Transcription elongation factor B polypeptide 1 OS=Rattus norvegicus 
GN=Tceb1 PE=1 SV=1 
RAT 1 0,9578 
 
132 2 2,13 5,2 sp|Q4V8C3|EMAL1_RAT 
Echinoderm microtubule-associated protein-like 1 OS=Rattus norvegicus 
GN=Eml1 PE=2 SV=2 
RAT 1 0,929 
 
434 2 2,09 31,2 sp|Q9Z1H9|PRDBP_RAT 
Protein kinase C delta-binding protein OS=Rattus norvegicus GN=Prkcdbp 
PE=1 SV=1 
RAT 1 0,9079 
 
110 2 2,05 8,2 sp|P13596|NCAM1_RAT 
Neural cell adhesion molecule 1 OS=Rattus norvegicus GN=Ncam1 PE=1 
SV=1 
RAT 1 0,8177 
 
145 2 2,03 21,1 sp|P84817|FIS1_RAT Mitochondrial fission 1 protein OS=Rattus norvegicus GN=Fis1 PE=1 SV=1 RAT 1 0,8096 
 
209 2 2,03 7,4 sp|Q99372|ELN_RAT Elastin OS=Rattus norvegicus GN=Eln PE=1 SV=2 RAT 1 0,7733 
 
166 2 2 6,5 sp|Q9EPH2|MRP_RAT MARCKS-related protein OS=Rattus norvegicus GN=Marcksl1 PE=2 SV=3 RAT 1 0,7699 
 
76 2 2 6,6 sp|O08628|PCOC1_RAT 
Procollagen C-endopeptidase enhancer 1 OS=Rattus norvegicus GN=Pcolce 
PE=1 SV=1 
RAT 1 0,3894 
 
510 2 2,05 7,1 sp|P13264|GLSK_RAT 
Glutaminase kidney isoform, mitochondrial OS=Rattus norvegicus GN=Gls 
PE=1 SV=2 
RAT 1 
  
317 2 2,01 7,6 sp|P85973|PNPH_RAT Purine nucleoside phosphorylase OS=Rattus norvegicus GN=Pnp PE=1 SV=1 RAT 1 
  
34 1,96 2 6,3 sp|P61972|NTF2_RAT Nuclear transport factor 2 OS=Rattus norvegicus GN=Nutf2 PE=1 SV=1 RAT 1 0,8697 
 
537 1,96 2 11,8 sp|Q9WUC4|ATOX1_RAT 
Copper transport protein ATOX1 OS=Rattus norvegicus GN=Atox1 PE=1 
SV=1 
RAT 1 0,8315 
 
489 1,95 2,02 5,5 sp|P84092|AP2M1_RAT AP-2 complex subunit mu OS=Rattus norvegicus GN=Ap2m1 PE=1 SV=1 RAT 1 1,1429 0,6347 
414 1,95 2,01 19,4 sp|P19234|NDUV2_RAT 
NADH dehydrogenase [ubiquinone] flavoprotein 2, mitochondrial OS=Rattus 
norvegicus GN=Ndufv2 PE=1 SV=2 
RAT 1 0,8978 0,4758 
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286 1,94 2,54 6,5 sp|P16638|ACLY_RAT ATP-citrate synthase OS=Rattus norvegicus GN=Acly PE=1 SV=1 RAT 1 1,2843 0,269 
35 1,92 1,93 4 sp|P01048|KNT1_RAT T-kininogen 1 OS=Rattus norvegicus GN=Map1 PE=1 SV=2 RAT 1 
  
12 1,9 2,61 6,3 sp|P10688|PLCD1_RAT 
1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase delta-1 OS=Rattus 
norvegicus GN=Plcd1 PE=1 SV=1 
RAT 1 1,157 
 
78 1,9 2,12 35,8 sp|P61589|RHOA_RAT Transforming protein RhoA OS=Rattus norvegicus GN=Rhoa PE=1 SV=1 RAT 2 1,0274 0,9168 
486 1,89 1,95 21,2 sp|P62775|MTPN_RAT Myotrophin OS=Rattus norvegicus GN=Mtpn PE=1 SV=2 RAT 1 0,9607 
 
328 1,89 1,95 5,3 sp|Q9Z0J5|TRXR2_RAT 
Thioredoxin reductase 2, mitochondrial OS=Rattus norvegicus GN=Txnrd2 
PE=1 SV=3 
RAT 1 0,9025 
 
503 1,86 2,03 26,7 sp|P04644|RS17_RAT 40S ribosomal protein S17 OS=Rattus norvegicus GN=Rps17 PE=1 SV=3 RAT 1 1,1972 
 
457 1,85 2 23,5 sp|Q5BJP3|UFM1_RAT Ubiquitin-fold modifier 1 OS=Rattus norvegicus GN=Ufm1 PE=3 SV=1 RAT 1 1,6911 
 
528 1,85 1,93 8,3 sp|P85970|ARPC2_RAT 
Actin-related protein 2/3 complex subunit 2 OS=Rattus norvegicus GN=Arpc2 
PE=1 SV=1 
RAT 1 1,0878 
 
363 1,85 4,26 18,1 sp|P08753|GNAI3_RAT 
Guanine nucleotide-binding protein G(k) subunit alpha OS=Rattus norvegicus 
GN=Gnai3 PE=1 SV=3 
RAT 2 0,8842 
 
488 1,83 1,83 9,8 sp|Q63083|NUCB1_RAT Nucleobindin-1 OS=Rattus norvegicus GN=Nucb1 PE=1 SV=1 RAT 1 1,1456 0,4336 
4 1,83 1,93 17,6 sp|Q75UQ2|CFDP1_RAT 
Craniofacial development protein 1 OS=Rattus norvegicus GN=Cfdp1 PE=2 
SV=1 
RAT 1 1,111 
 
10 1,82 1,82 2,5 sp|Q5M7A4|UBA5_RAT 
Ubiquitin-like modifier-activating enzyme 5 OS=Rattus norvegicus GN=Uba5 
PE=2 SV=1 
RAT 1 1,2171 
 
60 1,82 1,82 8,9 sp|P85125|PTRF_RAT 
Polymerase I and transcript release factor OS=Rattus norvegicus GN=Ptrf PE=1 
SV=1 
RAT 1 1,1362 
 
46 1,82 1,86 4,6 sp|P31430|DPEP1_RAT Dipeptidase 1 OS=Rattus norvegicus GN=Dpep1 PE=2 SV=2 RAT 1 1,0726 
 
91 1,81 1,82 4,2 sp|Q60587|ECHB_RAT 
Trifunctional enzyme subunit beta, mitochondrial OS=Rattus norvegicus 
GN=Hadhb PE=1 SV=1 
RAT 1 1,5739 
 
180 1,81 1,85 13,8 sp|Q68FS2|CSN4_RAT 
COP9 signalosome complex subunit 4 OS=Rattus norvegicus GN=Cops4 PE=1 
SV=1 
RAT 1 0,9338 0,711 
476 1,79 1,79 15,2 sp|P06762|HMOX1_RAT Heme oxygenase 1 OS=Rattus norvegicus GN=Hmox1 PE=1 SV=1 RAT 1 2,6228 0,1107 
370 1,77 1,82 7,8 sp|P46413|GSHB_RAT Glutathione synthetase OS=Rattus norvegicus GN=Gss PE=1 SV=1 RAT 1 1,2461 
 
333 1,76 1,83 15,1 sp|Q9EQS0|TALDO_RAT Transaldolase OS=Rattus norvegicus GN=Taldo1 PE=1 SV=2 RAT 1 0,8833 0,5244 
522 1,74 1,79 3,5 sp|Q63016|LAT1_RAT 
Large neutral amino acids transporter small subunit 1 OS=Rattus norvegicus 
GN=Slc7a5 PE=1 SV=2 
RAT 1 1,7202 
 
380 1,74 1,74 4,7 sp|Q5PQP1|RBMS1_RAT 
RNA-binding motif, single-stranded-interacting protein 1 OS=Rattus norvegicus 
GN=Rbms1 PE=2 SV=1 
RAT 1 1,0329 
 
500 1,72 1,92 18,5 sp|Q3KRD5|TOM34_RAT 
Mitochondrial import receptor subunit TOM34 OS=Rattus norvegicus 
GN=Tomm34 PE=1 SV=1 
RAT 1 1,0575 0,8229 
157 1,72 1,72 27,2 sp|Q6PDU1|SRSF2_RAT 
Serine/arginine-rich splicing factor 2 OS=Rattus norvegicus GN=Srsf2 PE=1 
SV=3 
RAT 1 0,996 
 
299 1,72 1,78 21,6 sp|P35435|ATPG_RAT 
ATP synthase subunit gamma, mitochondrial OS=Rattus norvegicus 
GN=Atp5c1 PE=1 SV=2 
RAT 1 0,9178 
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379 1,69 1,69 13,5 sp|P07895|SODM_RAT 
Superoxide dismutase [Mn], mitochondrial OS=Rattus norvegicus GN=Sod2 
PE=1 SV=2 
RAT 1 1,3245 0,2546 
6 1,69 1,73 10,9 sp|Q4V8H8|EHD2_RAT EH domain-containing protein 2 OS=Rattus norvegicus GN=Ehd2 PE=1 SV=1 RAT 1 1,2851 0,1404 
22 1,68 1,91 14,1 sp|Q2LAP6|TES_RAT Testin OS=Rattus norvegicus GN=Tes PE=1 SV=1 RAT 1 1,2107 0,4195 
10 1,68 1,68 5,3 sp|P60901|PSA6_RAT 
Proteasome subunit alpha type-6 OS=Rattus norvegicus GN=Psma6 PE=1 
SV=1 
RAT 1 0,793 
 
24 1,67 2,04 6,7 sp|P09811|PYGL_RAT 
Glycogen phosphorylase, liver form OS=Rattus norvegicus GN=Pygl PE=1 
SV=5 
RAT 1 1,1972 
 
96 1,67 1,81 15,8 sp|O08557|DDAH1_RAT 
N(G),N(G)-dimethylarginine dimethylaminohydrolase 1 OS=Rattus norvegicus 
GN=Ddah1 PE=1 SV=3 
RAT 2 0,859 
 
469 1,64 1,69 9,4 sp|Q9QZR6|SEPT9_RAT Septin-9 OS=Rattus norvegicus GN=Sept9 PE=1 SV=1 RAT 1 1,0914 
 
44 1,64 1,73 16,3 sp|P62912|RL32_RAT 60S ribosomal protein L32 OS=Rattus norvegicus GN=Rpl32 PE=1 SV=2 RAT 1 0,9893 
 
440 1,64 1,64 3,3 sp|Q9EPJ0|NUCKS_RAT 
Nuclear ubiquitous casein and cyclin-dependent kinase substrate 1 OS=Rattus 
norvegicus GN=Nucks1 PE=1 SV=1 
RAT 1 0,903 
 
302 1,62 1,64 11,2 sp|Q6TUG0|DJB11_RAT 
DnaJ homolog subfamily B member 11 OS=Rattus norvegicus GN=Dnajb11 
PE=2 SV=1 
RAT 1 1,3369 0,2104 
430 1,61 1,61 11,2 sp|Q62969|PTGIS_RAT Prostacyclin synthase OS=Rattus norvegicus GN=Ptgis PE=2 SV=1 RAT 1 1,0576 0,511 
33 1,6 1,63 13,6 sp|E9PU28|IMDH2_RAT 
Inosine-5'-monophosphate dehydrogenase 2 OS=Rattus norvegicus GN=Impdh2 
PE=3 SV=1 
RAT 1 1,1711 0,4307 
533 1,59 1,62 7,3 sp|P17077|RL9_RAT 60S ribosomal protein L9 OS=Rattus norvegicus GN=Rpl9 PE=1 SV=1 RAT 1 1,3416 
 
201 1,59 1,66 5,3 sp|Q9WTT6|GUAD_RAT Guanine deaminase OS=Rattus norvegicus GN=Gda PE=1 SV=1 RAT 1 1,1741 
 
26 1,57 1,57 14,8 sp|Q6URK4|ROA3_RAT 
Heterogeneous nuclear ribonucleoprotein A3 OS=Rattus norvegicus 
GN=Hnrnpa3 PE=1 SV=1 
RAT 2 1,1338 0,4262 
541 1,55 1,73 13,6 sp|Q66HF9|LRRF1_RAT 
Leucine-rich repeat flightless-interacting protein 1 OS=Rattus norvegicus 
GN=Lrrfip1 PE=1 SV=1 
RAT 1 1,3797 0,3281 
407 1,55 2,37 23,4 sp|Q5I0E7|TMED9_RAT 
Transmembrane emp24 domain-containing protein 9 OS=Rattus norvegicus 
GN=Tmed9 PE=1 SV=1 
RAT 1 1,3624 0,4548 
419 1,55 1,55 7,2 sp|Q6AYD6|PDLI2_RAT PDZ and LIM domain protein 2 OS=Rattus norvegicus GN=Pdlim2 PE=1 SV=1 RAT 1 1,274 
 
82 1,52 1,52 11,6 sp|Q7TP40|PCNP_RAT 
PEST proteolytic signal-containing nuclear protein OS=Rattus norvegicus 
GN=Pcnp PE=2 SV=1 
RAT 1 1,1314 
 
446 1,51 1,51 4,2 sp|P28073|PSB6_RAT Proteasome subunit beta type-6 OS=Rattus norvegicus GN=Psmb6 PE=1 SV=3 RAT 1 1,4239 
 
280 1,49 1,57 11,1 sp|O08629|TIF1B_RAT 
Transcription intermediary factor 1-beta OS=Rattus norvegicus GN=Trim28 
PE=1 SV=2 
RAT 1 1,1803 0,6213 
493 1,49 1,49 23,4 sp|Q03344|ATIF1_RAT ATPase inhibitor, mitochondrial OS=Rattus norvegicus GN=Atpif1 PE=2 SV=2 RAT 1 0,9757 
 
255 1,48 1,56 23,1 sp|P62268|RS23_RAT 40S ribosomal protein S23 OS=Rattus norvegicus GN=Rps23 PE=1 SV=3 RAT 1 1,492 0,1583 
498 1,48 1,48 23,6 sp|Q6IG12|K2C7_RAT Keratin, type II cytoskeletal 7 OS=Rattus norvegicus GN=Krt7 PE=2 SV=1 RAT 1 0,714 0,6212 
386 1,47 1,47 6,8 sp|Q63690|BAX_RAT Apoptosis regulator BAX OS=Rattus norvegicus GN=Bax PE=1 SV=2 RAT 1 1,792 
 
99 1,47 5,99 23,5 sp|Q5U206|CALL3_RAT Calmodulin-like protein 3 OS=Rattus norvegicus GN=Calml3 PE=2 SV=1 RAT 4 
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265 1,46 1,56 10,5 sp|Q6MG60|DDAH2_RAT 
N(G),N(G)-dimethylarginine dimethylaminohydrolase 2 OS=Rattus norvegicus 
GN=Ddah2 PE=1 SV=1 
RAT 1 0,8488 
 
385 1,46 1,58 5,6 sp|P02773|FETA_RAT Alpha-fetoprotein OS=Rattus norvegicus GN=Afp PE=2 SV=1 RAT 1 0,7834 
 
319 1,43 21,68 41,6 sp|Q4QRB4|TBB3_RAT Tubulin beta-3 chain OS=Rattus norvegicus GN=Tubb3 PE=1 SV=1 RAT 16 1,2267 
 
452 1,43 1,56 9,4 sp|Q9Z2Q1|SC31A_RAT 
Protein transport protein Sec31A OS=Rattus norvegicus GN=Sec31a PE=1 
SV=2 
RAT 1 0,9436 0,5381 
224 1,39 1,42 9,5 sp|O89046|COR1B_RAT Coronin-1B OS=Rattus norvegicus GN=Coro1b PE=1 SV=1 RAT 1 1,1452 0,269 
199 1,37 1,41 7 sp|Q9JMI1|AACS_RAT Acetoacetyl-CoA synthetase OS=Rattus norvegicus GN=Aacs PE=1 SV=1 RAT 1 1,5969 
 
4 1,37 1,4 26,9 sp|P25886|RL29_RAT 60S ribosomal protein L29 OS=Rattus norvegicus GN=Rpl29 PE=1 SV=3 RAT 1 0,9932 0,9586 
72 1,37 1,37 5,2 sp|O89049|TRXR1_RAT 
Thioredoxin reductase 1, cytoplasmic OS=Rattus norvegicus GN=Txnrd1 PE=1 
SV=5 
RAT 1 0,9696 0,9282 
267 1,35 1,62 11,5 sp|B5DFC8|EIF3C_RAT 
Eukaryotic translation initiation factor 3 subunit C OS=Rattus norvegicus 
GN=Eif3c PE=2 SV=1 
RAT 1 1,4354 0,0475 
373 1,33 1,33 24,2 sp|Q5XI72|IF4H_RAT 
Eukaryotic translation initiation factor 4H OS=Rattus norvegicus GN=Eif4h 
PE=1 SV=1 
RAT 1 0,9989 
 
54 1,32 1,35 17,6 sp|Q9ES40|PRAF3_RAT PRA1 family protein 3 OS=Rattus norvegicus GN=Arl6ip5 PE=1 SV=1 RAT 1 2,232 
 
428 1,32 1,36 8,1 sp|Q62786|FPRP_RAT 
Prostaglandin F2 receptor negative regulator OS=Rattus norvegicus GN=Ptgfrn 
PE=1 SV=1 
RAT 1 1,2184 
 
442 1,32 1,34 16,7 sp|Q6PEC1|TBCA_RAT Tubulin-specific chaperone A OS=Rattus norvegicus GN=Tbca PE=1 SV=1 RAT 1 1,1565 0,3894 
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Supplementary Table S2 – Proteins differentially expressed in PASMCs treated with TMP compared with 
control in SHAM group. 
 
 
Supplementary Table S3 – Proteins differentially expressed in PASMCs treated with TMP compared with 
control in MCT group. 
MCT 
Acession Gene ID Name 
Log2  
(TMP/CONT) 
p value 
P13941 CO3A1_RAT Collagen alpha-1(III) chain -1.3108 0.0000 
P02454 CO1A1_RAT Collagen alpha-1(I) chain -1.0058 0.0003 
P04692 TPM1_RAT Tropomyosin alpha-1 chain -0.9811 0.0000 
P02466 CO1A2_RAT Collagen alpha-2(I) chain -0.7961 0.0011 
P05964 S10A6_RAT Protein S100-A6 -0.7634 0.0156 
P37397 CNN3_RAT Calponin-3 -0.6808 0.0042 
P35704 PRDX2_RAT Peroxiredoxin-2 -0.6613 0.0371 
P41350 CAV1_RAT Caveolin-1 -0.6054 0.0455 
Q63355 MYO1C_RAT Unconventional myosin-Ic -0.5720 0.0120 
P09495 TPM4_RAT Tropomyosin alpha-4 chain -0.5355 0.0003 
Q63610 TPM3_RAT Tropomyosin alpha-3 chain -0.4761 0.0000 
B3GNI6 SEP11_RAT Septin-11 -0.4521 0.0182 
Q5QD51 AKA12_RAT A-kinase anchor protein 12 -0.4438 0.0047 
P85125 PTRF_RAT Polymerase I and transcript release factor -0.4152 0.0057 
SHAM 
Acession Gene ID Name 
Log2  
(TMP/CONT) 
p value 
P62329 TYB4_RAT Thymosin beta-4 -0.5825 0.0416 
Q64119 MYL6_RAT Myosin light polypeptide 6 -0.5756 0.0463 
P18666 ML12B_RAT Myosin regulatory light chain 12B -0.5328 0.0150 
P05964 S10A6_RAT Protein S100-A6 -0.3655 0.0052 
Q05175 BASP1_RAT Brain acid soluble protein 1 -0.3623 0.0001 
P58775 TPM2_RAT Tropomyosin beta chain -0.3185 0.0088 
P05942 S10A4_RAT Protein S100-A4 -0.3129 0.0057 
P04692 TPM1_RAT Tropomyosin alpha-1 chain -0.2802 0.0100 
P11762 LEG1_RAT Galectin-1 -0.2735 0.0193 
Q62736 CALD1_RAT Non-muscle caldesmon -0.2576 0.0002 
P63018 HSP7C_RAT Heat shock cognate 71 kDa protein -0.1875 0.0042 
P09495 TPM4_RAT Tropomyosin alpha-4 chain -0.1568 0.0154 
P19804 NDKB_RAT Nucleoside diphosphate kinase B 0.2016 0.0481 
P04785 PDIA1_RAT Protein disulfide-isomerase A1 0.3093 0.0013 
P04764 ENOA_RAT Alpha-enolase 0.3455 0.0006 
O35763 MOES_RAT Moesin 0.4484 0.0041 
Q3KRE8 TBB2B_RAT Tubulin beta-2B chain 0.6872 0.0067 
P63259 ACTG_RAT Actin, cytoplasmic 2 0.9750 0.0000 
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P58775 TPM2_RAT Tropomyosin beta chain -0.4127 0.0133 
P49134 ITB1_RAT Integrin beta-1 -0.4016 0.0076 
P47875 CSRP1_RAT Cysteine and glycine-rich protein 1 -0.3876 0.0002 
P62982 RS27A_RAT Ubiquitin-40S ribosomal protein S27a -0.3857 0.0256 
P04256 ROA1_RAT 
Heterogeneous nuclear ribonucleoprotein 
A1 
-0.3761 0.0312 
P13084 NPM_RAT Nucleophosmin -0.3748 0.0211 
Q811A3 PLOD2_RAT 
Procollagen-lysine,2-oxoglutarate 5-
dioxygenase 2 
-0.3731 0.0010 
P63159 HMGB1_RAT High mobility group protein B1 -0.3609 0.0388 
Q05175 BASP1_RAT Brain acid soluble protein 1 -0.3412 0.0212 
Q9WVC0 SEPT7_RAT Septin-7 -0.3408 0.0030 
D3ZBN0 H15_RAT Histone H1.5 -0.3401 0.0468 
Q9WUH4 FHL1_RAT Four and a half LIM domains protein 1 -0.3335 0.0109 
P45592 COF1_RAT Cofilin-1 -0.3312 0.0176 
A7VJC2 ROA2_RAT 
Heterogeneous nuclear 
ribonucleoproteins A2/B1 
-0.3103 0.0460 
Q62736 CALD1_RAT Non-muscle caldesmon -0.3006 0.0052 
Q62812 MYH9_RAT Myosin-9 -0.2895 0.0001 
Q99MZ8 LASP1_RAT LIM and SH3 domain protein 1 -0.2447 0.0105 
P04636 MDHM_RAT Malate dehydrogenase, mitochondrial -0.2316 0.0051 
P13383 NUCL_RAT Nucleolin -0.2022 0.0058 
D3ZHA0 FLNC_RAT Filamin-C -0.1647 0.0107 
Q9EPH8 PABP1_RAT Polyadenylate-binding protein 1 0.1879 0.0463 
O88600 HSP74_RAT Heat shock 70 kDa protein 4 0.1898 0.0304 
O35763 MOES_RAT Moesin 0.1975 0.0310 
Q63716 PRDX1_RAT Peroxiredoxin-1 0.2106 0.0138 
P04937 FINC_RAT Fibronectin 0.2129 0.0480 
P11980 KPYM_RAT Pyruvate kinase PKM 0.2293 0.0076 
P11598 PDIA3_RAT Protein disulfide-isomerase A3 0.2309 0.0276 
P10719 ATPB_RAT 
ATP synthase subunit beta, 
mitochondrial 
0.2370 0.0464 
P05197 EF2_RAT Elongation factor 2 0.2537 0.0168 
P21533 RL6_RAT 60S ribosomal protein L6 0.2669 0.0241 
Q63617 HYOU1_RAT Hypoxia up-regulated protein 1 0.2715 0.0451 
P04642 LDHA_RAT L-lactate dehydrogenase A chain 0.2751 0.0316 
P16086 SPTN1_RAT Spectrin alpha chain, non-erythrocytic 1 0.2830 0.0000 
P27952 RS2_RAT 40S ribosomal protein S2 0.2853 0.0441 
P61354 RL27_RAT 60S ribosomal protein L27 0.2911 0.0379 
P04785 PDIA1_RAT Protein disulfide-isomerase A1 0.2985 0.0011 
P34058 HS90B_RAT Heat shock protein HSP 90-beta 0.3004 0.0195 
P11442 CLH1_RAT Clathrin heavy chain 1 0.3015 0.0009 
P05982 NQO1_RAT NAD(P)H dehydrogenase [quinone] 1 0.3129 0.0119 
O35142 COPB2_RAT Coatomer subunit beta 0.3308 0.0473 
P48721 GRP75_RAT Stress-70 protein, mitochondrial 0.3657 0.0009 
P62271 RS18_RAT 40S ribosomal protein S18 0.3782 0.0339 
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P38659 PDIA4_RAT Protein disulfide-isomerase A4 0.3896 0.0037 
O08651 SERA_RAT D-3-phosphoglycerate dehydrogenase 0.3977 0.0156 
P62494 RB11A_RAT Ras-related protein Rab-11A 0.3993 0.0382 
P06761 GRP78_RAT 78 kDa glucose-regulated protein 0.4182 0.0000 
P19804 NDKB_RAT Nucleoside diphosphate kinase B 0.4558 0.0228 
P49242 RS3A_RAT 40S ribosomal protein S3a 0.4910 0.0265 
Q6NYB7 RAB1A_RAT Ras-related protein Rab-1A 0.5449 0.0046 
P31000 VIME_RAT Vimentin 0.5528 0.0003 
P63029 TCTP_RAT Translationally-controlled tumor protein 0.6450 0.0426 
 
 
 
 
 
 
 
 
 
 
APPENDIX – SUPPLEMENTARY DATA 
218 
 
 
Supplementary Figure S1 – Pie charts of proteins identified in the PASMCs from SHAM rats grouped 
based on their molecular function (A), biological process (B) and protein class (C), by PANTHER, v8.0 [24]. 
PANTHER analysis showed that 42.9 % of the proteins have structural molecule activity. Cellular (21.1 %) 
and developmental (17.5 %) processes are the biological processes associated with the majority of the 
proteins. Furthermore, 47.4 % of the proteins are cytoskeletal. Release date: June 20, 2015. 
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Supplementary Figure S2 – Pie charts of proteins identified in the PASMCs from MCT rats grouped based 
on their molecular function (A), biological process (B) and protein class (C), by PANTHER, v8.0 [24]. 
PANTHER analysis showed that 32.9 % of the proteins have structural molecule activity, 24.7 % have 
catalytic activity and 23.5 % have binding function. Metabolic (20.8 %) and cellular (18.5 %) processes are 
the biological processes associated with the majority of the proteins. Furthermore, 21.4 % of the proteins are 
cytoskeletal and 13.1 % are nucleic acid binding proteins. Release date: June 20, 2015. 
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Supplementary Figure S3 – Terameprocol protein targets prediction (SwissTargetPrediction) [43]. Release 
date: September 8, 2014. 
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Supplementary Figure S4 – ClueGo+CluePedia analysis [26, 27] of protein-protein interactions considering 
the proteins identified as up- and down-regulated in PASMCs from MCT rats treated with TMP. Purple 
nodes represent the biological processes related with the proteins identified experimentally, while blue nodes 
refer to the ones predicted using SwissTargetPrediction tool [43]. Release date: May 15, 2015. 
 
